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ABSTRACT OF THESIS (Regulation 7.9)
It is well known that the presence of metastatic disease
in colorectal carcinoma is associated with a dire prognosis. It
has more recently been shown that prognosis following
apparently-curative resection for colorectal carcinoma is
principally determined by the presence or absence of occult
metastatic disease at the time of surgery. There is evidence
furthermore, based on study of the rate of growth of metastases
from these tumours, to suggest that they may behave as
metastasizing or non-metastasizing variants from a very early
stage in their natural history. There is however no clinically
applicable means currently available of accurately predicting
the metastatic potential of a primary tumour. This is of
considerable importance in planning and evaluating further
therapeutic strategies.
A study was therefore undertaken to attempt to pheno-
typically characterise colorectal cancer by cloning
complementary DNA (cDNA) libraries representing individual
highly-and moderately-abundant mRNA species. cDNA was
transcribed from polyadenylated RNA from two tumour specimens,
one from a patient with disseminated disease and the other from
a patient who had remained disease-free. Approximately 1,000
recombinant clones were picked for each library and were
cross-screened using Grunstein-Hogness and, subsequently, dot
hybridisation techniques to select the four most consistent
putatively metastasis-related clones. These clones were then
used as radiolabelled probes to screen mRNA from a series of
samples of colorectal carcinomas (n=12), normal mucosa,
adenomatous polyps and other tumour and tissue types.
Steady-state transcription levels of these sequences were in
general higher in the colorectal carcinomas than in normal
mucosa. These RNA transcripts were also seen in several other
tumour types but were scarcely detectable in normal cells such
as leucocytes and cultured fibroblasts. The elevations seen in
the colorectal tumours did not correlate with conventional
staging criteria nor with clinical outcome over a follow up
Period of up to three years nor, in particular, with the
development of metastatic disease. The presence of high
steady-state levels of these RNA sequences appears therefore to
ue only tumour-associated. The lack of correlation between them
and a possible metastatic phenotype suggests that if such
sequences exist they may be expressed at low levels or
.hat relatively small differences of expression may occur either





1. Metastasis: General Considerations
Cancer metastasis, that is the growth of a tumour at a
site separate and distinct from the primary, is one of the
critical and defining characteristics of malignancy and as
such is responsible for most therapeutic failures in cancer
medicine. This is a fact of considerable significance
given that approximately half of all malignant tumours will
have already metastasized by the time of clinical
presentation (Sugarbaker and Ketcham, 1977). Little
however is known of its biological basis despite its being
the object of much study and there is in particular no
clinically-applicable means of accurately predicting the
metastatic potential of a primary tumour, clearly of
importance in determining subseguent therapeutic
strategies.
It is recognised that the process is complex and
multifactorial, involving a sequence of steps each of which
is in itself necessary but not sufficient although which of
these might be most critical is not clear. (For reviews
see Carter, 1976; Weiss, 1977; Poste and Fidler, 1980;
Folkmann, 1982). The sequence includes the initial growth
and vascularisation of the primary tumour, invasion of
adjacent normal tissues, (largely it is thought, as a
consequence of tumour pressure, active cell movement and
release of lytic enzymes) and penetration into blood and
lymphatic vessels within and around the tumour, as well as
penetration of body cavities. Detachment of cells from the
primary tumour must then occur which may again be related
to the activity of proteolytic enzymes.. It has long been
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known that in many tumours the cells are more readily
disassociated than in normal tissue (Coman, 1953). These
cells are then disseminated throughout the body although it
has been inferred from clinicopathological (Willis, 1973)
as well as direct experimental studies (Fidler, 1970;
Butler and Gullino, 1975) that this step is highly
inefficient and in one model system it has been shown that
less than 1% of potentially-metastatic cells injected
survived to produce metastases (Fidler, 1970). It has
similarly been shown in human tumours that the presence of
circulating cancer cells by no means correlates with
subsequent development of metastatic disease (Salsbury,
1975). It is nonetheless generally considered that good
surgical technique should minimise the vascular
dissemination of tumour cells or possible local wound
implantation. Factors which are thought to be important at
this stage include cell size, clumping of cells (which
generally produces a higher incidence of metastases in any
tumour cell type (Liotta et al, 1976)) and cell-deform-
ability, which may favour survival in passage through
capillaries. It is known that the circulation is an
inimical environment in any case to many normal cells e.g.
fibroblasts. To survive at a distant site cells must then
adhere to and penetrate the vascular (usually capillary)
endothelium. For reasons which are not understood this
involves arterial walls infrequently. This step apparently
involves embolic trapping in fibrin and platelet thrombi,
classically described in the rabbit ear-chamber by Wood
(Wood, 1958), although it is not clear at what stage of
arrest these coagulation phenomena occ.ur. Tumour cells
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must then adhere to a probably exposed and possibly damaged
endothelial basement membrane by means of mechanical and
electrostatic forces as well as, probably, tumour cell
receptors for e.g. laminin and fibronectin. Extravasation
of cells occurs either by a process akin to diapedesis
and/or bursting through. Growth and invasion of tissue at
the new site then occurs, dependent upon the acquisition of
a vasculature, probably promoted by substances such as
tumour angiogenesis factor (TAF) (Folkmann, 1974) and
possibly upon local cellular (e.g. inflammatory cells, or
osteoclasts in bone) or tissue effects (e.g. mediated by
growth and/or chemotactic (Lam et al, 1981) factors).
These may be critical since the presence of viable tumour
cells in any organ does not guarantee metastatic tumour
growth (Hewitt and Blake, 1975) and see below. The
prognostic significance of the presence of tumour cells in
regional lymph nodes is also unclear and may simply reflect
in the early stages an active filtering role which may be
later overcome when nodes may act themselves to generate
metastatic disease. The therapeutic implications of such
nodes similarly remains controversial (Weiss, 1977;
Sugarbaker and Ketcham, 1977; Folkmann, 1982).
It is of interest that many features of the metastatic
process undergone by malignant tumour cells have parallels
in normal physiology e.g. the invasive behaviour of tropho-
blast, the extensive migrations undergone in embryogenesis
by e.g. neural crest cells and the emigration of leucocytes
out of the blood stream (Sherbet, 1982). It would appear
that "reactivation" of the genetic loci responsible for
such behaviour also occurs in malignant cells.
Both clinical (Willis, 1973) and various experimental
observations have revealed a number of further unexplained
and curious features of the metastatic process. These
include the marked variation in metastatic potential of
different tumour types (including the existence of a group
of so-called "intermediate" tumours such as basal cell
carcinoma or ameloblastoma which, although locally
invasive, do not appear to metastasize) and differences in
routes of metastasis in different tumour types. (It is
well known that in general sarcomas preferentially
metastasize via the blood stream whereas carcinomas do so
more via lymphatics although these routes are far from
mutually exclusive due to the existence of extensive
lymphatico-venous anastamoses; tumours such as melanoma,
neuroblastoma and teratoma appear to utilise both routes
egually). There are, in addition, marked differences in
organ predilection for metastases from different tumours
which cannot entirely be accounted for in haemodynamic
terms, although such an explanation has been put forward
(Ewing, 1928), and current accounts generally conflate
this view with one deriving from the hypothesis describing
such events in terms of the properties of both "seeds" and
"soil" (Paget, 1889). Such differences are well
exemplified by the behaviour of nephroblastoma and of
adrenal neuroblastoma both of which drain into the renal
vein yet the preferred metastatic site for the former is
lung whereas the latter more frequently metastasises to
bone. The importance of haemodynamic factors is nonethe¬
less illustrated by the fact that carcinomas of the lower
third of rectum, which drain into the systemic circulation
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via the inferior vena cava, metastasize more frequently to
lung then to liver whereas for comparable tumours of the
upper third of rectum draining into the portal venous
system the converse is true (Weiss et al, 1984). Such
metastatic patterns may in addition be complicated by the
fact that metastases may themselves give rise to further
metastatic deposits. Interestingly, changes in patterns of
metastases have been observed in recent years following
chemotherapy in e.g. osteosarcoma (Folkmann, 1983) and
carcinoma of the breast (Amer, 1982). Clinically-evident
sites of predilection for metastatic disease cannot either
be accounted for in terms of type of tissue nor its embryo-
logical origin. The much more common involvement of
certain sites such as liver, lung, and bone as compared to
skeletal muscle or gut is poorly understood, although in
experimental models in vitro organ-specific adhesion of
metastatic tumour cells (Netland and Zetter, 1984) as well
as the existence of a hepatocyte receptor interacting with
1iver-metastasizing tumour cells (Cheingsong-Popov et al,
1983) have been demonstrated.
The existence of organ-specific cultured tumour cell
lines (e.g. Kim, 1979; Tao et al, 1979; Stackpole, 1981)
and demonstration of such specificity even towards
ectopically implanted e.g. lung in thigh (Sugarbaker et al,
1971) or parabiotic tissue (Schour and Faraci, 1974) is
evidence of the importance, at least experimentally, of
tumour cell properties in determining the outcome of the
metastatic process. The recent clinical demonstration that
the circulation of cancer cells as a consequence of
peritoneo-venous shunting for malignan.t ascites did not
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result in lung metastases is entirely consistent with such
experimental observations (Tarin et al, 1984).
A further poorly-understood feature of the metastatic
process is the phenomenon of "dormancy" of metastases, most
notably manifest as the late (years or decades after
initial tumour treatment) appearance of metastatic disease
in e.g. carcinoma of the breast or malignant melanoma.
Reasons suggested for this latency include a balance of
cell division and cell loss or suspension of cells in a
non-proliferative (Go) state possibly due to a lack of
mitogenic stimuli (Alexander, 1983). It is possible that
host factors may play a controlling role in this situation
(see (Woodruff, 1982) and below). The occasionally
observed clinical phenomena of regression (in e.g. clear
cell renal carcinoma) or of "rebound" growth of metastases
following removal of the primary,suggestive of some
systemic effect of a primary tumour on secondary deposits,
is similarly not understood (Folkmann, 1983). Although
there is circumstantial clinical and direct experimental
(e.g. Eccles et al, 1980) evidence (the latter using
antigenic tumours in immunosuppressed animals) implicating
host immune response in the outcome of tumour metastasis,
it is generally accepted, as discussed at greater length
below, that there is as yet no conclusive evidence for such
a response having any significant influence on the outcome
of established malignant disease (Weiss, 1977; Poste and
Fidler, 1980; Alexander, 1982).
Increasing awareness of the nature and complexity of
the metastatic disease process has also contributed to the
growing realisation that the biological nature of a tumour
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probably determines cure rates more than the type and
extent of local therapy and has correspondingly led to
greater conservatism in the use of radical surgery
(Forrest, 1976) as well as a re-assessment of the timing of
and indications for adjuvant therapy (Fisher, 1984).
2. The Natural History of Colorectal Carcinoma
Colorectal carcinoma, is the second most common cancer
in the western world (Doll, 1972) and accounts for about
one sixth of malignant disease in the U.K. The basis of
treatment is surgical resection. Estimates of the crude 5
year survival figure for patients presenting with colo¬
rectal cancer over the past 30 years have ranged from
approximately 25-45% (eg. Grinnell, 1953; Donaldson and
Welch, 1974 and Corman et al, 1979). A recent estimate
from the U.S. National Cancer Institute Surveillance,
Epidemiology and End Results Programme Update quoted a 5
year survival figure of just less than 50% (Cancer
Statistics, 1984). In these series approximately 20% of
patients already have disseminated disease at the time of
initial presentation and a further 5-10% have extensive
local disease which prevents curative resection. The 5
year survival however in the approximately 75% of patients
undergoing apparently-curative resection is only of the
order of 50-60%, with the majority of deaths occurring
within 2-3 years of surgery (Whittaker and Goligher, 1976;
Gill and Morris, 1978; Welch and Donaldson, 1978). Of
these patients undergoing apparently—curative resection
approximately 10-20% develop local recurrence, 20-30%
develop hepatic metastases and a further 5-10% develop
pulmonary metastases (Welch and Donaldson, 1978 and
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Hughes et al, 1981). Of these patients with recurrent
disease it is claimed that up to 20% may be cured by
further local resection or resection of hepatic or
pulmonary metastasis (August et al, 1984 and Hughes et al,
1981).
For those patients who have undergone apparently-
curative resection there is however at present no means of
predicting which patients will be cured and which will
ultimately develop a fatal recurrence of disease, although
many prognostic indices have been evaluated in this
context.
It is generally agreed that accurate and meaningful
staging of tumours is of the greatest importance in
interpreting and planning therapy (Beahrs and Myers, 1983
and International Union Against Cancer (UICC) TNM
classification, 1978). Current methods of tumour staging
are based largely upon anatomical and morphological
considerations. The most widely-used staging system in
colorectal carcinoma is based on that originally proposed
by Dukes (Dukes, 1932), initially in the context of rectal
carcinoma, where three stages of varying prognostic
significance were described based on the extent of tumour
invasion through the bowel wall and spread beyond. In this
system stage A describes tumour limited to within the bowel
wall, stage B describes extension to extra-rectal tissues
and stage C describes the presence of metastatic tumour in
regional lymph nodes. Various modifications of this system
have been subsequently described which to some extent have
also had the effect of confusing the interpretation of the
prognostic significance of this staging system (Phillips
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et al, 1984). These include that by Astler and Coller
(Astler and Coller, 1954) which subdivided stage B into B1
describing tumour extending into but not penetrating the
muscularis propria and B2 describing penetration of the
muscularis propria, as well as sub-divisions of stage C
into CI describing tumour limited to the wall but without
nodal involvement and C2 where tumour has penetrated
through the bowel wall in conjunction with involvement of
lymph nodes. Further variations of this Astler-Coller
staging have also been proposed (Gunderson and Sosin, 1974)
and a further category (Dukes D) is widely used to describe
the presence of metastatic disease. Although Dukes'
staging has been of some use clinically it has been long
recognised that this classification provides no more than a
relatively crude indication of prognostic probability
(Woods, 1980; Finlay and McArdle, 1982) and the clinical
outcome for patients within the differing stages may vary
significantly. Indeed, in the original series reported by
Dukes (Dukes, 1932) the 5 year survival of patients in his
group B was approximately 80%, but approximately 30% of the
patients in group C also survived 5 years. The other
prognostic index routinely employed is that of tumour
morphology. It has long been known that in general
poorly-differentiated tumours have a worse prognosis than
the well-differentiated ones (Grinnell,1939). However this
correlation with prognosis is also only very broad and
marked inconsistencies occur between the degree of tumour
differentiation and clinical outcome (Finlay and McArdle,
1982). The presence of perineural and in particular venous
invasion by the primary tumour has also been shown to be
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generally associated with a worsened prognosis (Talbot et
al, 1980). Measurement of serum levels of carcinoembryonic
antigen (CEA), despite initial enthusiasm regarding its
potential as prognostic index (NIH Consensus Statement,
1981), is not widely performed since it has been clearly
shown that the presence of elevated pre-operative levels do
not correlate with clinical outcome (Lewi et al, 1984), and
that subsequent elevations are not an invariable feature of
advanced recurrent or disseminated disease (Finlay and
McArdle, 1983) nor do they distinguish between these forms
of recurrence (Hine and Dykes, 1984). Studies of ploidy in
these tumours have shown in general an inverse relation
between increasing the degrees of aneuploidy and survival
although this is not absolute (Wolley et al, 1982 and
Rognum et al, 1983).
A number of other features of these tumours or of the
host response to them which are associated with worsened
prognosis have been described although none of them are of
absolute prognostic value individually. These include
tumour site, with rectal carcinomas in general having a
worse prognosis than colonic overall, and those of the
transverse and descending colon having a worse prognosis
than those of ascending colon and sigmoid colon. A
worsened prognosis is also seen in those tumours with a
reduced infiltrate of lymphocytes and plasma cells and with
decreased sinus histiocytosis and presence of para-cortical
immunoblasts in regional lymph nodes (Moertel and Thynne,
1982). Studies using a leucocyte adherence inhibition
test, initially thought to be of some prognostic value,
failed to distinguish clearly between prognostic categories
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(Ichiki et al, 1980). Studies of the length of the mucosal
transitional zone of increased intestinal crypt depth,
known to be associated with colo-rectal carcinomas, showed
a significant negative correlation with early Dukes' stages
but were apparently unable to distinguish prognostic
categories of more advanced disease (Greaves et al, 1980).
Other studies of features of possible prognostic
significance have included that of the demonstration of
circulating tumour cells in the mesenteric venous blood
draining colorectal carcinomas (Fisher and Turnbull, 1955)
although some doubt has subseguently been cast on the
validity of such studies due to inaccuracies in the
identification of cancer cells (Weiss, 1977). This can not
in any case be correlated with clinical outcome (Griffiths
et al, 1973; Salisbury, 1975). Other studies of tumour
characteristics have included that of the anomalous
expression of HLA-DR (class II major histocompatability)
antigens. In one study this could not obviously be related
to histological appearance (Daar et al, 1982 and Fabre,
1982) although in another study a more homogeneous staining
pattern was apparent in more poorly-differentiated tumours
although there was no clear relationship with overall
survival (Rognum et al, 1983). Expression of immuno¬
globulin secretory component (SC) is in general more
uniform and widespread in lower grade and stage carcinomas
although the prognostic value of reactivity is apparently
limited by the substantial heterogeneity of tumours in
their reactivity (Isaacson, 1982 and Arends, 1984a). It
has been suggested that variation in cell kinetic
parameters might be related to the behaviour of these
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tumours although one study reported was unable to confirm
this (Bleiberg et al, 1984). Expression of the gastro¬
intestinal carcinoma-associated antigen (GICA) is not
apparently related to prognosis as an independent parameter
(Arends, 1984b). Similarly, production of plasminogen
activator (PA) in these tumours although increased relative
to normal tissue (Corasanti et al, 1980), cannot be related
consistently to prognosis. Study of components of
epithelial basement membrane showed that no prognostic
significance could be related to the presence of fibro-
nectin in and around tumours but, interestingly, the amount
of laminin was shown to be, in general, greater in
low-grade tumours and inversely correlated with subsequent
development of metastatic disease and therefore with
increased survival (Forster et al, 1984).
3. Metastasis in Colorectal Carcinoma
Although it has long been known that the presence of
metastatic disease at the time of clinical presentation in
colorectal carcinoma is associated with a dire prognosis,
the median survival being only of the order of 6 months
(Bengtsson et al, 1981), it has been difficult to assess
the presence or absence of metastatic disease at initial
presentation as an independent prognostic factor since it
is well known from post-mortem studies of patients dying
post-operatively (Goligher, 1941) that its incidence has
been considerably underdiagnosed clinically. More recent
studies however using improved diagnostic techniques such
as the administration of radiolabelled microspheres (Mooney
et al, 1981) and computerised tomography (CT) (Finlay and
McArdle, 1982) have revealed an incidence of "occult"
J. o
hepatic metastases in about 30% of patients undergoing
apparently-curative resection. Follow-up of these patients
showed the presence of metastatic disease at the time of
clinical presentation to be in fact the most critical
prognostic factor regardless of Dukes' staging and that it
accounted almost entirely for the anticipated pattern of
mortality (Finlay and McArdle, 1982). In that study there
was a mortality of only 5% following apparently-curative
resection due to local disease but, most interestingly, no
further hepatic metastases were seen to develop following
surgical resection. Use of sequential CT scanning
furthermore has made it possible to study the rate of
growth of these metastases. This has shown that they
display Gompertzian growth kinetics (ie. characterised by
an increasing doubling time with growth) as has previously
been demonstrated for both experimental and human tumours
(Steel, 1982). Extrapolation based on that data showed
that the metastases had been in fact present for a mean
period of some 3 years prior to surgery (Finlay et al,
1982). This would be consistent with suggestions that
metastases may well develop at a time very close to the
establishment of a primary tumour beyond an in-situ state
(Franks, 1973; Fisher, 1984). It also raises the
possibility that these tumours may behave from an early
stage in their natural history as either metastasizing or
non-metastasizing variants, only indirectly related to the
extent of their anatomic spread.
Although satisfactory chemotherapeutic agents are not
yet available for this disease, those patients with
metastatic disease obviously constitute a high-risk group
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who ought to be considered for further therapy such as
regional administration of cytotoxic drugs (Taylor, 1981).
Experimental immunotherapy of patients with advanced
disease using autologous vaccines consisting of
X-irradiated, viable tumour cells admixed with BCG is also
being currently evaluated for these tumours (Hoover, 1984).
Similarly, identification of patients who have been cured
by surgery or who develop only localised recurrent disease,
which is at least partially-responsive to local radio¬
therapy (Moertel and Thynne, 1982), would be desirable.
Although the use of CT scanning would appear to be useful
it is expensive, time-consuming and only approximately
accurate, being associated with both false negatives and
positives (Finlay and McArdle, 1982; Koehler et al, 1984).
The phenotypic determinants however, or, possibly, features
of a host response which might be responsible for such
variation in the behaviour of tumours remain poorly-
understood and there is in particular no precise means of
predicting the metastatic potential of a tumour, clearly of
importance in addressing these therapeutic issues.
4. Approaches to the Study of Metastasis
Despite increasing refinement and sophistication of
investigative techniques the study of metastasis has
advanced conceptually little beyond the hypothesis of Paget
(Paget, 1889) describing the process in terms of the
property of "seeds" and "soil".
Any experimental and especially quantitative study of
metastasis, which is an exclusively in vivo phenomenon, is
complicated by the lack of suitable models, since few
tumours in experimental animals metastasize and no useful
animal system yields quantitatively predictable metastases,
and amongst transplantable tumours very few metastasize.
Furthermore, the applicability to the clinical situation of
results derived from highly artificial in vivo-in vitro
experimental systems is open to serious doubt (Weiss, 1977;
Hewitt, 1978; Rockwell, 1980; Fisher, 1984). This is
compounded by the fact that in normal situations such as
embryogenesis, as is well recognised, local tissue
environment is important in determining subsequent
development (Tarin, 1976 and Sherbet, 1982), and the
existence of possible "tissue phenotypes" (Pitts, 1980) may
be of critical importance in the development of neoplasia.
The properties of tumour cells themselves have been
the subject of extensive investigation, although the exact
relevance of such observations as have been made to the
processes of invasion and in particular metastasis remain
in most cases, unclear (Carter, 1976; Fisher, 1984).
The morphology of the constituent cells of a malignant
tumour gives, in general, as mentioned in the context of
colorectal carcinoma, some indication of its metastatic
propensity, with poorly-differentiated tumours being in
general more likely to metastasize than those which are
well-differentiated (Glucksmann, 1948) although this is far
from consistent.
Non-morphological criteria of metastatic propensity
remain poorly defined. Study of variation in cell kinetics
between the tumours has shown correlations between the
rapidity of doubling time and risk of development of
metastasis (Slack and Bross, 1975). This however may
simply be due to a higher growth rate .in both primary and
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secondary tumour since rapid growth may also be seen in
benign tumours, e.g. giant fibroadenoma of the breast,
which do not metastasize. In addition, certain carcinomas
of e.g. thyroid, prostate and kidney which have relatively
long doubling times produce metastases with a high
frequency.
The cell surface of neoplastic cells has been
particularly closely studied on the assumption that their
behaviour may be mediated thereby through interaction with
the extra-cellular environment. Changes in almost all
aspects of the cell surface have been described in relation
to malignant transformation (Nicolson and Poste, 1976).
Attempts to relate these changes to the metastatic
potential of different tumour cells however have been in
general unrewarding and at times contradictory, different
changes varying apparently in relation to different
experimental systems. At best, guantitative changes have
been observed in tumour cells of differing metastatic
capability and no consistent biochemical changes have so
far been identified in relation to a metastatic phenotype
(Guy et al, 1979; Raz et al, 1980; Steck and Nicolson, 1983
and Steele et al, 1983). The involvement of tumour cell
surface changes in the metastatic process has however been
demonstrated by various approaches. These include
modification of cell-surface properties by e.g. enzymatic
means which has shown some alteration of experimental
tumour cell metastatic capability following trypsinisation
(Sargent et al, 1983). Similarly, use of the glycosylation
inhibitor tunicamycin in B16 melanoma cells causes
biosynthetic alterations of cell-surface glycoproteins and
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causes both morphological and adhesive changes with
consequent reduction in metastatic capability (Irimura
et al, 1981). These changes were also shown to be
correlated with the loss of a specific class of B16 sialo-
galacto-protein. Further experimental evidence implicating
cell surfaces in metastatic colonisation potential comes
from experiments using shed plasma-membrane vesicles from a
highly-metastatic B16 cell line to modify a low-metastatic
cell line by surface membrane fusion which conferred an
increased metastatic ability onto the originally low-
metastasizing sub-line (Poste and Nicolson, 1980). Overall
differences in cell surface characteristics have also been
implicated relative to separability by density gradient
centrifugation of cells of different lung colonisation
potential (Grdina et al, 1977).
Study, mostly in vitro, of defined tumour cell
populations of known metastatic capability have also been
undertaken on the assumption that such changes may reflect
phenotypic characteristics related to metastases. These
have included study of cell-surface glycoproteins which are
thought to play a particularly important role in cell
behaviour. These have been studied by e.g. assays of
radiolabelled lectin binding to specific cell-surface
glycoproteins (Nicolson, 1982) and in certain model
systems, notably the B16 melanoma, some changes in
metastatic cell-surface proteins have been shown, e.g. in
brain metastasizing melanoma sub-lines (Brunson et al,
1978).
Similarly changes in the expression of carbohydrates
on cell-surface glycoproteins in cells, of differing
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metastatic capability have been seen e.g. in an
experimental model using murine lymphoma cells (Cheingsong-
Popov et al, 1983). In addition, guantitation of the
neuraminidase-accessibility of cell-surface sialyl residues
have shown changes apparently correlated with metastatic
capability in some systems (Yogeeswaran and Salk, 1981)
although this does not seem to be a general feature of
other systems and this finding contradicts other studies
(e.g. Raz et al, 1980).
The study of glycolipids in highly metastatic cells
has revealed changes in certain species although the
changes in general seem to be complex and non-specific
(Nicolson, 1982). One study however, using high-resolution
nuclear magnetic resonance (NMR) has claimed that in one in
vitro model system at least a highly-metastatic cell line
was associated with an increased ratio of cholesterol to
phospholipids and an increased amount of plasma membrane-
bound cholesterol ester. (Mountford et al, 1984).
Study of the adhesive properties of metastatic cells
have also been undertaken since this may be obviously of
considerable importance in determining the metastatic
potential of tumour cells as well as of their organ
preferences (Nicolson, 1982). In experimental studies
using B16 melanoma cells, monoclonal antibodies which block
adhesion of these cells to tissue culture plastic can also
be used to abrogate their metastatic potential (Vollmers
and Birchmeier, 1983). Other studies using shear-
techniques in model systems have similarly, demonstrated
differences in adhesive properties between cell lines of
different metastatic potential (Elvin and Evans, 1984).
Study of cell deformability, possibly of much
importance in permitting tumour cells to partake in the
metastatic process, has also been studied in vitro using
the B16 melanoma system (Raz and Ben Ze-ev, 1983). It was
found in this study that growth of melanoma cell lines of
low metastatic potential in vitro in spherical
configuration on a non-adhesive substrate showed a marked
increase in the metastatic capability of those cells as
compared to those grown as a monolayer in a flat con¬
figuration. This was accompanied by a marked decrease in
synthesis of the intermediate filament vimentin. Further
study using the B16 melanoma model also demonstrated an
apparent correlation of intracellular cyclic AMP (cAMP)
accumulation with capacity for experimental metastasis and
it may be that, at least in this system, cAMP metabolism i
linked with biochemical pathways responsible for the
generation of metastasis (Sheppard et al, 1984).
Study of the production of gap junctions in tumour
cells has shown this to be variably disorderd (Loewenstein
1979) although a relationship of this to the metastatic
potential of tumour cells has not been demonstrated (Pauli
et al, 1978).
Study of the production of a variety of, mostly
degradative, enzymes in tumour cells has revealed a large
number of changes many of which are doubtlessly important
in metastasis. As with many other features of the
metastatic process, their production may be considered
individually as probably necessary but not sufficient.
Thus, differences in production of these enzymes has not
been convincingly correlated with metastatic potential
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(Nicolson, 1982). These enzymes may be important in
breaking down the extra-cellular matrix and surrounding
tissue as well as perhaps activating host enzymes. High
levels of proteases, especially collagenases, are usually
present in invasive tumours and metastatic potential has
been experimentally related to degradation of basement
membrane collagen (Liotta et al, 1980) whilst its absence
has been correlated with a low-metastasizing experimental
tumour (Tarin et al, 1982). This enzyme may be
particularly important in degrading components of
epithelial and endothelial basal lamina and abnormalities
of the presence of e.g. laminin have been reported to be
associated with adverse prognosis in colorectal carcinoma
(Forster et al, 1984). Other lysosomal proteases such as
cathepsin B may also be important in this context. The
serine protease plasminogen activator has also been shown
to be present in general in high levels in tumour cells
including human colorectal carcinoma (Corasanti et al,
1980) although apparently the levels of this enzyme in a
variety of systems cannot be correlated with metastatic
potential (Nicolson, 1982). Its important role in
fibrinolysis however, may also implicate it in the
phenomenom of platelet aggregation around tumour cells
which has, in some cases at least, been shown to be
associated with increased metastatic potential of tumour
cells lines (Perlstein et al, 1980).
A variety of other products have been shown to be
released from tumour cells which may be of importance in
their successful completion of the metastatic process.
These may include e.g. tumour antigens., the shedding of
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which may represent a means of evading host tumour
responses (Woodruff, 1982). Tumours are also known to
secrete substances such as prostaglandins which may affect
processes such as bone resorption, macrophage function and
platelet aggregation (Nicolson, 1982). The production
e.g. of prostaglandin D2 in the B16 melanoma system
correlates with metastatic potential (Fitzpatrick and
Stringfellow, 1979). Similarly secretion of substances
such as osteoclast-activating factor may be of importance
in determining the survival of metastases (Carter, 1976).
The production of angiogenesis factor by both primary and
secondary tumour cells is clearly of great importance in
order to produce neovascularisation (Folkman, 1982).
However, abnormal production of this factor is by no means
exclusively associated even with malignancy and has also
been shown in premalignant breast disease (Jensen, 1982).
It would thus appear that, as with many features of
malignancy, phenotypic alterations important in metastasis
may represent abnormalities of only a quantitative or
temporal rather than absolute nature.
5. The Relation of Phenotypic Variation in Primary
Tumours to Metastasis.
Evaluation of any tumour cell characteristic in
relation to metastatic potential would clearly be
complicated if it is heterogeneously expressed among the
cell population of the primary tumour. It is generally
accepted that most spontaneously-occurring human tumours
are monoclonal in origin, this having been most notably
demonstrated by studies of the X-linked heterozygosity of
black women for the two forms of the enzyme glucose-6-
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phosphate dehydrogenase, only one form of which is
expressed in any somatic cell (Fialkow, 1976). This
proposition is further supported by the finding of
consistent karyotypic abnormalities in certain leukaemias
and by the production of monotypic immunoglobulins in
plasma cell myelomas. It has however long been recognised
that tumours may undergo progression of various
characteristics (Foulds, 1969). It has been further
suggested that such progression and generation of pheno-
typic diversity occurs as a consequence of the well-
recognised genetic instability of malignant tumour cells
(Nowell, 1976). Thus, phenotypic heterogeneity of both
primary tumours and their metastases has been demonstrated
for a variety of characteristics (Woodruff, 1983). These
include ploidy measurements in primary and metastatic
tumour (Rabotti, 1959), expression of oestrogen receptors
in breast cancer (Holdaway and Bowditch, 1983) cell DNA
content in small-cell carcinoma of lung as measured by
flow cytometry (Vindelov et al, 1980) and of a variety of
biochemical markers and cell-surface antigens in the same
tumour (Minna et al, 1982; Baylin et al, 1978).
Quantitative study of tumour cell nuclear DNA content in
different primary breast tumours and their metastases
showed however similar patterns in the different sites
suggesting a homogeneity of cell populations for a primary
tumour and its secondaries (Auer et al, 1980). In vitro
characterisation of cloned cell lines from a primary colon
carcinoma has also shown variation of growth rates and of
histological appearance (Brattain et al, 1981). Hetero¬
geneity of cell-surface antigen expression has been
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observed in e.g. cell lines established from various
melanoma metastases where variation in pigmentation and
expression of HLA-DR antigens was also observed (Albino et
al, 1981) as well as in expression of the Ca antigen in
various tumours (McGee et al, 1982). Variation in
immunological characteristics of tumour cell sub-
populations has also been observed (e.g. Miller and
Heppner, 1979). Of some therapeutic importance also is the
observation of heterogeneity of responsiveness to
chemotherapy observed in various clinical and experimental
tumours and their metastases (Donelli et al, 1977; Sch.lag
and Schreml, 1982).
It has furthermore been suggested on the basis of
experimental work using in vitro-in vivo animal models,
initially with the B16 mouse melanoma tumour (Fidler and
Kripke, 1977), that primary malignant tumours are also
heterogeneous with respect to the metastatic potential of
cell sub-populations within this tumour. This proposition
was initially based on tumour cell cloning experiments from
a transplanted B16 melanoma when individual clones were
compared for their metastatic potential and it was found
that experimental lung colonisation varied widely between
cloned B16 cell populations. Using this model it was
demonstrated that the metastatic heterogeneity between
different cell clones was not produced by the cloning
procedures and it was concluded that some cells with a
higher metastatic potential existed within the parental B16
tumour (Fidler and Kripke, 1977). Similar results have
been obtained by different investigators using different
tumour types e.g. lymphosarcoma (Nicolson et al, 1981),
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carcinoma (Talmadge et al, 1981) and sarcoma (Chambers et
al, 1981). Variant metastatic cell sub-populations have
thus been obtained by selection procedures either in vivo
or j-n vitro and the implications of these findings as
regards such a hypothesis are propounded by various of
these authors (e.g. Poste and Fidler, 1980; Hart and
Fidler, 1981). Other investigators however, using
different model systems have failed to confirm these
findings and have shown that random selections of cell
populations from primary tumours have comparable metastatic
potential and that, in particular, biopsies of metastasis
showed a comparable potential, although one of the
implications of the sub-population hypothesis would be that
a selected metastatic population should have a higher
overall metastatic capability (Tarin and Price, 1979;
Giavazzi et al, 1980; Weiss et al, 1983 and Alexander,
1983). The criticism has also been voiced (e.g. Alexander,
1983) that the sub-population hypothesis as regards
metastatic potential of a primary tumour is based entirely
upon experiments in which in vitro cloning procedures were
used prior to tumour cell inoculation. This procedure may
well vitiate interpretation of such results since it is
well known that cells in culture undergo phenotypic drift
and this has also been shown in the context of metastatic
properties (Neri and Nicolson, 1981; Tveit and Pihl,
1981). Interestingly, in this context it has also been
shown using B16 melanoma lines that propagation in culture
of mixed cell lines appears to have the effect of
conferring an overall phenotypic stability on the cell
populations although when cloned individually the cell
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lines give rise to clones of highly variable metastatic
potential (Poste et al, 1981).
So far, therefore, there appears to be no direct
evidence for the applicability of any hypothesis regarding
metastatic heterogeneity in spontaneously-arising human
primary tumours although clearly only a relatively small
proportion of the cells in any tumour will be clonogenic.
In colorectal carcinoma this has been estimated to be of
the order of 15% (Wright, 1984). In addition, as mentioned
previously, there now appears to be good evidence that
colorectal carcinoma behaves consistently overall from an
early stage in its natural history as metastasising or non-
metastasis ing variants.
6. Study of Host Response in Metastasis
Tumour metastasis can be shown at least in
experimental systems to be influenced by host local tissue
factors at the site of metastasis (Milas, 1984). It may be
that variation in e.g. the reaction of stromal cells and
the production of a tumour capsule may be of importance in
determining the successful growth of metastatic deposits.
It has been clearly shown that local tissue damage,
inflammation, as well as hormonal microenvironment may
influence the outcome of tumour metastasis. Experimental
metastasis of a mammary carcinoma cell line in nude mice is
for example increased by the administration of exogenous
oestrogens. An increased incidence of experimental
metastases has been shown at sites of tissue trauma or
inflammation, following radiotherapy and hormonal treatment
(Milas, 1984). It has however not been shown that
variation in such host response is of importance in
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determining variation in the incidence of tumour metastases
in human tumours.
In the investigation of possible host factors involved
in determining the outcome of the metastatic process,
study has been principally directed towards possible host
immune response and over recent years has produced a vast
and contradictory literature the full implications of which
are not yet clear (Alexander, 1982; Woodruff, 1982 and
Lachmann, 1984). Much of this study was based on the,
initially widely-accepted, immune-surveillance hypothesis
which attributed a host resistance to tumours through the
destruction of immunogenic tumours by mature immune
T-lymphocytes (Burnet, 1970). This theory however has
been subject to considerable criticism in recent years
(Prehn, 1977; Poste and Fidler, 1980; Lachmann, 1984) and
although it has long been known that many experimentally-
induced tumours in animals carry tumour-specific
transplantation antigens (Alexander, 1982),it has not been
convincingly shown that spontaneously-arising human tumours
posess any or significant immunogenicity (Prehn, 1977;
Hewitt, 1978; Klein and Klein, 1977; Lachmann, 1984) and in
general the attempt to define human tumour-specific
antigens has not been successful (Old, 1981). Furthermore
it has not been shown that patients suffering from
deficiencies of either specific or non-specific immune
mechanisms nor those immune-depressed or suppressed develop
a greater than expected incidence of the majority of tumour
types. Thus, although variation in the outcome of tumour
metastases has been shown in a number of experimental
animal tumour systems, where, incidentally, manipulation of
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immune responses may result in either increases or
decreases in the incidence of metastases (Nicolson, 1984;
Alexander, 1982), it is not clear how far, if at all, such
data can be extrapolated to human tumours (Alexander, 1982;
Lachmann, 1984).
The failure to demonstrate such mechanisms does not of
course preclude their existance (Woodruff, 1982) and it may
be that this represents some immune selection or escape
mechanisms possibly involving antigen "shedding" and immune
complexes which may act as blocking factors. Such a
phenomenon has been demonstrated in vitro where it can be
shown that tumour-bearing animals lymphocytes demonstrate
positive cytotoxicity which can be blocked by their serum
(Lachmann, 1984). It may also be the case that in the
early stages of tumour development or in weakly-antigenic
tumours a weak stimulatory anti-tumour response may occur
which may have the effect of stimulating the growth of
tumours rather than suppressing it, a phenomenon which has
been described as "sneaking through" (Prehn, 1972).
Changes in cell-surface antigen expression between
metastatic deposits and a primary tumour have been
described in experimental systems (Schirrmacher and
Bosslet, 1980) in a murine lymphoma although such antigen
loss does not appear to be a common characteristic of
metastatic cells (Nicolson, 1984).
More recent work has concentrated on the possible role
of non-adaptive immune responses in determining the outcome
of metastases. These include the role of armed or
tumouricidal macrophages which are frequently found in the
context of primary tumours and which are experimentally
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demonstrable to have tumouricidal properties. However
there appears to be no direct evidence that their presence
plays a significant role in the outcome of the metastatic
process (Alexander, 1976). It has also been postulated
that natural killer (NK) cells may be effective against
metastatic cells during their transport in the circulatory
system, and in many experimental models levels of NK
activity correlates inversely with subsequent formation of
metastases. It has thus been shown experimentally for
example that resistance to leukaemia in mice is associated
with a high NK cell phenotype and that grafting of high NK
bone marrow to deficient animals confers an increased
resistance (Karre et al, 1980; Warner and Dennert, 1982).
Similarly it has been shown that in a spontaneously-
occurring mammary carcinoma of rats that tumour cells in
metastatic deposits possessed a higher resistance to
NK-mediated cytolytic killing (Brooks et al, 1981). Again
there is no direct evidence of the involvement of these
mechanisms in the development of metastases in human
tumours and the evidence in favour of this view remains
circumstantial (Lachmann, 1984). It is also of interest to
note that deficiencies of these non-adaptive immune
mechanisms are associated with problems with infections and
immune-complex disease rather than with the development of
tumours (Lachmann, 1984).
Study of alterations in the expression of membrane-
associated antigenic determinants encoded by the major
histocompatibility complex (MHC) in various experimental
systems (Katzav et al, 1983 and Eisenbach et al, 1983) has
however provided further suggestive evidence for the
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importance of host-tumour cell interaction in determining
the outcome of the metastatic process. It is well-known
that these antigens play a critical role in the elicitation
of immune responses against cell surface antigens of both
virus-infected and some malignant cells (Stutman and Shen,
1978) and it has thus been postulated that variable
expression of MHC components expressed on neoplastic cells
may determine host-tumour immune relationships and thereby
affect the capability of tumour cells to evade immune
destruction and subsequently generate metastases. How far
the phenotypic shifts seen in the expression of the murine
H2 locus are paralleled by events in spontaneous human
tumourigenesis, particularly in the context of metastasis,
are however not clear, although, as mentioned in the
context of colorectal carcinoma, anomalous expression of
HLA-DR antigens of the MHC class II has been observed in
various primary tumours.
There appears therefore as yet to be no conclusive
evidence that any host immune response, still poorly
understood, plays a critical role in controlling the
development of human tumours or more particularly that of
their metastases.
7. Predictive Assays for Metastasis
There is no clinically-useful biological assay system
currently available for predicting the metastatic potential
of a primary tumour. In vitro-in vivo models have been
developed for the study of tumour invasion using techniques
such as inoculation adjacent to rat femurs (Pauli et al,
1980) or invasion of tumour cells into precultured
fragments of embryonic chick cardiac muscle (Mareel, 1984)
which may be able to define features of tumour cell
invasiveness which are important in the formation of
metastasis. Use of a clonal assay using a bi-layer Agar
system has also been used to successfully culture clono-
genic tumour cells including metastatic melanoma (Meyskens
et al, 1981). A test based on subjective "epigenetic
grading" of the cellular responses of relatively
undifferentiated chick embryo blastoderms following
implantation of tumour cells was able to distinguish
experimentally metastasizing and non-metastasizing
(essentially benign) forms of a hamster lymphosarcoma
(Sherbet et al, 1980). A similar model for the assay of
metastasis using a chick chorio-allantoic membrane in which
an increased incidence of metastasis generally correlates
with tumour size on the membrane has also been reported
(Ossowski and Reich, 1980). Preliminary data have also
been obtained using a variety of human tumour biopsies,
including colorectal carcinoma, for injection into athymic
nude mice (Hart, 1984). Variable factors such as site of
injection and the hormonal status of the recipient mice
appear to have significant effects on the metastatic
behaviour of the tumour although it appears that the most
important factor is the intrinsic character of the tumour
cells themselves. It is however not yet clear whether such
a test can be used to predict the behaviour of primary
human tumours. Evaluation of such biological assays
appears to be generally very subjective, the results are
highly empirical and they do not so far appear to have
applicability as useful, routine prognostic tests.
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8. Molecular Approaches to the Study of Cell Phenotype:
General Considerations
Different cell types are distinguished by both
qualitative and quantitative differences in their protein
content. These arise as a result of variation in the
transcription, processing, stability and translation of
cellular messenger RNA (mRNA), and steady-state levels of
mRNA constitute the principal determinant of phenotypic
differences between cells (for reviews see Lewin, 1980;
Perry, 1981; Brown, 1981; Darnell, 1982; Alberts et al,
1983 and Nevins, 1983). It has been estimated that in
typical eukaryotic cells, with the exception of neural
cells, there exist some 10,000-20,000 individual mRNA
species each present at markedly-different copy numbers.
These are generally divided into three categories
corresponding to those of high-, moderate- and low-
abundance (Lewin, 1980; Williams, 1981; Alberts et al,
1983). The low-abundance mRNAs comprise the vast majority
with approximately 10,000 different species which are
present at only 5-15 molecules per cell. A further
500-1,000 species are present at a moderate abundance of
several hundred copies per cell and relatively few species,
approximately 5-10, are present at a high-abundance of
several thousand copies per cell. It is clear that a
typical eukaryotic cell contains therefore several hundred
thousand RNA molecules representing the 10,000-20,000
different RNA species present.
Comparison of total mRNA populations by hybridisation
analysis has shown clear, although often subtle,
differences overall in different normal cell types
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(Young et al, 1976; Hastie and Held, 1978), in cells at
different stages of development e.g. during myogenesis
(Affara et al, 1977) and in normal compared to regenerating
rat liver (Wilkes et al, 1979) as well as in virally-
transformed cells (Williams et al, 1977), in normal
compared to neoplastic rat liver (Jacobs and Birnie, 1980)
and between normal and neoplastic rat mammary tissue
(Supowit and Rosen, 1980). Although overall differences in
the steady-state transcription levels of mRNA populations
may be detected by hybridisation analysis such an approach
is relatively crude since possibly-significant differences
in the abundances of individual mRNAs may be obscured.
However recent developments in molecular cloning techniques
have made possible the study of, at least moderately-and
highly-abundant, individual mRNAs. (See below).
Variations in the steady-state levels of different
mRNA species are held to be the overall result of variation
in the series of steps (described below) which constitute
RNA biosynthesis, the exact contribution of each of which
is not yet fully understood but of which transcriptional
control (see Tobin, 1979) is thought to be by far the most
important although the importance of the role played by
variation in e.g. message stability and translation is also
becoming increasingly apparent.
9. RNA Biosynthesis
(For reviews see Lewin, 1980; Perry, 1981; Brown,
1981; Darnell, 1982; Alberts et al, 1983 and Nevins, 1983).
Transcription of eukaryotic RNA from its DNA templates
catalysed by three distinct RNA polymerase enzymes (I-III)
which are involved in transcription of.ribosomal (pol I),
33
messenger (pol II) and of 5S ribosomal and transfer
(pol III) RNA respectively. Control of transcription as
judged by the rate of synthesis of nuclear RNA appears to
be the most important level of control. Although the
details of these mechanisms are not yet fully understood it
is thought that site-specific binding proteins may either
alter chromatin structure or facilitate or prevent the
attachment of RNA polymerases to specific sites of the DNA.
Generation of a primary transcript occurs from a region of
the genome described as a transcriptional unit which
contains the appropriate signals for initiation and
termination of transcription. These units may be described
as simple or complex depending on whether they have the
potential to generate single or multiple proteins. The
transcription start site is located around a codon of AUG
and is at the sequence specifying the 5' terminus which
ultimately generates the amino (NH2) terminus of the
protein. So far, however, recognisable sequences
representing a termination signal have not been defined.
Initiation of RNA synthesis by RNA polymerase requires also
the presence of further as yet poorly-characterised factors
as defined by in vitro assay systems.(Alberts et al, 1983
and Nevins, 1983). Transcription of mRNA from various
genes depends also on the, markedly-differing, efficiency
with which differing RNA polymerase II start sites
function.
Further elements acting on gene transcription include
a promotor region approximately 25-30 base pairs upstream
from the transcriptional start site, including the sequence
TATA known as the Goldberg-Hogness Box, and whose function
34
appears to be related to the accurate positioning of the
start of transcription. This sequence appears to be
analogous to the prokaryotic proraotor sequence known as the
Pribnow Box, which is required to initiate transcription,
although deletion of the TATA sequence does not abolish
transcription of eukaryotic genes (Rosenberg and Court,
1979). Further sequences known as enhancers have also been
described. These are usually present far upstream (200-300
nucleotides) from the site of transcription and are able to
confer high levels of expression on genes transcribed at
low levels and apparently act in a tissue-specific fashion.
They are able to act on heterologous genes in cis and
independently of position or orientation in in vitro
systems. They have been shown to be present in nucleosome-
free regions and it is thought that such a chromatin
structure, which is hypersensitive to the action of
nucleases, may also be associated with enhancer activity.
Such elements were first and most fully characterised in
viruses, notably Simian virus 40 (SV40), and were shown in
this context to be capable of acting in a wide variety of
tissues and hosts. The enhancer elements present in
retroviruses play in addition a critical role in onco¬
genesis. It has more recently been suggested however that
enhancer and the promotor elements overlap in fact, both
physically and functionally, and that these regulatory
elements are comprised of a modular arrangement of short
sequence motifs each with a specific function in conferring
inducibility, tissue-specificity or a general enhancement
of transcription. These appear to be binding sites for
nuclear proteins whose mechanism of action on chromatin is
not yet clear (Serfling et al, 1985; ReudelhUber, 1984).
These would include positive and negative regulatory
elements as have been described e.g. in the context of
responsiveness to hormones, heavy metal ions, heat shock
or, negatively, as in the T antigen of the SV40 early
transcript. Such transcriptional control has been
demonstrated to be tissue-specific e.g. for liver-related
mRNA (Derman et al, 1981) and also e.g. for the expression
of ovalbumin RNA in chicken oviduct and non-target tissues
prior to hormonal stimulation where scarcely detectable
levels of transcription are observed, in contrast to the
thousands of cytoplasmic copies generated following
hormonal induction (Tsai et al, 1979). Variation in
transcription has also been demonstrated to be develop-
mentally regulated in e.g. Dictyostelium (Blumberg and
Lodish, 1980) and for myoglobin (Affara et al, 1977). It
should be noted that the existence of such control does not
of course preclude regulation at subsequent levels of
processing. Variation of the actual start site has also
been shown to be involved in differential tissue expression
e.g. in transcription of pancreatic and salivary mouse
alpha amylases (Hagenbuchle et al, 1981).
A specific transcription termination site has not yet
been identified although termination occurs downstream of
the 3* polyadenylation site and it is possible that
sequences beyond this participate in generating an RNA
cleavage site. Control of transcription at this point
could be important in transcriptional units encoding
multiple proteins as in e.g. the adenovirus late t
transcripts, immunoglobulin heavy p chadns and calcitonin
36
mRNA (Nevins, 1983). The frequently observed phenomenon of
premature termination of transcription, whose significance
is not yet understood, could also conceivably play a
regulatory role in transcription. At the 3' end of the
transcript in approximately one quarter of primary
transcripts a poly A tail of some 100-200 residues of
adenylic acid are added. This is catalysed by a further
poly A polymerase enzyme and occurs approximately 30 base
pairs downstream of a region which includes an AAUAAA
sequence whose exact significance is not understood but may
be spatially related to transcript cleavage and subsequent
poly A polymerisation. (Fitzgerald and Shenk, 1981). The
function of this poly A tract is not yet entirely clear but
is thought to be possibly related to processing and export
of the transcript and cytoplasmic stability of mRNA. This
represents a further possible regulatory step in tran¬
scription and differential poly A site selection appears to
occur for e.g. adenovirus major late proteins (Nevins,
1983). Further modifications of the RNA pol II primary
transcript include the internal methylation of
approximately 1/400 adenylate residues at the N^ position
and in the 2'0 ribose position of the penultimate
nucleotide throughout the RNA (Banerjee, 1980). The
significance of these modifications is not yet known. In
addition (probably before transcription is complete) a 7mG
cap at the 5' end of the transcript is also added whose
function is thought to lie probably in subsequent
initiation of translation through interaction with specific
proteins and binding to ribosomes. These modifications are
also possibly protective against exonupleolytic
37
degradation. Primary transcripts (known as heterogeneous
nuclear RNA-hnRNA - due to their variety of sizes) form
nuclear complexes with several proteins to form ribo-
nucleoprotein packages. This is thought to be important in
subsequent processing and transport. Only a small fraction
of these short-lived and unstable hnRNAs survive to become
stable cytoplasmic mRNA. The latter represents only
approximately 3% of the steady-state total cell RNA
although hnRNA accounts for more than a half of RNA tran¬
scription. The remaining approximately 97% is composed of
ribosomal RNA (Alberts et al, 1983).
Before mRNA is exported from the nucleus to the
cytoplasm, splicing of transcripts occurs which removes
non-coding intervening sequences or introns which are a
marked feature of eukaryotic genes in contrast to to those
of prokaryotes (Cech, 1983). This results in the
conversion of very long hnRNA to much shorter mRNA
molecules of some 500-3,000 nucleotides in length. Most
eukaryotic genes (with exceptions such as the histones and
alpha interferon) contain several and in some instances
(e.g. the alpha chain of procollagen) up to 50 such
introns. Their excision involves complexing to small
nuclear ribonucleoprotein particles (snRNP) which are a
minor component of ribonucleoproteins. These are
characterised by the presence of many small and ubiquitous
nuclear RNAs such as the U1 RNA (so-called due to the
abundant presence of uracyl nucleotides) which has been
shown to bind to 5' splice sites. Splicing is thought to
be accomplished by the enzymatic cleavage and ligation
reaction which removes the intron sequences by the
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production of a so-called lariat formation, whose three
dimensional conformation is probably of great importance,
and which leaves the coding sequences intact. In some
cases e.g. ribosomal and mitochondrial RNA it has been
shown that the excision and ligation process is catalysed
by the intron itself (Cech, 1983). Further snRNP molecules
may be involved in the direction of processing and in
guiding RNA molecules. Much of these intron sequences is
thought to represent random evolutionary material, although
certain highly conserved donor and acceptor splice sites
must also be present (Breathnach and Chambon, 1981). It is
also thought to be possible that the structure of the
introns themselves may be important in the generation of
different transcripts. One consequence of the presence of
multiple introns is that differential splicing patterns may
generate different protein products from the same primary
RNA transcripts. How this is controlled is not yet clear.
This has been demonstrated for adenovirus P16 major late
proteins where, in addition, differing 3' ends may be
generated by differential cleavage and adding of A at
different points (Ziff, 1980). Such mechanisms are also
involved in the generation of membrane and secreted forms
of immunoglobulin p heavy chains during the process of
lymphocyte differentiation (Early et al, 1980). Transport
of mRNA then occurs into the cytoplasm although only for
fully-processed molecules.
Regulation of gene expression may also occur due to
variation in the stability and half-life of cytoplasmic
mRNA molecules both for different specific mRNAs in the
same cell as well as variation in the half-life of the
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same mRNA species in a given cell type under different
circumstances. This has been shown for casein mRNA in
mammary glands whose mRNA copy number increases enormously
in rsponse to prolactin treatment and which is associated
with an approximately 20 fold increase in the half-life of
the mRNA (Guyette et al, 1979). In addition, specific
destruction of certain mRNA species appears to occur in
e.g. developing erythroblasts where globin is conserved
preferentially when non-globin RNAs appear to be destroyed
(Bastos et al, 1978). Similarly, during the development of
the slime-mould Dictyostelium, a new set of RNA species is
formed following cell aggregation but which is specifically
destroyed if its developmental cycle is interrupted
following aggregation (Chung et al, 1981). A further
extreme example of mRNA stability is the well-known
"masking" of mRNA in unfertilised sea-urchin eggs. This
RNA is capable of involvement in rapid protein synthesis
however following fertilisation (Brandhoest, 1976).
Thus, although steady-state cellular mRNA levels
reflect the outcome of various regulatory steps in RNA
biosynthesis and as such constitute the principal
determinant of cell phenotype, it is clear that variation
in those preceding steps as well, in particular, as in
subsequent translation may also have considerable
phenotypic significance.
10. Approaches to the Study of Individual mRNA Species:
Cloning of Complementary (c)DNA Libraries
Study of the molecular determinants of variation in
cell phenotype have been greatly advanced in recent years
by the use of techniques making possible the cloning of
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individual mRNA species into complementary (c)DNA libraries
(Old and Primrose, 1981; Williams, 1981; Maniatis et al,
1982). This has been made possible in large part by the
use of DNA recombinant and molecular cloning technology
based on the isolation of viral and bacterial enzymes used
for reverse transcription, ligation and cleavage of DNA
molecules and the use of both plasmid and bacteriophage as
vectors for recombinant molecules (Paul, 1982). Cloning
and characterisation of the approximately 10,000-20,000
individual mRNAs transcribed actively in a typical
eukaryotic cell clearly offers a greatly refined approach
to the characterisation of cellular phenotype. Such a
library can be much more easily screened than a comparable
genomic one which would contain approximately 100,000 to
1,000,000 fragments of clonable size, and in addition
yields far fewer false positives since every cDNA clone
contains an mRNA seguence (Williams, 1981). The number of
clones reguired to produce with a given probability a
certain cDNA clone can be calculated according to the
formula of Clarke and Charbon (Williams, 1981), and
predicts that to clone the majority of the abundant and
moderately-abundant mRNA species a library of some 1,000
clones would be reguired. In such libraries a cDNA clone
is a bacterial cell transformed by a plasmid containing a
DNA copy of an RNA molecule. These are created after the
synthesis of double-stranded DNA copies from polyadenylated
(poly A) RNA which are subsequently ligated into a
restriction enzyme cleavage-site within the plasmid
molecule. The plasmids used in cloning are genetically-
engineered derivatives of naturally occurring drug-
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resistance plasmids which contain sufficient genetic
information to ensure their own replication and to include
proteins which confer resistance to one or more
antibiotics. These properties are made use of in
subsequent screening procedures. Screening of such
libraries using radiolabelled reverse-transcribed cDNA
probes containing the sequences of interest may be
performed on bacterial colonies lysed in situ initially or
in secondary procedures using bulk preparations of plasmid
DNA. Such screening procedures permit detection of
sequences expressed at down to, at best, 0.1% of the mRNA
population (Williams, 1981). Detection of low-abundance
sequences however is very much more complicated due to very
low "signal to noise" ratios at these levels.
Isolation and characterisation of an individual cDNA
clone permits determination of its nucleotide sequence and
may be used to study its corresponding genomic clone if
available.
The use of such techniques has made it possible to
isolate cDNA clones representing mRNA sequences which are
differentially expressed in differing normal human tissues
(Crampton et al, 1980 and Affara et al, 1983), in cells at
different stages of development (Williams and Lloyd, 1979),
in virally-transformed cells in vitro (Scott et al, 1983)
in normal and neoplastic (experimentally-induced) mouse
colon (Augenlicht and Kobrin, 1982) and in normal and
neoplastic rat liver (Yamamoto et al, 1983). Such
techniques have also been used in a molecular approach to
the classification of human leukaemias by study of
differences in abundance of individual.mRNA sequences as
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defined by hybridisation with selected cDNA clones
(Wiedemann et al, 1983; Birnie et al, 1983).
11. The Molecular Pathology of Cancer;
General Considerations
It has long been assumed that somatic genetic mutation
and/or transposition and subseguent abnormalities of gene
expression play an important role in carcinogenesis
(Cairns, 1981 and Klein, 1981). Evidence for this has
included the fact that various forms of radiation and most
known carcinogens or their active metabolites are mutagens
(Poirier and DeSerres, 1979) as well as the demonstration
of tumour-specific chromosomal abnormalities, most notably
the so-called Philadelphia chromosome in chronic myeloid
leukaemia (Weiss and Marshall, 1984; Klein and Klein,
1984). Chromosomal abnormalities such as trisomy 7 and
12g- have also been reported at the premalignant stage in
colorectal cancer (Becher et al, 1983). These non-random
cytogenetic abnormalities have been further implicated in
carcinogenesis by their location, in many cases, at or near
chromosomal regions bearing cellular oncogenes (see below
and Yunis, 1983). Thus, in chronic myeloid leukaemia the
c- abl oncogene is translocated from chromosome 9 to 22
(de Klein et al, 1982) and in Burkitt's lymphoma the
c- myc oncogene is translocated from chromosome 8 to 14 and
juxtaposed to an active immunoglobulin locus (Dalla-Favera
et al, 1982). The documentation of heritable (LeBeau and
Rowley, 1984) and constitutive (Yunis and Soreng, 1984)
chromosomal "fragile" sites in cancer and their association
in some cases with such chromosomal rearrangements is of
further interest in this context. Such sites are evident
as non-stained gaps, usually on both chromatids, seen in
metaphase chromosome preparations. Their structure is not
understood but they are thought to represent chromosomal
segments which do not undergo normal compaction during
mitosis (LeBeau and Rowley, 1984). It may well be that
these "fragile" sites act as predisposing factors for
chromosomal rearrangements in cancer and that they bear
genes of importance in carcinogenesis. Further cytogenetic
abnormalities apparent as deletions and seen in association
with certain tumours e.g. with a hereditary component such
as Wilms' tumour (Koufos et al, 1984) and retinoblastoma
(Murphree and Benedict, 1984) have furthermore been adduced
as evidence for the existence of a group of tumour-
suppressor genes or "anti-oncogenes" whose function must be
lost in the process of carcinogenesis. Thus in the case of
retinoblastoma both alleles of the rb-1 gene on chromosome
13 are lost in the tumour cells (Murphree and Benedict,
1984). This evidence is consistent with earlier reports of
the suppression of tumourigenic behaviour in hybrids
derived from the fusion of malignant with normal cells
(e.g. Harris et al, 1969; Stanbridge et al, 1982).
Further evidence for a somatic mutation theory is
derived from the high incidence of cancer in patients
suffering from conditions such as xeroderma pigmentosum and
ataxia telangiectasia which are characterised by defects in
DNA repair mechanisms (Paterson, 1976).
Evidence does also exist that cancer may not always
involve irreversible mutation but rather epigenetic control
mechanisms, as in the well-documented case of apparent
normalisation of teratocarcinoma stem cells in chimaeric
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mice following their inoculation into blastocysts (Mintz
and Illmensee 1975 and Pierce et al, 1979). The increasing
weight of evidence however implicates genetic abnormalities
in the development of most tumours. Much of this has again
been provided through the recent application of DNA
recombinant and cloning techniques to isolate and
characterise individual genes involved in oncogenesis.
12. Oncogenes
The documentation in recent years of the activity of a
group of cellular oncogenes, first identified as homologues
of known oncogenic retroviruses (see Table 1, after Paul,
1984), has been contributing greatly to the understanding
of cancer at the molecular level (Bishop, 1983; Paul, 1984;
Weiss and Marshall, 1984). The concept of oncogenes was
first proposed in the context of animal tumour viruses when
it was suggested that such retroviral oncogenes might
reside dormant in the germ lines of all species (Huebner
and Todaro, 1969). It has however been consequently shown
that retroviral oncogenes have been derived by a process of
recombination and mutation from normal cellular proto-
oncogenes which appear to be highly conserved in evolution.
The use of cloned retroviral oncogene probes has shown
several such oncogenes to be the transforming genes in
biological transfection assays using tumour DNA to
transform NIH 3T3 fibroblasts in culture, and abnormal
oncogene activity at either a qualitative (e.g. point
mutations as in the case of ras ) or quantitative level
(e.g. increased expression of a normal gene product by
mechanisms such as gene amplification or chromosomal
translocation as in the case of myc ) h.as now been
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demonstrated in a variety of culture-derived and primary
human tumours (Cooper, 1984). Activated oncogenes have
also been detected in tumours induced experimentally by
agents such as radiation (Guerrero et al, 1984) or chemical
carcinogens (Sukumar et al, 1984; Balmain and Pragnell,
1983) confirming that their activation in carcinogenesis is
consistent with the pre-existing evidence from classical
experimental and epidemiological studies. Although
activated cellular oncogenes related to known retroviral
oncogenes were initially defined in terms of their ability
to transform 3T3 fibroblasts in culture, by no means all of
the cellular homologues of the retroviral oncogenes are
active in this assay which appears preferentially to
detect ras genes. In addition several further oncogenes
have been detected using this assay which do not appear to
be related or only distantly to any known viral oncogene
(e.g. B- lym and N- ras ). Precise definition of what
actually constitutes an oncogene has become therefore
somewhat unclear in order to accomodate the still-growing
list (currently about 40) and has been generally extended
to include both the above categories as well as cellular
proto-oncogenes abnormally expressed in primary tumours.
Transcription of a number of cellular proto-oncogenes has
been similarly demonstrated in a variety of tissue types
and at various developmental stages (Gonda et al, 1982;
Muller et al, 1982), although in the majority of cases very
little is yet known of their exact physiological roles. It
is generally thought however that they are concerned with
the regulation of cell growth and development (Heldin and
Westermark, 1984) and it has been hypothesised that
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abnormalities of such growth-regulatory mechanisms may be
critically concerned with the generation of malignancy
(Sporn and Roberts, 1985).
On the basis of what is known of the biochemical
properties and cellular-localisation of the various
oncogene products they are generally assigned to four broad
groups (Hunter, 1984).
(i)Phosphokinases, associated with the cell membrane.
This group includes src , yes , fps / fes , fgr ,
ros , abl and erb -b, which have a specific tyrosine
phosphokinase activity, as well as a smaller related
group including fras , mos , and raf / mil . All of
these have in common a region of homology with the
catalytic unit of cAMP-dependent kinase. The erb -b
gene product has been shown to have extensive homology
with a truncated form of the epidermal growth factor
(EGF) receptor. In addition to possessing tyrosine
phophokinase activity the src and ros products have
been shown to have the ability to phosphorylate
phosphatidyl inositol, a precursor of diacyl-glycerol
and triphospho-inositide, both of which can act as
second messengers.
(ii)GTP Binding Proteins. This group is represented by
the ras family of proteins which are also associated
with the cell membrane. Along with the src product
these are probably the best characterised of the
oncogene products. These proteins have both GTP
binding and GTP-ase activities. The latter is
markedly reduced in the mutated oncogenic version
(Sweet et al, 1984). They show significant homology
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to the G binding proteins (Hurley et al, 1984) and
more recent evidence based on study of mutant ras
genes in yeast suggest that ras p21 is involved in
modulating adenylate cyclase activity (Toda et al,
1985) and thus in regulating cellular cAMP levels and
may thus function as a second messenger of transducer
between receptors and adenylate cyclase.
This gene family has been shown to be dispersed on
various chromosomes with Ha- ras 1 and 2 localised on
chromosomes 11 and X respectively and Ki- ras 1 and 2
on 6 and 12 respectively (O'Brien et al, 1983).
(iii)Growth Factors. The sis oncogene has extensive
homology with the beta chain of platelet-derived
growth factors (PDGF). This appears to be the only
growth factor encoded by an oncogene itself.
(iv)Nuclear Proteins. This group includes myc , myb ,
fos , B- lym and p53. These display only distant
similarities and less significant evolutionary
conservation. Expression of e.g. myc and fos appears
to follow mitogenic stimulation of cells by exogenous
growth factors and may well play a role in the
regulation of cell entry from GO to Gl.
An alternative division of oncogenes into two
"complementation" groups has also been used (Land et al,
1983) to distinguish them on the basis of their effects on
cell transformation in vitro. It has been shown that one
group including ras , src and polyoma middle T, is
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responsible for anchorage independence in culture and
production of tumour growth factors (TGFs), whereas members
of a second group, including myc , myb , p53 and
adenovirus E1A, confer sensitivity to the effects of the
first group and are responsible for conferring
immortalisation on cells in culture. This boundary does
not appear to be completely hard and fast however since
transformation of primary rat embryonic cell lines can be
achieved by a mutated ras gene alone in conjunction with
transcriptional enhancers (Spandidos and Wilkie, 1984).
The idea of complementary oncogenes is nonetheless
consistent with the well-established notion of carcino¬
genesis being a multi-step process, variously estimated to
involve from 2-7 steps (Klein and Klein, 1984; Paul, 1984),
as is the fact that in many tumours several oncogenes
appear to be activated (e.g. B- lyra or ras and myc in
Burkitt's lymphoma) although what contribution exactly each
one may play and at what stage is not understood.
Such classifications are still also consistent with a
modified version of an autocrine hypothesis of cancer,
which as originally propounded (Sporn and Todaro, 1980)
suggested that generation of a malignant phenotype might
occur by endogenous production of growth factors acting on
receptors of their producer cell. It would now appear that
cancer cells may also become independent of growth factors
by abnormalities in post-receptor controlling events.
Thus, although it is known that many tumour cells, both
spontaneously-occurring and virally-induced, produce a
variety of growth factors, including tumour growth factors
(TGF alpha and beta) and PDGF, the growth factor autonomy
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of cancer cells may be more critically related to
alterations of a receptor or post-receptor signalling
pathway, which may also have theeffect of altering cell
sensitivity to exogenous growth factors (Sporn and Roberts
, 1985). The demonstration, furthermore of growth
inhibitory effects of TGF beta (Roberts et al, 1985)
suggests that abnormalities of such "negative" growth
factors may also be critical in malignancy.
Although activation of various oncogenes has been
demonstrated in a wide range of tumour types and at
different stages of tumourigenesis, the implications of
such activity are not yet fully understood. Nor is it
clear how far such activity may be responsible for
variation in the malignant phenotype. It appears that in
any one tumour type different oncogenes or versions of an
oncogene may be active and there appears to be no absolute
tissue specificity of oncogene activation ( ras family
oncogene activation has been described in e.g. lymphoma,
melanoma, carcinoma and sarcoma (Balmain, 1985)), although
some pattern of preferential tissue involvement may yet
emerge. In addition only about 10-15% of tumours can be
shown to contain an activated oncogene using current
transfection assays. This figure may reflect variation in
the nature of oncogene mutations which in the case of
ras most commonly involves "hot spots" around codons 12 and
61 (Balmain, 1985), although in a series of urothelial
tumours recently reported (Fujita et al, 1984) neither the
presence of a transforming ras oncogene in a small
percentage (10%) of cases nor the presence or absence of a
documented mutation in these appeared to be related to
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tumour stage. Indeed activation of ras oncogenes has been
reported at the premalignant stage in the mouse skin
carcinogenesis model (Balmain et al, 1984) as well as in a
late and highly-aggressive variant arising from a mouse
lymphoma (Vousden and Marshall, 1984).
Of the 10-15% of tumour DNAs active in the 3T3
transfection assay the majority appear to contain activated
members of the ras family of oncogenes. Activated Ki- ras
genes have been demonstrated in colorectal carcinomas
(Pulcini et al, 1982 and McCoy et al, 1983) due in one case
to a codon 12 mutation in a Ki- ras 2 gene resulting in a
coding substitution of valine for glycine at this position
(Capon et al, 1983).
Oncogene amplification however has been shown to be
correlated in the case of N- myc to advancing tumour stage
in neuroblastoma (Brodeur et al, 1984) and in the case of
c- myc to a more aggressive tumour variant in small-cell
carcinoma of the lung (Little et al, 1983). Variably
elevated levels of steady-state transcripts of several
oncogenes have now been reported in a wide range of tumours
(Slamon et al, 1984) but the possible clinical significance
of this is not yet clear.
13. Other Tumour-Associated Genetic Abnormalities
Further understanding of the molecular pathology of
cancer will also depend on the characterisation of other
genes inappropriately activated or inactivated in
malignancy by use for example of further biological assay
systems and by techniques such as the cloning of
complementary (c)DNA libraries. As mentioned previously
this approach has already been used to .isolate sequences
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from virally-transformed cells in vitro (Scott et al, 1983)
and the isolation of sequences expressed in different
classes of leukaemia (Birnie et al, 1983). Whether such
genes are activated in conjunction with or as a consequence
of other oncogene activation is not yet clear.
Other apparently non-specific genetic abnormalities
occurring in malignancy include gene amplification, i.e.
increased copy number of genes (Schimke, 1984; Stark and
Wahl, 1984), associated cytogenetically with chromosomal
double-minutes (DM) and homogeneously-staining regions
(HSR). These have been demonstrated in primary colorectal
cancer (Reichmann et al, 1980) and an overall increase in
the incidence of such double-minutes in metastatic relative
to primary breast tumours was reported in one study
although this was not an invariable finding (Gebhart et al,
1984). Amplification of various oncogenes has also been
reported in different tumour types as previously mentioned,
including amplification of c- rayc in a colonic carcinoma
cell line (of neural endocrine characteristics) although
the significance of this is not clear (Alitalo et al,
1983) .
Hypomethylation as a general feature of genomic DNA in
cancer has been reported in a variety of tumour types
(Diala et al, 1983) and this phenomenon has also been
observed in specimens of colorectal carcinoma as well as in
premalignant polyps (Goelz et al, 1985). The implications
of this in terms of phenotypic variation is again not
clear.
The demonstration of overall degeneration of DNA
sequence organisation in a series of g.ut cancers using a
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complex mixture of many human foetal liver DNA fragments as
probe (Humphries, 1981) appears similarly to be a gross
finding which could not easily be related to subtle
differences related to variation in a malignant phenotype.
The existence of an, as yet uncharacterised, multi-
gene family, apparently activated in a range of different
tumours (Haninia et al, 1983), although possibly of
fundamental importance in carcinogenesis, has not yet been
evaluated with reference to variation in a malignant
phenotype.
A further approach to the definition of variation
amongst tumours may lie in the study of genomic restriction
fragment length polymorphisms (RFLPs) generated by the use
of restriction endonuclease enzymes, which may arise due to
single base changes in particular genes or as variable
length polymorphisms due to differences in the copy number
of tandem repeat seguences in non-coding flanking regions
(Wainscoat and Thein, 1985). These technigues, although
hitherto most useful in the study of disease linkages, in
prenatal diagnosis and in study of somatic homozygosity in
loci associated with familial cancers (Wainscoat and Thein,
1985) have also been used to demonstrate oncogene
activation (of e.g. Ki- ras codon 12 using the Sac I
enzyme (Santos et al, 1984)) and, conversely, to
demonstrate the absence of such mutations in Gardner's
Syndrome with its predisposition to colorectal cancer
(Barker et al, 1983). Similarly, study of the inheritance
of different variable length polymorphisms associated with
the Ha- ras oncogene in the normal (white) cells of cancer
patients showed the presence of abnormal allelic
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restriction fragments (Krontiris et al. 1985). Such studies,
however, are still at an early stage and whether they will
ultimately contribute to the characterisation of the genetic
determinants of variation in a malignant phenotype remains
speculative.
14. Plan of Investigation
In an attempt to define a clinically-useful marker for
metastasis in colorectal cancer as well as to provide a possible
means of studying the biology of metastasis and perhaps
ultimately contribute to new therapeutic approaches to it, it was
decided to make use of novel techniques which have recently
become available and which make it possible to clone individual
RNA sequences into cDNA libraries and so study cell phenotype at
this level. This approach affords the particular advantage of
isolating and studying previously-unknown gene sequences. The
strategy employed was to use two different tumours, one of which
had already metastasised (a Dukes D) and one which had not done
so at the time of surgery, nor did so on follow-up of more than
three years (a Dukes B), as the source of material for
construction of cDNA libraries. It was thus hoped, by cross-
screening these libraries, to identify cloned sequences related
to such differences in behaviour and to correlate transcription
of these with metastatic capacity in a series of tumours.
Since (Ki) ras oncogenes have been shown to be activated in
colorectal cancer it was also decided to study the significance
of variation in the level of ras family oncogene RNA transcripts
in relation to variation in the clinical behaviour of the same
tumours.
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3. Bacterial and Plasmid Strains used for Cloning
The plasmid vector used for cloning purposes was the
Ml3mp7-derived pUC8 plasmid which contains a multiple
cloning site and the bacterial host strain which was used
for transformation was the E. coli K-12 strain JM83 (Vieira
and Messing, 1982). Details of the plasmid cloning site
are shown in the genetic map below.
Genetic manipulations were carried out under GMAG
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Genetic map of pUC plasmids (from Vieira and Messing, 1982)
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B. METHODS
1. Collection of Specimens
Colectomy specimens were opened in operating theatre and
blocks of tumour tissue of approximately lg in weight,
subsequently confirmed by histology, were dissected out
and snap frozen immediately in liquid nitrogen and
stored at -70°C. Specimens of adjacent, histologically
normal, colorectal mucosa were similarly dissected off
and stored.
2. Treatment of Glassware and Culture Media
Glassware for use with solutions of RNA were siliconised
with "Repelcote" and sterilised in 0.1% diethylpyro-
carbonate. After each of these procedures glassware
was baked overnight at 80°C. All solutions employed in
bacterial culture were sterilised by autoclaving at
14.5psi (120°C) for 20 minutes.
3. Preparation of Total Cellular RNA
Specimens were pulverised under liquid nitrogen in a
procedure devised to handle solid tumour specimens by
several blows with a mallet and grinding with a mortar
and pestle. Powdered tumour was then suspended in a
solution of 5M guanidinium thiocyanate, 50mM Tris-HCl,
50mM EDTA, and 5% 3 mercaptoethanol (pH 7.0) as
described by Chirgwin (Chirgwin et al, 1979). Long DNA
strands were sheared by a 15 second burst of sonication
sonication. Sodium lauryl sarcosine from a 20% (w/v)
stock solution was then added up to 2% (w/v). The
solution was warmed at 65°C for 3 minutes until clear
and then cooled on ice. The solution was then overlaid
onto a 2.5ml cushion of 5.7M CsCl (which had previously
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been passed through chelex to remove heavy metal ions),
60mM EDTA pH 7.0 (R.I. 1.3994) in 14ml polypropylene
tubes. The tubes were balanced and centrifuged at
35,000rpm at 15°C for 20 hours on a B60 6x14 swing-out
rotor. The supernatant was then aspirated and the tubes
drained and wiped clean. The RNA pellets were dissolved
in sterile water and precipitated twice from 0.2M sodium
acetate (pH 6.8) and 2.5 volumes of absolute alcohol at
-20°C overnight. Concentration of RNA was measured
using a Unicam SP500 spectrophotometer at A260. An
O.D. 260nm. (optical densitometry) measurement of 1 is
equivalent to 40pg.ml of RNA.
4. Isolation of Polyadenylated RNA by Oligo (dT) Cellulose
Chromatography
Poly(A)+ RNA was isolated from total cellular RNA as
originally described by Aviv and Leder (Aviv and Leder,
1972) by the use of oligo(dT) -cellulose to bind the 3'
poly(A) "tail" present in a a small percentage of
RNAs. A 2ml column of swollen oligo (dT)-cellulose (T3)
was prepared and poured and then washed thoroughly with
at least 10 bed volumes of 0.1M NaOH. This was then
washed thoroughly with more than 20 bed volumes of
binding buffer (0.5M NaCl, lOmM Tris-HCl, 0.1% (w/v)
Sodium lauryl sarcosine, ImM EDTA pH 7.5). Total RNA
was dissolved in sterile water and an equal volume of 2x
binding buffer at a concentration of, optimally,
lOOpg/ml to minimise aggregation and non-specific
binding. The RNA was passed over the column twice,
which was then washed with 10 bed volumes, of lx binding
buffer and the O.D. of 1ml. fractions was read until the
O.D. = 0. The poly(A)+ bound to the column was then
eluted with sterile water and its concentration
measured by O.D. before being pooled and the whole
procedure repeated. The final eluate was precipitated
with l/10th volume 2M sodium acetate (pH 6.8) and 2.5.
volumes of absolute alcohol, and recovered by
centrifugation in a Sorvall HB4 rotor at 10,000rpm at
-10°C for 20 minutes.
Synthesis of First Strand of Complementary (c) DNA
This was carried out by oligo (dT)-primed reverse
transcription using a method similar to that described
by Getz (Getz et al, 1975) to a specific activity of
500cpm/ng. This was achieved by using a 1:20 dilution
of low activity 20 Ci/mmol 3^ dCTP to prevent excess
breakdown. The following reagents were used in a 1ml
reaction mix containing 10pg of poly(A)+ RNA: a
triphosphate mix containing dATP, dGTP, and dCTP to a
final concentration of ImM and 3^ dCTP to a final
concentration of 0.05mM all of which was lyophilised and
then added to 50mM Tris-HCl, (pH 8.2), lOmM magnesium
acetate lOmM D.T.T., 40mM NaCl, lOOpg actinomycin D and
60 units/ug of RNA AMV reverse transcriptase. The RNA
and oligo dT and H2O were mixed first and heated to 60°
for 1 minute, then left to anneal for 30 minutes at room
temperature. The other reagents were then added, the
reverse transcriptase last of all, and the mix was
incubated at 37°C for 1.5 hours. The reaction was
terminated by adding EDTA to a final concentration of
25mM. The mix was then eluted with 50mM Tris pH7, 50mM
NaCl over a Sephadex G-50 column together with 20ug of
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yeast tRNA to separate unincorporated 3h dCTP. The
solution was made 0.1M NaOH and left at 37°C for 1 hour
to hydrolyse the RNA template. It was then neutralised
with acetic acid using a drop of phenol-red indicator
until its colour turned salmon pink. The yield of
(c)DNA was calculated by counting 5pl fractions mixed
and vortexed with 500pl H2O and 5ml of Packard M196
scintillant fluid. The yield in ng of ss (single-
stranded) cDNA = cpmx200/ml.
500cpm/ng
An aliquot of lpl was reserved to be used as a control
in the SI assay. The (c)DNA was then precipitated by
adding l/10th vol. 2M sodium acetate (pH 6.8) and
absolute ethanol to 2.5 volumes and leaving overnight at
-20°C. This was again pelleted by centrifugation at
20 , OOOrpm,-10°C for 20 minutes.
6. Synthesis of Second Strand of Complementary (c)DNA
This was performed by a modification of the method
described by Affara et al (Affara et al, 1981). The
single-stranded cDNA was incubated in a 500jj1 reaction
mix containing 30mM Tris-HCl, 5mM MgCl2, 0.5mM
p-mercaptoethanol pH 7.5 and 1.5mM dCTP, dGTP, dATP,
dTTP and 200 units of DNA polymerase ("Klenow" fragment)
at room temperature for 5 hours. The mix was extracted
in phenol: chloroform twice and the aqueous ethanol
layer precipitated at -20°C and dissolved in lOmM
Tris-HCl, ImM EDTA pH8.
7. Trial SI Nuclease Digestion
Prior to bulk SI digestions a trial was performed to
ensure that an acceptable degree of double-stranding was
present. lpl aliquots of both single-stranded cDNA and
double-stranded cDNA were incubated in a 350pl reaction
mix containing 30mM sodium acetate, 50mM NaCl, ImM
ZnSo4' 5% glycerol, pH 4.6 with 6 units of SI nuclease
(Vogt, 1973) at 37°C for 1.5hours. The mixes were then
chilled on ice. A lOOpl aliquot was taken from each and
counted after mixing with 0.5ml H20 and 5ml M196
scintillant fluid. A 200pl aliquot was then mixed with
50pl of DNA/BSA carrier (100ug/ml E.Coli DNA and lpg/pl
BSA) and 50pl of ice-cold 2M perchloric acid. After 20
minutes on ice the mix was centrifuged at l,000rpm or 3
minutes at 0° C. 150yl of each supernatant was removed
and counted. These represent the acid-soluble DNA. The
acid-soluble fraction of total cDNA represents the
fraction which is single-stranded.
Bulk SI Nuclease Digestion of ds cDNA
Cleavage of hairpin loops in the synthesised double
stranded cDNA was performed using a modification of the
method described by Fantoni (Fantoni et al. , 1979). The
double-stranded cDNA was dissolved in 500pl of lOmM
Tris-HCl pH 8.0, ImM EDTA, 200pl of 3x SI Buffer (90mM
sodium acetate, 150mM NaCl, 3mM ZnS04 45% glycerol pH
4.6) and 30pl (150 units) of SI nuclease. The mix was
incubated for 3 hours at 37°C. The reaction was stopped
with lOpg of 0.25M EDTA and tRNA carrier was added.
The mix was extracted twice in phenol: chloroform and
chloroform extracted in ether which was blown off
finally with gaseous N2. The DNA was recovered by
precipitation with 2.5 volumes of absolute alcohol in
0.2M sodium acetate pH 6.8.
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9. Repair Reaction to Generate Blunt Ends
This was performed in a mix of lOOpl double-stranded
cDNA in 2x buffer (60mM Tris pH 7.5, lOmM MgCl2, ImM [3
mercaptoethanol), 80yl of 15mM stock triphosphates
(dGTP, dATP, dCTP, dTTP) and 20pl of DNA polymerase I (1
unit/pl). This was incubated at 37°C for 1 hour. The
reaction was stopped by the addition of sodium acetate
to 200mM and then extracted with an equal volume of
chloroform. lOqg of yeast tRNA carrier were then added
and the double-stranded cDNA was precipitated in 2.5
volumes of absolute alcohol and 0.2M sodium acetate pH
6.8. The pellet was then dissolved in 200ql of lOmM
Tris-HCl pH 7.5, ImM EDTA.
10.Ligation of Double-Stranded cDNA into Smal Cut pUC 8
"Blunt end" ligation of double-stranded cDNA into Sma I
cut and phosphatased pUC8 plasmid vector (kindly
provided by Dr. M. Ramsden of the Beatson Institute) was
performed by a modification of the method of Cochet
(Cochet et al, 1979) and Fantoni (Fantoni et al, 1979).
The following reaction mix was employed: 5ng double-
stranded cDNA (10yl), 50ng pUC8 (1.6pl), lyl 20x
Ligase Buffer (0.6m Tris pH 8.0, lOOmM MgCl2, 200mM
DTT, 25mM EDTA), 1.5yl 15mM ATP, lyl T4 Ligase (1000
units/ml) and 5pl H20. This was incubated for 3 hours
at room temperature.
11.Preparation of Competent Cells
The JM83 strain of E.Coli was used for transformation
and cells were prepared by a modification of the method
of Dagert and Ehrlich (Dagert and Ehrlich, 1979). An
inoculum of E.Coli JM83 was incubated overnight at
37°C in 4ml of L-broth (lOg. Bactotryptone, 5g yeast
extract, lOg NaCl in 11, of distilled water). This
was then added to 100ml of L-broth in a 500ml Erlenmeyer
flask and incubated in an orbital shaker at 37°C until
the O.D. 600nm, was approximately 3.0. This was then
decanted into sterilised plastic gasketed Sorvall
bottles and chilled on ice for 10 minutes. They were
then centrifuged for 5 minutes at 4.500rpm at 4°C in a
Sorvall GS-3 rotor. The pellets were then suspended in
20ml of ice-cold 0 . 1M filter-sterilised calcium chloride
and kept on ice for 20 minutes. They were then
centrifuged again at 4.5K, 4°C for 5 minutes and the
pellet re-suspended in 2ml of 0.1M CaCl2 and stored at
4° C overnight.
12.Transformation of Competent Cells with pUC8 Recombinant
Plasmid
The 20pl ligation mix previously described was added to
80pl of transformation buffer (50mM MOPS pH 7.8, 75mM
CaCl2, ImM EDTA, lOOmM KC1, 5% v/v glycerol) and mixed
with a lOOpl aliquot of competent cells. This mix was
left on ice for 20 minutes and then at 37°C for 15
minutes, before being inoculated into 1.8ml of pre-
warmed L-broth. This was then incubated for 2 hours at
37°C to permit the establishment of plasmid-conferred
antibiotic resistance. lOOql aliquots were then plated
out onto 5cm-1.5% L-agar-containing Petri dishes (7.5g.
Bacto-agar in 500ml of L-broth and overlayed with 10ml
1.5% w/v agar containing 20jjg/ml of "X-Gal" (2% w/v
solution of phenylmethyl sulphuryl fluoride) and
lOOpg/ml of ampicillin). The plates were incubated for
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18 hours at 37°C. The transformation efficiency was
determined by calculating the number or colonies grown
per pg of uncut plasmid used in a control experiment to
generate transformants. Negative controls were also
undertaken using cut plasmid without additional ligated
double-stranded cDNA.
13.Identification and Harvesting of Transformed Cells
The pUC8 plasmid (Vieira and Messing, 1982) is a Rec A+
Ml 3 derivative of approximately 1.8md containing both an
ampicillin and p-Galactosidase gene. The latter
contains the palindromic Smal site CC"CGG which is
G "GCC
rendered inactive by insertional mutagenesis if foreign
cDNA is ligated into it. These features make it
possible to identify cDNA containing recombinants when
grown in transformed E.Coli on ampicillin and "X-Gal"
containing medium. The latter is in consequence no
longer metabolised by p-Galactosidase to produce the
characteristic blue colony colour but appears instead
white. The latter colonies growing on ampicillin
containing medium should therefore contain cDNA-plasmid
recombinants. Such colonies were picked-out using
sterile tooth picks and grown in 96 well microlitre
plates in lOOpl of L-broth containing 5%(v/v) glycerol
and lOOpg/ml of ampicillin. These plates containing
colonies of transformed cells collectively constitute a
cDNA "library".
14.Screening of cDNA Libraries using the Grunstein -
Hogness Technique: Preparation of Filters
The microtitre plates containing colonies of transformed
cells were replica-plated onto autoclaved Millipore
nitrocellulose filters (0.45pm pore) using transfer
plates and grown on 9cm L-agar Petri dishes
supplemented with lOOpg/ml ampicillin, for 18 hours at
37°C. The filters were then removed and the bacterial
colonies lysed in-situ and the DNA immobilised by the
method of Thayer (Thayer, 1979). The filters were
placed on sheets of Whatmann 3MM paper in a plastic tray
saturated sequentially with lysis and neutralising
solutions. Between each application the filters were
blotted for one minute on dry Whatmann 3MM paper. The
solutions used were as follows:-
1) lOmM Tris-HCl pH 8.0, 4% (w/v) sucrose, lOmg/ml
lysozyme applied twice for 5 minutes.
2) 0.2% Triton-X-100, 0.5M NaOH twice for 5 minutes.
3) 1.5M NaCl, 1.0M Tris-HCl pH 7.6 twice for 3 minutes.
5) 2x SSC once for 1 minute. The filters were applied
colony side uppermost. They were air-dried and baked
for 2 hours at 80°C.
Prehybridisation was performed by immersing the filters
overnight at 65°C in heat-sealed plastic bags containing
20mls of the following solution:-
5xSSC, lOx Denhardt's solution (0.02% bovine serum
albumin, 0.02% poly vinyl-pyrollidone, 0.02% Ficoll
400), 0.1%SDS, lOmM NaP4 pH 7.4, 10pg/ml heat
denatured poly A, 10ug/ml heat denatured poly C, and
lOOpg/ml heat denatured Salmon Sperm DNA.
5.Preparation of 32P-dCTP cDNA Probe
This was done by a modification of the method of
Rothenburg and Baltimore (Rothenburg and Baltimore,
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1976) and probe was labelled to a specific activity of
5x107 counts/minute/pg. A typical reaction mixture of
50pl contained lpg of poly (A)+ RNA, lOOpCi 32P-dCTP
(400Ci mmol), actinomycin D 70pg/ml, 200pm dATP, dGTP,
dTTP, oligo dT 500pg/ml, RNAsin 20 units, and AMV
reverse transcriptase 24 inits reverse transcriptase
buffer (50mM Tris-HCl pH 8.3, 8mM MgCl2' 50mM KC1, 25mM
Dithiothreitol). This mixture was incubated for 1.5
hours at 37°C. NaOH was then added to a final
concentration of 300mM for a further 20 minutes at 37°C
to remove the template RNA. 3pl of phenol red indicator
was then added and the solution neutralised by adding 2M
sodium acetate (pH 4.8) until the solution turned salmon
pink. Unincorporated nucleotides were removed by
passing the mixture over a Sephadex G-100 column pre-
treated with 50pg of yeast tRNA in O.lxSSC (0.15M NaCl,
0.015M Na citrate). One ml fractions were collected and
5pl aliguots counted on a scintillation counter after
mixing with 0.5ml H2O and 5ml of Packard M196
scintillant fluid. The pooled 32p dCTP-labelled
fractions were then denatured by boiling for 5 minutes
followed by immediate cooling on ice prior to being
added to pre-hybridisation buffer.
16.Grunstein-Hogness Hybridisation
32p-dCTP radiolabelled cDNA probe was added to plastic
bags containing filters and approximately 10ml pre-
prehybridisation buffer at a concentration of
5xl06Cpm/10ml and the bags were thermally sealed.
These were then incubated at 65°C for 18 hours. The
filters were then washed as follows:-
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In 3xSSC, 0.1% SDS at 65°C with agitation for 30
minutes, once in lxSSC , 0.1% SDS for 30 minutes,
and three times in O.lxSSC, 0.1% SDS at 65°C for 30
minutes. The filters were then air-dried on
Whatmann's 3MM paper before being sealed in plastic
bags. They were then exposed to Kodak X-omat film
with Ilford Fast Tungstate intensifying screens in a
Harmer Cassette at -70°C for between 1 to 7 days.
17.Small-Scale Isolation of Plasmid DNA
This was carried out essentially as described by
Birnboim and Doly (Birnboim and Doly, 1979). 5yl
inocula of bacterial clones of interest from the
libraries were grown up overnight in a 3ml culture in
L-broth at 37°C. These were then divided and
centrifuged in microfuge tubes in an Eppendorf microfuge
(8,000g.) for 15 seconds. The pellet was resuspended in
200pl of lysis buffer (25mM Tris-HCl pH8, lOmM EDTA pH8,
50mM sucrose, and 2mg/ml lysozyme) and incubated on ice
for 30 minutes. 200jj1 of alkaline/SDS solution (0.2N
NaOH, 1% SDS) were then added and the mixture was left
on ice for 5 minutes. 300pl of 3M potassium acetate
(pH4.8) was then added and gently mixed by inversion.
This mixture was then kept for 60 minutes on ice and the
DNA clot was then spun down in a microfuge for 3
minutes. The supernatant was removed and divided into
two microfuge tubes. 1ml of cold ethanol was added to
each and precipitation achieved at -20°C for 30
minutes. This was again microfuged for 2 minutes and
the supernatant discarded. The pellet was then
resuspended in 200pl of a Tris-acetate solution (0.1M
MATERIALS AND METHODS
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sodium acetate pH8 , 500mM Tris HC1 pH8) .
A further precipitation in 2 volumes of absolute
alcohol was performed at -20°C for 10 minutes and the
precipitate spun down for 2 minutes in a microfuge. The
pellet was then taken up in 40pl of RNase (lOOyg/ml )
and incubated at 37°C for 1 hour. This was then alkali
treated in 0.05N NaOH and incubated at 37°C for 30
minutes before being boiled for 10 minutes. It was
thereafter cooled on ice prior to use for dotting.
18.DNA Dot Hybridisation
This was performed essentially as described by Thomas
(Thomas, 1980). 4pl aliguots of plasmid DNA were dotted
onto sheets of Sartorious nitrocellulose paper which had
previously been immersed in 20x SSC for 5 minutes.
These were then air-dried and baked for 2 hours at 80°C
prior to prehybridisation. This was performed as for
the Grunstein-Hogness technique for 18 hours at 65°C in
a shaking water bath. 32P cpNA radiolabeled probe was
similarly added and allowed to hybridise for 18 hours at
65°C. Washing of filters and autoradiography were
performed according to the same methods.
19.Bulk Isolation of Recombinant pUC8 Plasmids
This was again performed essentially as described by
Birnboim and Doly (1979). Inocula of 5pl of selected
bacterial clones from the cDNA libraries were grown up
for approximately 16 hours in 3mls of ampicillin-
containing L-broth (100ug/ml) and then added to 0.51 of
L-broth. The cells were then harvested after overnight
culture by centrifugation in a Sorvall (GS-3) rotor for
5 minutes at 5,000rpm. The pellet.was then suspended
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and lysed in 25ml of freshly prepared lysozyme (2mg/ml)
in 25mM Tris-HCl, lOmM EDTA, 25% (w/v) sucrose, pH8.0
and left on ice for 30 minutes as described originally
by Clewell and Helinski (1970). 50ml of 0.2N NaOH, 1%
(w/v) SDS were added mixed by inversion and left on ice
for 5 minutes. 37.5ml of sodium acetate (pH 4.8) were
then added, and the solution gently mixed. After a
further 1 hour on ice the mixture was centrifuged in a
Sorvall GS-3 rotor for 10 minutes at 8.500rpm at 0° C.
The supernatant was removed and DNA precipitated with
0.6 volumes of isopropy1-alcohol at -20°C for 1 hour.
The DNA was pelleted by centrifugation for 20 minutes
at 10,000rpm at -20°C and resuspended in 5mls O.lxSSC.
6g of CsCl were added and vortexed to dissolve it.
Ethidium bromide 0.25ml (lOmg/ml) was then added and
the overall R.I (refractive index) was adjusted to
1.3940. Each solution was then added to 10ml
polycarbonate centrifuge tubes (M.S.E.) which were
topped up with liquid paraffin and finely balanced.
These buoyant density gradients (Birnie, 1978) were
then centrifuged at 40,000rpm at 20°C for 40 hours
using an M.S.E. 10x10ml titanium fixed-angle rotor.
The lower of two bands which appear in the tubes (and
which are easily visible in U.V. light) contains
supercoiled plasmid DNA and the upper band contains
both chromosomal and open circular plasmid DNA.
Supercoiled DNA was thus recovered using a fixed,
repelcoted Pasteur pipette. The ethidium bromide was
removed by several extractions with CsCl saturated
isopropanolo1. The remaining aqueous layer was then
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extensively dialysed in Collodion bags (Sartorious)
against lOmM Tris-HCl, ImM EDTA pH 7.6, to remove the
CsCl. The plasmid DNA was then precipitated in 200mM
sodium acetate (pH 6.8) and 2.5 volumes of absolute
alcohol overnight and pelleted by centrifugation in a
Sorvall GS-3 for 20 minutes at 10,000rpm at -20°C.
After washing the pellet in 70% alcohol it was suspended
in 1ml lOmM Tris-HCl, ImM EDTA and its concentration
determined by measuring its optical density at A260nm
when 1 O.D. unit = 50pg DNA.
20.Quantitative Dot Hybridisation
This was performed as described previously (Thomas,
1980) using fixed lOOng amounts of recombinant plasmid
DNA per dot and 3 2p_,jCTPcDNA probes as described
previously.
2 1. Preparation of Nick-Translated 32p-pa5eigecj Recombinant
Plasmid Probes
Labelled plasmid probes were prepared (to a specific
activity of lxlO^cpm/ml using a commercially available
kit (Amersham International Inc.). 0.5pg of plasmid DNA
was incubated with 20pl of nucleotide buffer solution
(containing 100pm dATP, dGTP, dTTP) in a concentrated
nick-translation buffer (containing Tris-HCl pH 7.8,
MgCl2 and mercaptoethanol) and 20pl of an enzyme
solution (containing 5 units of DNA polymerase I and
lOOpg DNA-ase I in a buffer solution containing
Tris-HCl pH 7.5, MgCl2, glycerol and BSA) in a total
reaction mix of 50pl at 15°C for 3 hours.
Unincorporated material was removed by passage over a
Sephadex G100 column in O.lx SSC. .The labelled plasmid
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was boiled for 5 minutes and cooled on ice before
addition to hybridisation buffer.
22.RNA Doubling-Dilution Dot Hybridisation
This was performed essentially as described by Birnie
(Birnie et al, 1983). From a stock solution of RNA at
a concentration of 500pg/ml twelve doubling dilutions
were made by transferring a volume from each tube egual
to an aliquot of sterile water previously added to it.
The tubes were heated for 15 minutes at 65°C to denature
the RNA and then chilled on ice. 4pl of each dilution
was then dotted onto a Sartorious nitrocellulose membrane
which had been previously soaked for 5 minutes in 20x
SSC. This was air-dried and the RNA immobilised by
baking at 80°C for 2 hours. The filter was prehybridised
for at least 4 hours in lOmls of prehybridisation buffer
(containing 50% formamide, 5x Denhardt's solution, -
50mM sodium phosphate pH 6.8, 200pg/ml of sonicated,
denatured salmon sperm DNA, 10pg/ml poly(A) and lOyg/ml
poly(C)) at 42°C. Hybridisation was performed in 10ml of
buffer (containing 50% formamide 5X SSC, IX Denhardt's
solution, 10% Dextran sulphate) containing labelled,
denatured probe labelled to a specific activity of
lxlO^cpm per ml at 42°C for 18 hours. The filters were
then washed in 3x SSC, 0.1% SDS at room temperature
twice for 20 minutes and in 0.5x SSc, 0.1% SDS at 65°C
for 20 minutes and repeated as necessary until back¬
ground radioactivity was minimal. The filters were air-
dried and autoradiographed as before, using Kodak X-omat
film in conjunction with a Dupont Cronex intensifying
screen at -70° C for 1-5 days. The .end point of the RNA
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titration was taken as the lowest dilution giving a
signal above background on the film.
23.Dot Hybridisation with ras -family Oncogene Probes
Dot hybridisation with single lOpg aliquots of total
cellular RNA was also performed as previously described
(Spandidos and Kerr, 1984 ) using 32p_iabepie(j nick-
translated Hi Hi3 (Ellis et al, 1980) and BS9 (Ellis et
al, 1981) recombinant probes containing the viral
Kirsten and Harvey ras DNA sequences respectively.
24.Quantitative and Qualitative Controls
of RNA Preparations
This was performed using the pL335 (Dalla Favera et al,
1982), pAM91 (Minty et al, 1982) and pHR28 (prepared by
Anne Sproul of the Beatson Institute) probes containing
the human cellular sis , mouse actin and human 28S
ribosomal DNA sequences respectively to check the
quantity of RNA present in a specimen and was
undertaken in conjunction with Dr. D.A. Spandidos
(Beatson Institute, Glasgow) as previously described
(Spandidos and Kerr, 1984). The quality of the RNA
preparations was similarly checked by formaldehyde-
agarose gel electrophoresis, followed by ethidium
bromide staining, blotting onto nitro-cellulose and
hybridisation to DNA probes. Fot blotting,lyphophilysed
RNA was taken up in 50% formamide, 2.2M formaldehyde and
1 x MOPS buffer, heated at 55°C for 15 minutes, made 10%
glycerol, 0.1% dye and layered on to a gel. The gel
containing 1% agarose, 1 x MOPS buffer, and 2.2M
formaldehyde was made as follows
the agarose was melted in H2O, cooled to 60°C and the
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10 x MOPS buffer and 13.2M formaldehyde were added.
The gel was run for 3-4 hours at 3V/cm until the
marker dye had migrated 8-10cm. It was then soaked in 10
volumes of 1 x MOPS buffer (two changes of 15 min each)
and subsequently in 20 x SSC (two changes of 30 min
each). RNA was blotted onto nitrocellulose in 20 x SCC
for 4-6 hours. The nitrocellulose filter was washed in
3 x SSC, air-dried and baked for 3-4 hours in an 80°C
oven.
25.Histopathological Evaluation of Tumour Specimens
Histopathological reports were based on standard 5pm
paraffin-embedded sections stained with haematoxylin
and eosin. These were checked in conjunction with
Dr. F.D. Lee (Department of Pathology, Glasgow Royal
Infirmary).
26.Clinical Follow-Up
Patients in this study were follow up routinely as out¬
patients in the Department of Surgery, Glasgow Royal
Infirmary at three-monthly intervals with biannual







5. The Sephadex G-50 column was prepared by swelling 2g
of G-50 overnight in 100ml of distilled water; this was
then poured on top of 1ml chelating resin in a Bio-Rad
lc x 20c column.
Neutralisation with acetic acid was performed simply
drop-wise until the colour of the solution turned salmon
pink.
6. Precipitation of double-stranded cDNA was as described
in Section 5, by addition of l/10th vol. 2M sodium acetate
(pH 6.8) and absolute ethanol to 2.5 volumes and leaving
overnight at -20°C. The mix was also extracted with
chloroform following phenol extraction.




1. Collection of Tumours and Preparation of RNA
A series of specimens comprising 24 colorectal carcinomas
along with, in most cases, adjacent histologically-normal
mucosa and, in some cases, adenomatous polyps found
incidentally was collected. The yield of total cellular
RNA from approximately lg of tumour was typically between
500-1,000/ug depending on the cellularity of the specimen.
Subsequent oligo-(dt)-cellulose chromatography then yielded
typically 10-20/t/g of poly(A)+RNA. Northern blot analysis
of these samples as described previously (Spandidos and
Kerr, 1984) showed a moderate amount of degradation of RNA
as would be expected from primary tumour samples. Clearly
identifiable and discrete bands were, however, easily
discernable when hybridised with e.g. the ras oncogene
probes. Similarly, the dot hybridisation signals obtained
from these samples (Spandidos and Kerr, 1984) using the
actin (pAM91) and ribosomal (pHR28) probes as positive
controls (these are uniformly highly expressed in these cell
types) showed uniformly high intensities. The sis oncogene
probe (pL335) conversely, generated scarcely-detectable
signals thus serving as a negative control.
2. Construction of cDNA Libraries
Double-stranded (ds) cDNA was made by a series of enzymic
reactions as outlined in Figure 1. From an initial mix
containing 10/yg of poly(A)+ RNA a final yield of
approximately lOOng of blunt-ended ds-cDNA was generated.
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This relatively low yield (compared to more recent
approaches) was due to the fact that each step (although
this number was minimised as far as possible) involved
substantial losses of cDNA. The efficiency of the initial
reverse transcriptase-catalysed cDNA synthesis was
calculated to be approximately 15%. Trial Sl-nuclease
digestion showed that approximately 60% of the cDNA was
double-stranded following the second strand synthesis.
Thus 40% was subsequently lost during the bulk Si digestion
performed to generate "blunt ends" by cleaving the hairpin
loops. Size fractionation of the cDNAs was not performed,
in order to randomly generate a full range of sequences of
differing size-lengths for cloning. (Augenlicht and Kobrin,
1982) .
The procedure for cloning recombinant pUC8 plasmid vector
following ligation of cDNA into the Sma 1 restriction
nuclease site is outlined diagramatically in Figure 2. The
volume and concentration of the ligation mix were the
optimum as previously determined by control experiments to
test the efficiency of blunt-end ligation using this vector
(performed by Dr M. Ramsden, Beatson Institute, Glasgow).
The transformation efficiency obtained when plasmid was
transfected into the JM83 strain of E.coli was approximately
4
1x10 colonies//yg, compared to a transformation rate of
approximately 1 x 10^ colonies per //g for uncut plasmid.
Approximately 800 antibiotic-resistant transformants were
picked for each of the 2 libraries and were grown
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individually in wells in microtitre dishes.
3. Screening of the cDNA Libraries
This was performed initially using the semi-quantitative
Grunstein-Hogness technique as outlined in Figure 3. By
this means a total of 96 clones were identified representing
mRNA species which appeared to differ significantly in
abundance when screening of the two libraries was performed
using homologous (same tumour) and heterologous (different
tumour) probes, the majority of which (75%) were present in
the library from the primary tumour which had metastasized
and which were absent in the library from the primary tumour
which had not. Examples of such clones are illustrated in
Figure 4 which shows the results of screening of the replica
of one of the microtitre dishes from the metastatic library.
The other 25%, conversely, were apparently highly-abundant
in the tumour which had not metastasised relative to the one
which had. Due to the relative crudity of the
Grunstein-Hogness technique, a further round of screening
was carried out using more quantitative (but labour-
intensive) dot hybridisation techniques using mini-
preparations of the 96 selected recombinant clones. These
were also screened using homologous and heterologous probes
in order to select those sequences which differed most
consistently in transcriptional levels between the two
tumours. These blots were not retained. On this basis 4
recombinant clones only were selected for bulk preparation
of quantifiable amounts of plasmid DNA for use as probes to
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screen a series of tumour and other tissue types. These
putative metastasis-related clones (PMRC) selected from the
original 96, were numbers PMRCl, PMRC7, PMRC35 and PMRC89
and were all selected from the "metastatic" tumour library.
4. Screening of a Series of Tumours and Normal Tissue
32
Samples with p-labelled Recombinant DNA Probes (PMRCl,7,35
& 89) .
This was performed by RNA doubling-dilution dot
hybridisation, the results of which are shown in Figures
5-8, and which represent the best obtained after several
rounds of screening; these although individually of
variable quality technically were, in general, consistent.
This technique allows obvious and sensitive (although
subjective) visual comparison to be made between specimens,
the range of intensities is exponenial, and also permits
numerical quantitation of reactivity and hence abundance of
a particular RNA species in a given specimen. ("Cut off"
points were also independently assessed by another group
member). Quantitation is based on a value of 1 arbitrarily
ascribed to the first dot andysubsequently,values of 2,4,8
etc. for subsequent dilutions. The arbitrary hybridisation
"cut-off" point is in fact somewhat easier to interpret on
the original autoradiographs when trans-illuminated than in
the Figures shown.
The complete list of values obtained for a series of
specimens including colorectal carcinomas, adenomas, normal
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mucosa and other tumour and cultured tissue types is shown
in Table 2. It is evident that the range of values obtained
extends up to one hundred-fold, and, in a few cases (e.g.
specimens 2,10,19), several hundred-fold. Abundance of
these RNAs is generally (e.g. PMRC 1) much higher in
carcinomas than in normal mucosa where this was available
for comparison, as in specimens 20/21 and 22/23, where the
difference is approximately ten-fold. Relatively low
steady-state transcript levels of these sequences,
comparable to that seen in normal mucosa, were observed in
the two adenomatous polyps studied.
The numbers (n) of different tissue types falling into
different arbitrary categories of RNA abundance for e.g.
PMRCl-related sequences shows this overall pattern clearly
when tabulated as follows:-
Abundance of PMRCl- Colorectal Adenomatous Mucosa
related RNA Carcinoma (n) Polyp (n) (n)
Low levels only were seen in the specimens of carcinoma of
breast (specimen 29), melanoma (specimen 30) and HL60
promyelocytic leukaemia cell line (specimen 31). Very low
steady-state transcript levels only were seen in the














or in whi"tX- cells specimen 28). (RNA from HL60 leukaemia
and from white cells was kindly provided by Jennifer Burns
of the Beatson Institute).
Although in general higher values were seen using e.g.
PMRCl, it is not possible to compare directly the levels of
RNA transcripts seen with the different probes in this
series since the reactivity seen depends also on variable
32
factors such as degree of P radiolabelling, which in turn
depends also on the length of cDNA insert in the respective
probes. Similarly, because of the variability in using the
same probe on different occasions, use of a constant
internal control (e.g. a cell line such as HL60 or
preferably of a colorectal carcinoma) would be necessary for
any extended series.
Due to limitations of re-using nitrocellulose filters, it
was not possible to perform direct quantitative comparisons
using other selected "random" probes, as would have been
ideal. However, aliquots of the same specimens were
separately quantitated by densitometric analysis as
previously described (Spandidos and Kerr 1984) and this,
together with the generally-consistent pattern of results
between probes and amongst specimens, supports the overall
accuracy of the original quantitations based on optical
densitometry. (See Methods, Section 3).
Thus, transcript levels of these sequences appear to be
higher, though variably so, in the specimens of colorectal
carcinomas relative to othere tumours or normal tissue
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types. The values observed in the samples of mucosa were,
however, in several cases also higher than in other tumour
or tissue types, suggesting that their transcription may be
tissue (i.e. colorectum)-related. It should be noted that
where different biopsies of the same tumour were studied as
an incidental look at possible tumour cell heterogeneity,
broadly similar ranges of value (within 1-2 dilutions) were
in fact obtained (e.g. tumours 2/22. 16/17. 19/20). However,
some discrepancies did also occur e.g. samples of mucosae
15/21 in general and 16/17 probed with PMRC89.
A few further anomalies were also apparent in
interpretation of the hybridisation signals in e.g. Figure 5
where no signal is seen for dilution 1 in samples 12 and 13.
This may be due to this aliquot having been accidentally
omitted or been subject to pressure by adhesive tape (as
appears to have occurred over e.g. specimens 16-18 for
dilution 7). In e.g. Figure 8, the signal seen over dilution
3 of sample 4 may have been due to filter irregularity
causing probe stain, or to inadvertent deposition of RNA
from another aliquot.
Even if these results are excluded from consideration,
the overall lack of correlation between abundance of these
RNA species to tumour metastatic potential observed in the
series of carcinomas (specimens 1-12, Table 3 (a-d) remains
clear. (See Section 5 and scattergram in Figure 10.).
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5. Correlation of Levels of Steady-State Transcripts of RNA
Corresponding to PMRC1,7,35 and 89 with Conventional Staging
Criteria and Clinical Outcome in a Series of Colorectal
Carconimas
The relation of values obtained for each PMRC with
conventional staging criteria and clinical outcome is shown
in Table 3 (a-d) and Figure 10. Follow-up on all survivors
exceeds 2 years which, although relatively short, is the
period during which patients who have undergone apparently-
curative resection would be expected to develop disseminated
disease if they are going to do so. It is in any case
clear from the range of values obtained in specimens of
tumours which have already metastasised that they do not
appear to be related consistently to metastatic tumour
behaviour.
Similarly, the range of values overlaps all Dukes' stages
and histological types. They do not, in addition, appear
to be related to tumour site. Although the variably-
elevated levels of transcripts of these abundant RNA
species appear to be cancer-related in colorectal tumours,
the degree of elevation of transcript levels for the four
sequences does not appear to be related either to
conventional staging criteria nor to their clinical
behaviour with particular reference to the development of
metastatic disease.
Correlation of Levels of Steady-State RNA Transcripts
of Ras Family-Oncogenes with Conventional Staging
Criteria and Clinical Outcome in a Series of
Colorectal Carcinomas
Specimens of RNA prepared from the same series of
tumours was also probed with the recombinant HiHi3
(Ellis et al, 1980) and BS9 (Ellis et al, 1981) probes
which contain the viral Kirsten and Harvey ras DNA
sequences respectively. Variably-elevated steady-state
transcript levels of these oncogenes have already been
reported by our group (Spandidos and Kerr, 1984), and
I
the level of elevation, relative to an arbitrary value
of 1 ascribed to normal mucosa, quantitated by
densitometric scanning of single dot hybridisations.
The relation of these values to clinical outcome is
shown in Table 4 and to Dukes' staging and tumour
histology in Figure 9. Although the elevation of
steady-state levels of transcripts range from 2-20 fold
these appear to overlap in all histological types and
Dukes' stages. Similarly, the values obtained do not
appear to related to the clinical behaviour of these
tumours with particular reference to the development of
metastatic disease, on follow-up over a period of more
than 2 years. This is evident even from the range of
values seen within the group of tumours which have
already metastasized although, as discussed above, those
which have not metastasized within 2 years would be
unlikely to do so.
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Thus, although variably elevated steady-state levels of
ras -related RNA transcripts are seen in these tumours
i
they do not appear to be related to either conventional
staging criteria nor to clinical behaviour with




Tumour and tissue specificity of PMRCS 1,7,35,89
hybridised with doubling-dilutions
of total cellular RNA.
Specimen Number
(Patient/Specimen) Probes
PMRC1 PMRC7 PMRC35 PMRC89
1. (Ca-PK) 128 128 32 64
2. (Ca-EL) 512 512 256 256
3. (Ca-JF) 64 16 16 8
4. (Ca-HRo) 64 32 16 8
5. (Ca-HM) 64 8 8 -
6. (Ca-HRe) 32 16 8 8
7. (Ca-WP) 64 16 8 4
8. (Ca-MM) 64 512 128 256
9. (Ca-BH) 32 8 2 16
10. (Ca-ASh) 1024 256 128 128
11. (Ca-JG) 64 32 8 16
12. (Ca-DJ) \zs 8 8 8
13. (Ca-GC)(A)+ 128 64 lb 16
14. (Polyp-IM) 1 128 £>4- 64
15. (Mucosa-GC) 1 8 4 8
16. (Ca-MM2) 64 128 64 256
17. (Ca-MM3) 64 32 16 32
18. (Mucosa-MM) 64 4 4 2
19. (Ca-GC2) 256 4 16 8
20. (Ca-GC3) 256 4 16 16
21. (Mucosa-GC) 32 2 4 1
22. (Ca-EL,2) 256 64 512
23. (Mucosa-EL) 64 8 8 4
24. (Polyp-MB) 32 4 - 1
25. (Mucosa-MB) 16 4 1 4
26. (Fibroblast*) 4 1 - -
27. (Fibroblast-PC*) 8 1 - -
28. (Leucocytes) 16 2 2 1
29. (Ca-Breast) 16 4 4 4
30. (Melanoma) 16 16 4 2
31. (Leukaemia-HL60*) 64 16 16 2
Abbreviations - 1,2,3. - refers to different biopsies.
*
- cell line.
(A) + - adjusted value for sample of
(A)+ RNA.
PC - Polyposis coli.
Table3 .
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Outline of protocol for Enzymic Synthesis of cDNAs.






















Outline of protocol for screening a cDNA library
using the Grustein-Hogness technique.
SCREENING BY COLONY HYBRIDIZATION
Transfer
Plate






I Hybridization to 32p cDNA probe
lAutoradiography
Autoradiograph.
Signal intensity <* abundance of sequence
in probe
Figure 4.
Example of a plate from the "metastatic" tumour cDNA
library screened with probe made from its own RNA
(above) and probe made from "non-metastatic" tumour RNA
(below) in homologous and heterologous screening
respectively. The arrows show examples of clones
which were picked due to their differing abundance as
shown by a markedly-differing hybridisation signal.
Since the replica filters were screened with probes
used on different occasions and labelled to differing
extents, it is the relative overall pattern of
intensity which is compared. A control is not
included since the only relevant one would be RNA
homologous to the cDNA used as probe, which the various




Results of doubling-dilution RNA dot hybridisation
of specimens 1-31 with PMRCI.
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Results of doubling-dilution RNA dot hybridsation
of specimens 1-15 with PMRC7. (The blot showing
specimens 16-31 was accidentally discarded).
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Figure 7.
Results of doubling-dilution RNA dot hybridsation
of specimens 1-31 with PRMC35.
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Results of doubling-dilution RNA dot hybridisation
of specimens 1-31 with PMRC89.
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Relation of (a) Ki- ras and (b) Ha- ras related
oncogene expression to Dukes' stage (i) and degree of























Relation of steady-state transcription levels of
(a) PMRC-1, (b) PMRC-7, (c) PMRC-35 and (d) PMRC-89



















































































The aim of this study was to identify possibly
metastasis-related differences between two primary colo¬
rectal carcinomas, which represented clinically tumours one
of which had already metastasised and one which had not
done so after a follow up period of, now, over 3 years.
The strategy employed was to construct cDNA libraries from
the moderately-and highly-abundant mRNA species from each
tumour and to identify differences between them by
screening these libraries using radiolabelled probe made
from their RNAs in homologous (same tumour) and hetero¬
logous (different tumour) screening. cDNA clones most
consistently representing differences between the two were
selected and used to determine the steady-state
transcription levels of these RNA sequences in a series of
tumours as well as in various normal tissues and specimens
of different tumour types. The values obtained were then
correlated in a series of 12 carcinomas with conventional
staging criteria and clinical outcome with particular
reference to the development of metastatic disease. It was
hoped that the transcription of such sequences might
consistently relate to differing behavioural character¬
istics of these tumours and thus provide a means of
studying the molecular pathology of metastasis as well as
being of clinical usefulness as a predictive test.
A similar evaluation of the clinical significance of
the variable elevation in ras family oncogene RNA
steady-state transcripts which had been observed in these
tumour specimens relative to normal mucosa in conjunction
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with Dr. D.A. Spandidos (Beatson Institute, Glasgow), was
also undertaken.
As shown in the previous section the four putative
metastasis-related recombinant clones isolated from the
cDNA libraries appeared to represent mRNA species present
in general at elevated levels in a series of carcinomas of
the colorectum as compared to normal mucosa and to other
tumour and tissue types. Elevated steady-state
transcription levels of these sequences did not however
appear to be consistently related in the series of
carcinomas to either conventional staging criteria
(Dukes'stage or degree of tumour differentiation) nor to
the clinical behaviour of the tumours with particular
reference to the development of metastatic disease. These
results suggest that if differing steady-state transcript
levels of critical mRNA species do occur in a metastatic
phenotype then it may be in RNA species of very low
abundance or may be by relatively small differences in
transcript levels in abundunt RNA sequences or possibly by
a "battery" of changes, perhaps of a subtle nature, in a
large number of RNA species. Differences in the former
would not be amenable to study in such a cDNA library in
which they would not be expected to be either cloned or
detectable. Alternatively it is possible that such
sequences may be abundantly-present in only a subpopulation
of a primary tumour, or perhaps expressed only transiently.
The lack of correlation of degree of elevation of ras
oncogene transcription with conventional staging criteria
or clinical outcome similarly suggests that expression of
these sequences is not directly related to clinically-
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apparent phenotypic differences in these tumours although
abnormal expression of these oncogenes may be, as previously
suggested (Spandidos and Kerr, 1984), critical in the
generation of malignancy.
In the interpretation of these results and consideration of
further strategies to study the molecular pathology of
metastasis, various points arise both in consideration of the
techniques and strategy employed in the present study as well
as of a more general nature.
2. Collection of Tumours and Preparation of RNA
Biopsies of tumour specimens were of a random nature,
although in several cases multiple biopsies were taken of a
single tumour and the expression of the PMRCs was generally
equivalent (see Results, Section 4). The validity of this
observation would appear to be confirmed by the generally
comparable readings seen in e.g. different samples of normal
mucosa. If the hypothesis relating to cell heterogeneity with
respect to metastatic potential in primary tumours were indeed
true in this tumour type, then such random sampling would not
be expected to identify the presence of sequences consistently
related to such a cell phenotype, although this hypothesis is
currently held by several authors to be extremely contentious
(Weiss et al. 1983; Tarin & Price 1979; Alexander 1983 and
Giavazzi et al. 1980) (see Introduction, Section 5). Nor is
there any direct evidence so far of its applicability to
primary human tumours. There is, however, good evidence that
these colorectal tumours consistently behave clinically as
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metastasising or non-metastasising variants (see Introduction,
Section 3). Random sampling of primary tumours, however,
unless dealing with fairly gross differences in gene expression
within populations of tumour cells, undoubtedly remains the
major conceptual restriction to this approach and it is
possibly surprising that bigger differences in transcriptional
levels of the cloned sequences between biopsies of the same
tumours were not seen. Such differences might occur due to
e.g. differences in stromal cell admixture, varying tumour cell
kinetics or degree of necrosis.
The samples of mucosa, although histologically normal and
taken from sites several centimetres distant from tumour, might
well have displayed certain cancer-associated "transitional"
changes as has been previously well-documented, although the
exact significance of such changes is not yet clear (see
Williams 1985). It seems unlikely, however, that such minor
phenotypic changes would constitute a significant problem in
cross-screening RNAs for frankly cancer-/or metastasis-
associated sequences. This possibility could in any case be
checked if so desired by screening with probe made from RNA
from non tumour-bearing mucosa, although such a specimen was
not available for this study.
Yields of poly (A)+ RNA per weight of tumour were in general
much lower than per comparable weight of tissue culture cells
as described in previous studies due not only to lower cell
content but also to difficulties in rapidly mincing tissue for
treatment with guanidinium thiocyanate (Methods, Section 3) to
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prevent excess degradaion of RNA by endogenous nucleases. The
difficulty in obtaining intact RNAs from primary tumours is
well-recognised (Slamon et al. 1984). This problem was
eventually circumvented using the procedure described of
pulverising tumour under liquid nitrogen (see Methods, Section
3). Nonetheless, substantial quantities (approximately lg) of
tumour material were required to extract sufficient
polyadenylated RNA to clone a cDNA library using the proocol
described. This precluded any consideration at the time of
using smaller biopsy specimens of either tumour or of
metastatic tumour deposits. Recent developments in the
technology of synthesising cDNA and its subsequent cloning
have, however, made it possible to generate similar-sized
libraries using approximately one-tenth as much poly (A)+ RNA
(see Gubler & Hoffman, 1983). Such newer methods circumvent
the relative inefficiency of the procedures described in this
study by greatly reducing the number of steps taken in
undertaking the various enzymic reactions.
3. Construction and Screening of cDNA Libraries
The cloning strategy employed to attempt to identify
phenotypic differences between 2 primary colorectal tumours,
one of which had metastasised and the other of which had not,
is outlined in the Results, Section 2 and Figures 1 & 2. Such
an approach has been made possible by the recent developments
in methods of transfection of E.coli with recombinant cDNA
plasmids and of methods for screening the transformed colonies
generated, each of which contains a cloned DNA copy
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representing one of the large number of diverse mRNA species.
This depends on the use of a variety of enzymes to synthesise
cDNA and to ligate them into a plasmid cloning site generated
by use of restriction endonuclease enzymes and the
identification of bacterial colonies subsequently transformed
by these plasmids which confer on their host particular
phenotypic characteristics (in this case ampicillin antibiotic
resistance and the inability to produce beta galactosidase).
Various procedures may be used for cloning and in this instance
"blunt-end" ligation into the Sma I site (rather than the
possibly more efficient procedure of using linkers) was used,
since it affords the considerable advantage of easy excision of
cloned inserts (for e.g. subsequent sequencing) using the
flanking EcoRl and BamHl restriction sites (see AVa.terfctls Section
3). Use of mutant, scarcely-viable bacterial host strains (in
this case the E.coli JM83 strain of the K12 mutant) ensures
compliance with the strict safety regulations surrounding such
work. The large number of colonies (800 in this study)
generated by this approach, collectively termed libraries,
represents a random selection of the RNA species present in the
population from which they were cloned. The 800 clones
picked represented the maximum number which could easily be
screened simultaneously using the methods described.
Although many of the recombinants will contain only partial
10
copies of the RNAs this is immaterial to the purposes of
identification and quantitation of the levels of
transcription of these sequences. Since as full a cross-
section as possible of RNA species was desired no selection
procedure, e.g. size fractionation of the cDNAs, was
carried out.
Although this strategy represents a very rewarding, if
complex, means of studying differences in the abundant RNAs
between different cell phenotypes, there are limitations
imposed both in terms of the number and nature of
individual RNA species which may be studied. Thus,
although a library of the size described above would be
expected to contain the majority of the highly-/and
moderately-abundant sequences (some several hundred) the
remainder of the cell RNAs (some 10,000 or so, see
Introduction), transcribed at only a few copies per cell,
(i.e. 0.1% of the population of RNAs) would have only a
small fraction of its total represented. The size of
library required to represent a whole range of cell RNAs
may be calculated by the formula of Clark and Charbon.
(See Williams, 1981 and Maniatis et al, 1982). Thus in the
case of a cultured fibroblast for example, it has been
calculated that N = 37,000 (P = 0.99) (where N = number of
clones and P = probability). For a P value of 0.90 however,
the number would be reduced drastically to about 7,000. It
is clear therefore that to generate libraries representing
all of a cellular RNA population, libraries of much greater
size would be required. However, more severe limitations
are imposed using these procedures on the identification of
sequences of interest using primary screening procedures
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such as the Grunstein-Hogness technique (see Methods, Section
14). Due to the very low copy number of such sequences
present also in the radiolabelled probe used, such a low
"signal to noise" ratio is obtained as to render impossible
the detection of such sequences when exposed auto-
radiographically. The Grunstein-Hogness technique is
furthermore only semiquantitative and rather unreliable since
the dot intensity obtained in screening depends on a variety
of factors including the extent of bacterial colony growth,
degree of lysis, length of cDNA insert and degree of
radiolabelling of the probe used. It has been calculated
that the limit of sensitivity of this technique is of the
order only of a 5 fold difference (Williams, 1981) which in
many biological situations would represent a gross
comparison. Indeed, of the 96 clones picked and grown in
"minipreps" for subsequent secondary screening using
quantitative dot hybridisation on the basis of the initial
Grunstein-Hogness screening, the majority did not
consistently differ on further cross-screening (see Results,
Section 3). It is correspondingly likely that many clones
representing sequences which did differ to a biologically
significant extent in their levels of steady-state
transcription would not have been identified using these
screening procedures.
One extremely labour-intensive strategy which might be
used to deal with these problems would be to make plasmid
preparations of entire libraries for use in quantitative dot
Ill
blots. A more sophisticated alternative would be the
isolation of sequences of interest by the use of subtractive
hybridisation procedures on the two RNA populations of
interest (See e.g. Scott et al. 1983 and pll7.)
Total plasmid recombinant probes were used for screening
the series of specimens, since it was felt that the
theoretical problem that variation in levels of bacterial
contamination, together with variation in levels of
transcription of homologous DNAs in that population, might
contribute to significant masking of the predominant (tumour)
RNA species was extremely remote.
This study has therefore addressed itself to a study of
mRNA sequences differing greatly in steady-state transcript
levels in the different tumours. This limitation has been a
major obstacle to the study of RNA transcription in a variety
of other biological systems in which this may differ by only
small amounts in different cell types or at different times.
Nonetheless, a considerable amount of useful information may
be expected to be gained using these techniques despite these
limitations (see Introduction, Section 10).
4. Significance of Transcription of RNA Sequences Related to
PMRCsl,7,35 and 89
Although the results of the dot hybridisations shown in
Figures 1-4 and referred to in Tables 2 & 3 are of a
relatively preliminary and technically imperfect nature, it
is nonetheless clear that, taking into account the comments
made regarding quantitation of specimens and a few individual
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anomalies apparent in Figures 1-4 (see Results Section 4),
PMRC1,7,35 and 89-related RNAs were not apparently confined
to those primary tumours which metastasised. These
sequences were in general more highly abundant in carcinomas
than in corresponding premalignant or normal colorectal
tissue or other tumour and tissue types. The significance
of this is not clear. It seems unlikely that the
differences observed between the colorectal carcinomas and
mucosa can be attributed to differences in cell growth
kinetics. Recent studies using stathmokinetic techniques
(Pritchett et al. 1982) have suggested that cell birth-rate
was only very slightly increased in the tumours, whilst the
cell turnover-time was actually longer (Bleiberg and Galand,
1976). The finding of such tumour-associated variation in
transcription of numbers of RNA sequences is, however,
certainly consistent with other studies using similar
approaches in e.g. experimental mouse colonic carcinoma
(Augenlicht & Kobrin, 1982) and human leukaemias (Weidemann
et al. 1983). These sequences may encode proteins which
may be critical to the malignant phenotype or may simply
represent genetic loci randomly and apparently
inappropriately activated in malignancy (e.g. in this tumour
type embryonic genes such as carcinoembryonic antigen).
If so desired, further study of such sequences in clones of
interest would be made possible by bulk isolation of
recombinant plasmid DNA to study the size of
1;
the transcripts by Northern Blotting techniques (Maniatis,
1982) to identify genomic clones where available (Maniatis
et al, 1982) and for use as radiolabelled probes for in
in situ hybridisation to permit both cellular and
chromosomal localisation of these genes and the site of
their transcription in vivo (Hafen et al, 1983; Cox et al,
1984). The nucleotide sequence of these clones may be
determined (Sanger et al, 1977) and used to determine the
primary protein structure encoded and thus its
identification if the protein is already known. Such
studies are not planned in the meantime since these
recombinant clones are not apparently related to the object
of the study, (i.e. characterisation of a possible
metastatic phenotype), although they are clearly of some
interest as cancer-associated sequences.
5. Significance of Transcription of Ras -Family Oncogenes
Although some elevation in steady-state transcription
levels of ras -related oncogene RNA was observed in all
these tumours the degree of elevation did not appear to be
related to clinically-apparent phenotypic variation. As
discussed above in the context of the PMRCs study of random
biopsies would mean that if critical differences in tumour
cell sub-populations did exist then these would not be
detected. In the context of ras oncogene expression in
these tumours we (Kerr et al, 1985) and others (Williams
et al, 1985) have however demonstrated widespread positive
staining of ras oncogene p21 by immunocytochemical means.
These findings are consistent with a more recently
published study showing similar elevations of ras oncogene
p21 protein levels in these tumours which could not be
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correlated exactly with conventional staging criteria.
Study of metastatic tumour deposits however, showed,
interestingly, that they contained relatively low levels of
p21 (Gallick et al, 1985). A previous immunocytochemical
study of p21 expression had shown variable reactivity in
formalin-fixed paraffin-embedded sections of tumours and
had suggested that this was related to more aggressive
behaviour (Thor et al, 1984). The reasons for the
discrepancy in reactivity seen in these studies is
discussed elsewhere (Kerr et al, 1985). Our own findings
have since been confirmed by subsequent reports in breast
tumours (Ghosh et al, 1986), using the anti-p21 antibody
described by Thor et al.
For reasons discussed in the preceding section it does
not seem likely that the differences observed were in any
way related to differences in cell-growth kinetics between
the carcinomas and normal mucosa.
Although activated ras oncogenes have been
demonstrated in a wide variety of human tumours (Balmain,
1985) it is not yet clear in general at what stage this
occurs. Ras activation has been shown experimentally in
mouse skin papillomas as well as carcinomas (Balmain et al,
1984) and in a more aggressive late tumour variant of a
mouse lymphoma (Vousden and Marshall, 1984). Variation in
the levels of transcription of various oncogenes, including
the ras family, has now been shown in a wide range of
tumours e.g. Slamon et al, 1984; Tatosyan et al, 1985)
although it is not yet clear in the majority of cases what
significance this might have in the context of the clinical
behaviour of these tumours. A recent s.tudy of the
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significance of elevated c- myc transcript levels in
colorectal tumours has similarly failed to demonstrate any
correlation with conventional staging criteria (Rothberg
et al, 1985). In a previously cited study, however, it was
noted, interestingly, that several specimens of metastatic
tumour (although not in colorectal carcinoma) showed
elevated levels of c- sis transcription (Tatosyan et al,
1985). A study of ras transcription in (B16) experimental
murine melanoma cell lines of differing metastatic
potential also failed to demonstrate differences in levels
of ras oncogene transcription (Kris et al, 1985). It has,
however, been shown that amplification of the N- myc
oncogene is related to tumour stage in neuroblastoma
(Brodeur et al, 1984) and a study of c- myc expression in a
series of human leukaemias showed increased levels of
transcripts to be apparently related to a more immature
phenotype (Birnie et al, 1986). In a related study, we
(Spandidos and Kerr, 1984) have shown elevated steady-state
levels of transcripts of ras family oncogenes in pre-
malignant as well as in malignant tumours of the colorectum
as compared to normal mucosa and have hypothesised that
activation of these genes at a premalignant stage might be
critical in the process of carcinogenesis but not in itself
sufficient. The results of the present study of the
clinical significance of this variation would certainly not
be inconsistent with such a hypothesis. It may therefore
be that activation of a variety of other gene loci,
possibly associated with the well-recognised genomic
instability in cancer, (Nowell, 1976) are more directly
involved in the generation of a frankly-malignant phenotype
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and its variants. Since Ha- ras activation has now also
been described in colorectal carcinoma (Greenhalgh and
Kinsella, 1985) it may also be that variation in the type
of ras oncogene activated where this occurs, or variation
in the nature of the mutations around codons 12 and 61 (see
Introduction, Section 12) may be significant in this
context. In a series of urothelial tumours recently
reported however (Fujita et al, 1984), neither the presence
of atransforming ras oncogene in DNA in a small percentage
of cases nor the absence or presence of a documented
mutation in them appeared to be related to tumour stage.
The presently-existing evidence would therefore seem to
suggest that activation of ras oncogenes may be a
relatively early event in colorectal carcinogenesis and
that expression of high levels of ras p21 certainly does
not appear to be necessary for a metastatic phenotype.
6. Future Investigations
The most obvious next step is to proceed to the
cloning of a cDNA library from a metastatic tumour deposit
itself, and a preliminary report by our group of the
results of such an approach has already been made (Elvin et
al, 1986). Developments in the techniques of cDNA synthesis
in a greatly-reduced number of steps have made it possible
to work with very much smaller amounts of polyadenylated
RNA. This strategy in addition obviates the problem raised
by the possibility that cells of metastatic potential may
exist as only a subpopulation of a primary tumour.
Identification of cDNA clones possibly associated with a
metastatic phenotype would in addition make it possible to
address the question of metastatic tumour cell
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heterogeneity in primary tumours by using probes prepared
from such clones for in situ hybridisation of tissue
sections (see Hafen et al & Cox et al, 1984). It does
remain possible of course that such changes observed in a
metastatic tumour deposit might be induced by local tissue
factors or be a result of fusion with host cells as has
been described in experimental systems at least (Kerbel
et al, 1983) although so far there is no evidence for this
being an occurrence in human cancer. In addition, recent
advances in cloning technology are making it possible to
study biologically-significant RNA populations possibly
present at only low abundance. Cloning vectors have
been described which permit the direct selection of such
cDNA clones. This approach uses single-stranded DNA
packaged into phage particles which provides the larger
amount of cDNA required to drive the hybridisation reaction
(Kowalski et al, 1985). An alternative approach has been
described to detect such low-abundance mRNAs using a probe
from which common mRNAs from differing cell populations
are removed by the use of plasmid DNA coupled to
cellulose to provide a reusable preparative hybridisation
probe capable of removing cell sequences present in common
(Scott et al, 1983). This approach requires however the
use of large amounts of RNA and it is not entirely clear
how accurate or reproducable this technique will be. Such
an approach to low-copy number sequences has, however, been
used to clone the T cell receptor (Hedrick et al, 1985),
although in that case a partial probe was already
available.
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The latter method in particular, dealing as it would
with very large numbers of low-abundance RNAs, would be
extremely labour-intensive. However, if no obvious
differences between the transcription of the highly-
abundant RNA species in metastases and non-metastatic
tumour are apparent then it would obviously be necessary to
consider such alternative strategies.
Approaches other than the use of cDNA libraries may
well also prove to be rewarding. These would include
consideration of the use of biological transfection assays
analagous to those used to detect activated oncogenes in
human tumour DNA (see Introduction, Section 12).
Preliminary attempts at such an assay using mouse epidermal
cells in culture transfected by an activated Ha-ras
oncogene have already been undertaken using DNA from a
series of metastatic tumour specimens in conjunction with
Dr. A. Balmain (Beatson Institute, Glasgow). This cell
line is locally invasive when injected subcutaneously into
syngeneic mice but does not metastasise. It is hoped that
transfection of tumour DNA from metastases from these and
other tumours might confer metastatic capability on these
cells following transfection. However, assay of their
growth and behaviour in mice has so far proved
unrewarding. Such approaches will undoubtedly depend on
the use of very carefully-defined model systems. One report
of the preliminary characterisation of a gene isolated by
such an approach from a cervical carcinoma cell-line and
apparently capable of conferring a metastatic phenotype
has already been made (Bernstein and Weinberg 1985).
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Both of the approaches discussed above attempt to
define activation of genes, possibly previously
uncharacterised, in the process of metastasis either by
empirical correlation based on clinical behaviour or by
biological assays.
A wide range of cloned gene probes is, however, now
becoming available and it is possible that a judicious
selection from these in study of metastatic tumour cells
would reveal useful information in relation to variation in
the behaviour of malignant cells. These include most
obviously the list of oncogenes (see Introduction, Section
12) and it is to be anticipated that a more full
documentation of their role in both carcinogenesis and
variation in the clinical behaviour of tumours will
generate information of biological interest and clinical
usefulness, as discussed in the preceeding section. Study
of the role of growth factors and their receptors in
tumours, overlapping as it does with the role of oncogenes,
will also undoubtedly yield information of considerable
usefulness. It has for example recently been shown that
the level of expression of epidermal growth factor (EGF)
receptors in a series of primary breast carcinomas is
related to their aggression (Sainsbury, 1985).
Study of the role of murine H-2 (MHC) determinants by
transfection of H-2 genes has shown in addition this to be
associated with the abrogation, in vitro at least, of the
metastatic properties of a tumour cell-line (Wallich et al,
1985).
Such studies will proceed not only by evaluation of
levels of transcription of these genes, but also of their
expression at the protein level by methods such as
immuno-cytochemistry where suitable antibodies are
available. Clearly the list of gene products of possible
relevance extends considerably and includes for example
various structural and immunological determinants of cell
behaviour and if such studies are not to become
unmanageable in size would clearly require to be rigorously
selective.
7. Conclusions
If, as seems reasonable to assume, the ability of a
tumour cell to metastasize is related to its phenotypic
characteristics then it may be expected that study of those
determinants at the level of gene transcription by the
methods described above will ultimately yield information
of considerable usefulness. Although there are, as
discussed above, limitations, rapidly diminishing, to the
techniques employed it appears from the initial part of
this study that variation in the metastatic behaviour of a
series of colorectal carcinomas can not be correlated with
single major differences in gene expression as determined
using the series of (PMRC) probes isolated and observed in
random biopsies.
Similarly, variation in steady-state levels of ras
family oncogene RNA transcripts in these biopsies do not
appear to be related to variation in the clinical behaviour
of these tumours, although ras oncogene activation has been
implicated in the genesis of colorectal carcinoma.
Nonetheless, it is to be anticipated that further such
studies of gene expression in metastatic tumours using
similar techniques and refinements of .them to study changes
in transcription of, possibly large, numbers of low-
abundance RNA species will contribute valuable insights
into the molecular pathology of metastasis.
This is particularly the case since such study may
describe expression of previously uncharacterised genes and
represents a significant advantage of the use of such
techniques.
As well as being of biological interest study of such
gene transcripts and their nucleotide sequences as well as
their encoded peptide gene products would permit for
example production of highly-specific immune reagents to
them (Vitteta et al, 1983). These could have considerable
diagnostic value in, for example, predictive clinical tests
or in study of tumour progression and of the possible
existence of metastatic cell sub-populations, as well as,
possibly, therapeutic potential.
The importance of new approaches to these problems
continues to be stressed in recent literature concerning
e.g. tumour staging in general (Henson, 1985), as well as
in the context of adjuvant local (Taylor et al, 1985) and
systemic (Gastro-Intestinal Study Group 1985) therapy for
colorectal cancer, in which the overall incidence and
significance of "occult" metastatic disease has been
confirmed by more recent studies (Leveson et al, 1985).
It is also to be anticipated that the numerous on¬
going studies, such as that described above, of the
clinical significance of the activation and expression of
cellular oncogenes and related genes such as those encoding
growth factors and their receptors will contribute
information of both diagnostic and possibly therapeutic
value.
1
It is thus to be hoped that such approaches will
shortly be contributing to the beginnings of an
under standing of the molecular pathology of the still very





Affara, N.A., Jaquet, M. , Jakob, H., Jacob, F., & Gros, F.
(1977)
Comparison of polysomal polyadenylated RNA from embryonal
carcinoma and committed myogenic and erythropoietic cell
1ines.
Cell, 12: 509-520.
Affara, N.A., Goldfarb, P.S, Vass, K., Lyons, A. &
Harrison, P.R. (1981)
Cloning of a new mouse foetal 3_globin mRNA sequence.
Nucleic Acids Research, 9_; 3061-3075.
Affara, N., Goldfarb, P.S., Yang, Q.S., & Harrison, P.R.
(1983)
Patterns of expression of erythroblast non-globin mRNAs.
Nucleic Acids Research, 1_1_: (4): 931-945.
Alberts, B.R., Bray, D., Lewis, J. et al. (1983)
In: The Molecular Biology of the Cell, Garland
Publishing Inc.
New York & London, 406-427.
Albino, A.P., Lloyd, K.O., Houghton, A.N., Oettgen, H.F., &
Old, L.J. (1981)
Heterogeneity in surface antigen and glycoprotein
expression of cell lines derived from different melanoma
metastases of the same patient. Implications for the
study of tumour antigens.
Journal of Experimental Medicine, 154: 1764-1778.
Alexander, P. (1976)
Dormant metastases which manifest on immunosuppression and
the role of macrophages in tumours. In: Fundamental
Aspects of Metastasis, (ed) Weiss, L., N . Holland
Publishing, Amsterdam-Oxford. 227-239.
Alexander, P. (1982)
Control of metastatic spread by the immune defence of the
host. In: Clinics in Oncology 1_: ( 2): 629-635.
Alexander, P. (1983)
Dormant metastases - studies in experimental animals.
Journal of Pathology, 141: (3): 379-384.
Alitalo, K., Schwab, M., Lin, C.C., Varmus, H.E. & Bishop
J.M. (1983)
Homogeneously staining chromosomal regions contain
amplified copies of an abundantly expressed cellular
oncogene (c- myc ) in malignant neuroendocrine cells from
a human colon carcinoma.
Proceedings National Academy of Science (USA), 80:
1707-1711.
Amer, M.H. (1982)
Chemotherapy and patterns of metastasis in breast cancer
patients.
Journal of Surgical Oncology, 19: 101-105.
1
Arends, J.W. , Wiggers, T., Thijs, C.T., Verstijnen, C.,
Swaen, G.J.V. & Bosman, F.T. (1984)(a)
The value of secretory component (sc) immunoreactivity
in diagnosis and prognosis of colorectal carcinomas.
American Journal of Clinical Pathology, 82; 267-274.
Arends, J.W., Wiggers, T., Vestijnen, C., Hilgers, J. &
Bosman, F.T. (1984)(b)
Gastro-intestinal cancer-associated antigen (GICA)
immunoreactivity in colorectal carcinoma in relation to
patient survival.
International Journal of Cancer, 34: 193-196.
Auer, G.U., Arrhenius, E. , Granberg, P.O., & Fox, C.H.
(1980)
Comparison of DNA distributions in primary human breast
cancer and their metastases.
European Journal of Cancer, 16: 273-278.
Astler, V.B. & Coller, F.A. (1954)
The prognostic significance of direct extension of
carcinoma of the colon and rectum.
Annals of Surgery, 139: 846-852.
Atkin, N.B. & Kay, R. (1979)
Prognostic significance of modal DNA value and other
factors in malignant tissues based on 1465 cases.
British Journal of Cancer, 40: 210-221.
Augenlicht, L.H., & Kobrin, D. (1982)
Cloning and screening of sequences expressed in a mouse
colon tumour.
Cancer Research, 42: 1088-1093.
August, D.A., Ottow, R.T., Sugarbaker, P.H. (1984)
Clinical perspective of human colorectal cancer
metastasis.
Cancer Metastasis Reviews, 3^: 303-324.
Aviv, H. & Leder, P. (1972)
Purification of biologically active globin messenger RNA
by chromotography on oligo thymidylic acid cellulose.
Proceedings National Academy of Science, 69: 1408-1412.
Balmain, A. (1985)
Transforming ras oncogenes and multistage carcinogenesis.
British Journal of Cancer, 51: 1-7.
Balmain, A. & Pragnell, I.B. (1983)
Mouse skin carcinomas induced in vivo by chemical
carcinogens have a transforming Harvey- ras oncogene.
Nature, 303: 72-74.
Balmain, A., Ramsden, M., Bowden, G.T. & Smith, J. (1984)
Activation of the mouse cellular Harvey- ras gene in




Si-Terminal Cap Structure in Eukaryotic Messenger
Ribonucleic Acids.
Microbiol. Review, 44: 175-205.
Barker, D., McCoy, M. & Weinberg, R.A. et al (1983)
A test of the role of two oncogenes in inherited
predisposition to colon cancer.
Mol. Biol. Med., 1: 199-206.
Bastos, R.N., Volloch, Z. & Aviv, A.J. (1977)
Messenger RNA population analysis during erythroid
differentiation.
Journal of Molecular Biology, 110: 191-203.
Baylin, S.B., Weisburger, W.R., Eggleston, J.C. et al.
(1978)
Variable content of histaminase L-Dopa decarboxylase and
calcitonin in small-cell carcinoma of the lung.
New England Journal of" Medicine, 299: 105-110.
Beahrs, O. & Myers, M. (1983)
(eds) Manual for staging of cancer 2nd Edn.
J.B. Lippincott, Philadelphia.
Becher, R., Gias, Z., & Sandberg, A.A. (1983)
Involvement of chromosomes 7 and 12 in large bowel cancer:
Trisomy 7 and 12q-
Cancer Genetics and Cytogenetics, 9_z 329-332.
Bengtsson, G.B., Carlsson, G., Hafstrom, L. et al. (1981)
The natural history of patients with untreated liver
metastases from colorectal cancer.
American Journal of Surgery, 141: 586-589.
Bernstein, S.C. & Weinberg, R.A. (1985)
Expressions of the metastatic phenotype in cells
transfected with metastatic tumour DNA.
Proceedings National Academy of Science (USA), 82:
1726-1730.
Beyer, A.L., Miller, O.L. & Mcknight, S.L. (1980)
Ribonucleoprotein structure in mascent hnRNA is non-random
and sequence-dependent.
Cell, 20 : 75-84.
Birnboim, H.C. & Doly, J. (1979)
A rapid alkaline extraction procedure for screening
recombinant plasmid DNA.
Nucleic Acids Research, l_z 1513-1523.
Birnie, G.D. (1978)
Isopyenic centrifugation in ionic media. In: Centrifugal
Separations in Molecular and Cell Biology, (eds) Birnie,
G.D. & Rickwood, D.
Butterworths, London, 167-217.
Birnie, G.D., Burns, J., Wiedemann, L. et al. (1983)
A new approach to the classification of human leukaemias:
measurement of the relative abundance' of a specific RNA
sequence by means of molcular hybridisation.
Lancet, i: 197-200.
12
Birnie, G.D., Warnock, A.M., Burns, J.H. & Clark, P. (1986)
Expression of the myc gene locus in populations of
leucocytes from leukaemia patients and normal individuals.
Leukaemia Research, In press.
Bishop, J.M. (1983)
Cellular oncogenes and retroviruses.
Annual Review of Biochemistry, 52: 301-354.
Bleiberg, H., Buyse, M., Vanden Heule, B. & Galand, P.
(1984)
Cell-cycle parameters and prognosis of colorectal cancer
European Journal of Cancer and Clinical Oncology, 20:
391-396.
Bleiberg, H. & Galand, P. (1976)
In vitro autoradiographic determination of cell kinetic
parameters in adenocarcinomas and adjacent healthy mucosa
of the human colon and rectum.
Cancer Research, 36: 325-328.
Blumberg, D.D., & Lodish, H.F. (1980)
Changes in the messenger RNA population during
differentiation of Dictyostelium discoideum.
Developmental Biology, 78: 285-300.
Brandhoest, B.P. (1976)
Two dimensional gel patterns of protein synthesis before
and after fertilisation of sea urchin eggs.
Developmental Biology, 52: 310-317.
Brattain, M.G., Fine, W.D., Khaled, F.M., Thompson, J. &
Brattain, D.E. (1981)
Heterogeneity of malignant cells from a human colonic
carcinoma.
Cancer Research, 41: 1751-1756.
Breathnach, R., & Chambon, P. (1981)
Organisation and expression of eukaryotic split genes
coding for proteins.,
Annual Review of Biochemistry, _50 : 34 9-383.
Brodeur, G.M., Seefer, R.C., Schwab, M., Varmus, H.E. &
Bishop, J.M. (1984)
Amplification of N- myc in untreated human neuroblastomas
correlates with advanced stage.
Science, 224: 1121-1124.
Brooks, C.G., Flannery, C.R., Willmott, N., Austin, E.B.,
Kenwick, S. & Baldwin R.W. (1981)
Tumour cells in metastatic deposits with altered
sensitivity to natural killer cells.
International Journal of Cancer, 28: 191-198.
Brown, D.D. (1981)
Gene expression in eukaryotes.
Science, 211: 667-674.
Brunson, K.W., Beattie, G. & Nicolson, G.L. (1978)




"Immune surveillance". Pergamon Press. Oxford.
Butler, T.P. & Gullino, P.M. (1975)
Quantitation of cell shedding into efferent blood of
mammary adenocarcinoma.
Cancer Research, 35; 512-516.
Cancer Statistics. (1984)
Ca. A Cancer Journal for Clinicians.
American Cancer Society, 34: 7-23.
Cairns, J. (1981)
The origin of human cancers.
Nature, 289: 353-357.
Capon, D.J., Seeburg, P.H., McGrath, J.P. et al (1983)
Activation of Ki-ras 2 gene in human colon and lung
carcinomas by two different point mutations.
Nature, 304: 507-513.
Carter, R.L. (1976)
'Metastasis' In: Scientific Foundation of Oncology
(ed) Symington T. & Carter, R.L.
Heinemann, London, 172-181.
Cech, T.R. (1983)
RNA splicing: Three themes with variations.
Cell, 34: 713-716.
Chambers, A.F., Hill, R.P., & Ling, V. (1981)
Tumour heterogeneity and stability of the metastatic
phenotype of mouse KHT Sarcoma cells.
Cancer Research, 41: 1368-1372.
Cheingsong-Popov, R., Robinson, P., Altevogt, P., &
Schirrmacher, V. (1983)
A mouse hepatocyte carbohydrate-specific receptor and i
interaction with 1iver-metastasizing tumour cells.
International Journal of Cancer, 32 : 359-366 .
Chirgwin, J.M., Pryzybyla, A.E., MacDonald, R.J. &
Rutter, W.J. (1979)
Isolation of biologically active ribonucleic acid from
sources enriched in ribonuclease.
Biochemistry, 18: 5294-5299.
Chung, S., Landfear, S.M., Blumberg, D.D., Cohen, N.S. &
Lodish, H.F. (1981)
Synthesis and stability of developmentally regulated




Clewell, D.B., & Helinski, D.R. (1970)
Properties of a supercoiled DNA-protein relaxation complex
and strand specificity of the relaxation event.
Biochemistry, 9_: 4428-4440.
Cochet, M., Perrin, F., Gannon, F., Krust, A., &
Chambon, P. (1979)
Cloning of an almost full length chicken covalbumin
double-stranded cDNA.
Nucleic Acids Research, j>: 2435-2452.
Coman, D.R. (1953)
Mechanisms responsible for the origin and distribution of
blood-borne tumour metastases.
Cancer Research, 13: 397-404.
Cooper, G.M. (1984)
Activation of transforming genes in neoplasms.
British Journal of Cancer, 50: 137-142.
Corasanti, J.G., Celik, G., Camiolo, S.M., et al. (1980)
Plasminogen activator content of human colon tumours and
normal mucosae: separation of enzymes and partial
pur ification.
Journal of National Cancer Institute, 65: 345-351.
Corman, M.L., Veidenheimer, M.C., Coller, J.A. (1979)
Colorectal carcinoma: A decade of experience at the Lakey
Clinic.
Diseases of Colon & Rectum, 22: 477-479.
Cox, K.H., Deleon, D.V., Angerer, L.M. & Angerer, R.C.
(1984)
Detection of mRNAs in sea urchin embryos by in-situ
hybridisation using asymmetric RNA probes.
Developmental Biology, 101: 485-502.
Crampton, J., Humphries, S., Woods, D. & Williamson, R.
(1980)
The isolation of clonal cDNA sequences which are
differentially expressed in human lymphocytes and
fibroblasts.
Nucleic Acids Research, 8^: 6 00 7-6017.
Daar, A.S., Fuggle, S.V., Ting, A., Fabre, J.W. (1982)
Anomalous expression of HLA-DR antigens on human
colorectal cancer cells.
Journal of Immunology, 129: 447-449.
Dagert, M., Ehrlich, S.D. (1979)
Prolonged incubation in calcium chloride improves the
competence of Escherischia coli cells.
Gene, 6^: 23-28.
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D.,
Gallo, R.C. & Crocc, C.M. (1982)
Human c- myc one gene is located on the region of
chromosome 8 that is translocated in Burkitt lymphoma
cells. .




Variety in the level of gene control in eukaryotic cells.
Nature, 297: 365-371.
deKlein, A., van Kessel, A.G., Groswold, G. et al (1982)
A cellular oncogene is translocated to the Philadelphia
chromosome in chronic myelocytic leukaemia.
Nature, 300: 765-767.
Derman, E.K., Krauter, L., Walling, C., Weinberger, M.R. &
Darnell, J.E. (Jnr) (1981)
Transcriptional control in the production of
liver-specific mRNAs.
Cell, 23: 731-739.
Diala, E.S., Cheah, M.S.C., Rowitch, D. & Hoffmann, R.M.
(1983)
Extent of DNA methylation in human tumour cells.
Journal of National Cancer Institute, 71: 755-764.
Doll, R. (1972)
Cancer in Five Continents.
Proceedings of the Royal Society of Medicine, 65: 49-55.
Donaldson, G.A. & Welch, J.P. (1974)
Management of cancer of the colon.
Surgical Clinics of North America, 54: 713-731.
Donelli, M.G. Colombo, T., Broggini, M. & Garattini, S.
(1977)
Differential distribution of anti-tumour agents in primary
and secondary tumours.
Cancer Treatment Report, 61: 1319.
Dukes, C.E. (1932)
The classification of cancer of the rectum.
Journal of Pathology and Bacteriology, 35: 323-332.
Early, P., Rogers, J., Davis, M. et al (1980)
Two mRNAs can be produced from a single immunoglobulin
M gene by alternative RNA processing pathways.
Cell, 20: 313-319.
Eccles, S.A., Heckford, S.E. & Alexander, P. (1980)
Effect of cyclosporin A on the growth and spontaneous
metastasis of syngeneic animal tumours.
British Journal of Cancer, \2_: 25 2-259.
Eisenbach, L., Segal, S. & Feldman, M. (1983)
MHC imbalance and metastatic spread in Lewis lung
carcinoma clones.
International Journal of Cancer, 32: 113-120.
Ellis, R.W., Defeo, D., Maryhak, J.M. et al. (1980)
Dual evolutionary origin for the rat genetic sequences of
Harvey murine sarcoma virus.
Journal of Virology, 36: 408-420.
1
Ellis, R.W., Defeo, D., Shih, T.Y. et al. (1981)
The p21 src genes of Harvey and Kirsten sarcoma viruses
originate from different members of a family of normal
vertebrate genes.
Nature, 292: 506-511.
Elvin, P. & Evans, C.W. (1984)
Cell adhesion and experimental metastasis: A study using
the B16 malignant melanoma model system.
European Journal of Cancer Clinics & Oncology, 20:
107-114.
Elvin, P., Kerr, I.B., Birnie, G.D. & McCardle, C.S. (1986)
Isolation of cloned cDNAs from mRNAs associated with
tumour progression and metastasis in colorectal cancer.
(B.A.C.R. Abstract). Br. J. Cancer (In Press).
Ewing, J. (1928)
In: Neoplastic Diseases 3rd Edn.
Saunders, Philadelphia.
Fantoni, A.J., Bozzoni, I., Ullu, E. & Farace, M.G. (1979)
Construction of a recombinant plasmid containing DNA
sequences for a mouse embryonic globin chain.
Nucleic Acids Research, 6q 3505-3517.
Fialkow, P.J. (1976)
Clonal origin of human tumours.
Biochem Biophys Acta, 458: 283-321.
Fidler, I.J. (1970)
Metastasis: Quantitative analysis of distribution and
fate of tumour emboli labelled with 125l-5-iodo-2l-deoxy-
uridine.
Journal of the National Cancer Institute, 45: 773-782.
Fidler, I.J. & Kripke, M. (1977)
Metastasis results from pre-existing variant cells within
a malignant tumour.
Science, 197: 893-895.
Finlay, I.G. & McArdle, C.S. (1982)
The identification of patients at high risk following
curative resection for colorectal carcinoma.
British Journal of Surgery, 69: 583-584.
Finlay, I.G., Brunton, E.F., Meek, D. & McArdle, C.S.
(1982)
Rate of growth of hepatic metastases in colorectal
carcinoma.
British Journal of Surgery, 69: 689.
Finlay, I.G. & McArdle, C.S. (1983)
Role of carcinoembryonic antigen in detection of
asymptomatic disseminated disease in colorectal carcinoma.
British Medical Journal, 286: 1242-1244.
Fisher, B. ( 1984 )
In: Cancer Invasion and Metastasis: Biologic and
Therapeutic Aspects (ed) Nicolson, G.L. & Milas, L.
Raven Press, New York, 27-43.
1
Fisher, E.R. & Turnbull, R.B.(Jnr). (1955)
Cytologic demonstration and significance of tumour cells
in the mesenteric venous blood in patients with colorectal
cancer.
Surgical Gynaecology & Obstetrics, 100: 102-108.
Fitzgerald, M. and Shenk, T. (1981)
The sequence 51-AAUAAA-31 forms part of the recognition
site for polyadenylation of late SV40 mRNAs.
Cell, 24; 251-260.
Fitzpatrick, F.A. & Stringfellow, D.A. (1979)
Prostaglandin D2 formation by malignant melanoma cells
correlates inverseley with cellular metastatic potential.
Proceedings National Academy of Science (USA), 76:
1765-1769.
Fo1kma n n, J. (19 7 4)
Tumour angiogenesis factor.
Cancer Research, 34: 2109-2113.
Folkmann, J. (1982)
Tumour invasion and metastasis. In Cancer Medicine,
(eds) Holland, J. & Frei E.
Lea & Febiger, Philadelphia, 167-175.
Forrest, A.P.M. & Cant, E.L.M. (1976)
Surgery and Malignant Disease: A Reappraisal in Scientific
Foundation of Oncology, (ed) Symington, T. & Carter, R.L.
Heinemann, London, 605-612.
Forster, S.J., Talbot, I.C. & Critchley, D.R. (1984)
Laminin and fibronectin in rectal adenocarcinoma:
Relationship to tumour grade, stage and metastasis.
British Journal of Cancer, 50: 51-61.
Foulds, L. (1969)
Neoplastic Development, London, Academic Press.
Franks, L.M. (1973)
In: Chemotherapy of Cancer Dissemination and Metastasis,
(eds) Garattini, S. & Franchi, G.
Raven Press, New York, 71-78.
Fujita, J., Yoshida, O., Ynasa, Y., Rhim, J.S., Hatamaka, M
& Aaronson S. (1984)
Ha- ras oncogenes are activated by somatic alterations in
human urinary tract tumours.
Nature, 309: 464-466.
Gallick, G.E., Kurzrock, R., Kloetzer, W.S.,
Arlinghaus, R.B. & Guttermann, J.U. (1985)
Expression of p21 ras in fresh primary and metastatic
human colorectal tumours.
Proceedings of the National Academy of Science (USA), 82:
1795-1799.
Gastrointestinal Tumour Study Group. (1985)
Prolongations of the disease-free interval in surgically
treated rectal carcinoma.
New England Journal of Medicine, 312: 1465-1472.
1
Gebhart, E., Brilderlein, S., Tulusan, A.H., Maillot, K.V. &
Birkmann, J. (1984)
Incidence of double minutes, cytogenetic equivalent of
gene amplification, in human carcinoma cells.
International Journal of Cancer, 34: 369-373.
Getz, M.J., Birnie, G.D., Young, B.D., MacPhail, E. &
Paul, J. (1975)
A kinetic estimation of base sequence complexity of
nuclear poly A- containing RNA in mouse Friend cells.
Cell, 4: 121-129.
Ghosh, A.K., Moore, M. & Harris, M. (1986)
Immunohistochemical detection of ras oncogene p21 product
in human benign and malignant mammary tissue.
Journal of Clinical Pathology, (In press).
Giavazzi, R., Alessandri, G., Spreafroo, F., Garattini, S.&
Mantovani, A. (1980)
Metastasizing capacity of tumour cells from spontaneous
metastases of transplanted murine tumours.
British Journal of Cancer, 42: 462-47 2.
Gill, P.G. & Morris, P.J. (1978)
The survival of patients with colorectal cancer treated
in a regional hospital.
British Journal of Surgery, 65: 17-20.
Glucksmann, A. (1948)
The relation of radiosensitivity and radiocurability to
the histology of tumour tissue.
British Journal of Radiology, 21: 559-566.
Goelz, S.E., Vogelstein, B., Hamilton, S.R. & Feinberg,
A.P. (1985)




The operability of carcinoma of the rectum.
British Medical Journal, ii: 393-397.
Gonda, T.J., Sheiness, D.K. & Bishop, J.M. (1982)
Transcripts from the cellular homologs of retroviral
oncogenes. Distribution among chicken tissues.
Molecular & Cellular Biology, 617-624.
Greaves, P., Filipe, M.I. & Branfoot, A.C. (1980)
Transitional mucosa and survival in human colorectal
cancer.
Cancer, 46: 764-770.
Greenhalgh, D.A. & Kinsella, A.R. (1985)




Grdina, D.J., Hittelman, W.N., White, R.A. &
Meistrich, M.L. (1977)
Relevance of density, size and DNA content of tumour cells
to the lung colony assay.
British Journal of Cancer, 36; 659-669 .
Griffiths, J.D., McKinna, J.A., Rowbotham, H.D. et al.
(1973)
Carcinoma of the colon and rectum; circulating malignant
cells and 5 year survival.
Cancer, 31; 226-236.
Grinnell, R.S. (1939)
The grading and prognosis of carcinoma of the colon and
rectum.
Annals of Surgery, 109: 500-533.
Grinnell, R.S. (1953)
Results in the treatment of carcinoma of the colon and
rectum. An analysis of 2341 cases over a 35 year period
with 5 year survival results in 1667 patients.
Surgical Gynaecology and Obstetrics, 96: 31-42.
Grunstein, M. & Hogness, D. (1975)
Colony hybridisation: a method for the isolation of cloned
DNAs that contain a specific gene.
Proceedings of the National Academy of Science (USA), 72:
3961-3965.
Guerrero, I., Calzada, P., Mayer, A. & Pellicer, A. (1984)
A molecular approach to leukaemogenesis: mouse lymphomas
contain an activated c- ras oncogene.
Proceedings National Academy of Science (USA), 81:
202-205.
Gubler, U. & Hoffman, B. (1983)
A simple and very efficient method for generating cDNA
libraries.
Gene, 25: 263-269.
Gunderson, L.L. & Sosin, H. (1974)
Areas of failure found at reoperation (second or
symptomatic book) following "curative surgery" for
adenocarcinoma of the rectum.
Cancer, 34: 1278-1292.
Guy, D., Latner, A.L. & Turner, G.A. (1979)
Surface protein distributions in cells isolated from
solid tumours and their metastases.
British Journal of Cancer, 40: 634-640.
Guyette, W.A., Matuskin, R.J. & Rosen, J.M. (1979)
Prolactin-mediated transcriptional and post-
transcript ional control of casein gene expression.
Cell, 17: 1013-1023.
1L
Hafen, E., Levine, M. , Garber, R.L. & Gehring, W.J. ( 1983)
An improved in-situ hybridisation method for the detection
of cellular RNAs in the Drosophila tissue sections and its
application for localising tanscripts of the homeotic
Antennapedia gene complex.
The EMBO Journal, 2: 617-623.
Hagenbiichle, 0. , Tosi, M. , Schibber, U. , Bovey, R. ,
Wellaner, P.K. & Young, R.A. (1981)
Mouse liver and salivary gland -amylase RNAs differ only
in 5l non-translated sequences.
Nature, 289: 643-646.
Haninia, N., Schaool, D., Hard, J., Wiels, J. & Tursz, J.
(1983)
Common multigenic activation in different human neoplasms.
The EMBO Journal, 2: 1621-1624.
Harris, H., Miller, O.J., Klein, G., Worst, P. &
Tachibana, T. (1969)
Suppression of malignancy by cell fusion.
Nature, 223: 363-368.
Hart, I.R. (1984)
In: UICC Study Group in Basic and Clinical Cancer
Research: Cancer Metastasis, (ed) Fidler, I.J. &
Burger, M.M.
International Journal of Cancer, 33: 1-3.
Hart, I.R. & Fidler, I.J. (1981)
The implications of tumour heterogeneity for studies on
the biology and therapy of cancer metastasis.
Biochem Biophys Acta, 651: 37-50.
Hastie, N.D. & Held, W.A. (1978)
Analysis of mRNA populations by cDNA: mRNA hybrid-mediated
inhibition of cell-free protein synthesis.
Proceedings of the National Academy of Science (USA), 75:
1217-1221.
Hedrick, S.M., Cohen, D.I., Nieldson, E.A. & Davis, M.M.
(1984)
Isolations of cDNA clones encoding T cell-specific
membrane-associated proteins.
Nature, 308: 149-153.
Heldin, C.H. & Westermark, B. (1984)





Archives of Pathology & Laboratory Medicine, 109: 13-16.
Hewitt, H.B. & Blake, E. (1975)
Quantitative studies of translymphnodal passage of tumour
cells naturally disseminated from a non-immunogenic
murine squamous carcinoma. <
British Journal of Cancer, 31: 25-35.
1
Hewitt, H.B. (1978)
The choice of animal tumours for experimental studies of
cancer therapy.
Advances in Cancer Research, 27: 149-200.
Hine, K.R. & Dykes, P.W. (1984)
Serum CEA testing in the post-operative surveillance
of colorectal carcinoma.
British Journal of Cancer, 49: 689-693.
Holdaway, I.M. & Bowditch, J.V. (1983)
Variation in receptor status between primary and
metastatic breast cancer.
Cancer, 5 2: 479-485.
Hoover, H.C. (1984)
In: UICC Study Group in Basic and Clinical Cancer
Research: Cancer Metastasis (ed) Fidler, I.J. &
Burger, M.M.
International Journal of Cancer, 33: 1-3.
Huebner, R.J. & Todaro, S.J. (1969)
Oncogenes of RNA tumour viruses as determinants of cancer.
Proceedings of the National Academy of Science, 64:
1087-1094 .
Hughes, E.S.R., McDermott, F.T., Johnson, W.R. (1981)
Management of recurrent large bowel cancer. In: Large
bowel cancer, (ed) deCosse, J.J.
Churchill Livingstone, Edinburgh. 205-215.
Humphries, P. (1981)




Oncogenes and Proto-oncogenes: How do they differ?
Journal of National Cancer Institute, 73: 773-786.
Hurley, J.B., Simon, M.I., Teplow, D.B., Robishaw, J.D. &
Gilman, A.G. (1984)
Homologies between signal transducing G proteins and
ras gene products.
Science, 226: 860-863.
Ichiki, A.T., Quirsh, Y.P., Collmann, I.R., Sonodo, T. &
Krauss, S. (1980)
Inhibition of leucocyte adherence by 3-M potassium
chloride extracts of human colorectal tumors.
Journal of National Cancer Institute, 64: 419-423.
International Union Against Cancer/Union Internationale
Centre le Cancer (U.I.C.C.) (1978)
TNM Classification of malignant tumours.
(Edn) 3: Geneva U.I.C.C.
12
Irimura, J. Gonzalez, R. & Nicolson, G.L. (1981)
Effects of tunicamycin on B16 melanoma cell surface
glycoproteins and blood-borne arrest and survival
properties.
Cancer Research, 41; 3411-3418.
Isaacson, P. (1982)
Immunoperoxidase study of the secretory immunoglobulin
system in colonic neoplasia.
Journal of Clinical Pathology, 34: 14-25.
Jacobs, H. & Birnie, G.D. (1980)
Post transcriptional regulation of messenger abundance in
rat liver and hepatoma.
Nucleic Acids Research, 8^: 3087-8103.
Jensen, H., Chen, I., deVault, M.R. St Lewis, A.E. (1982)
Angiogenesis Induced by "Normal" Human Breast Tissue: A
probable marker for precancer.
Science, 218: 293-295.
Karre, K. , Klein, G.O. , Kiessling, R. , Klein, G. St Roder,
J.C. (1980)
Low activity in vivo resistance to syngeneic leukaemias in
natural killer cell-deficient mice.
Nature, 284: 624-626.
Katzav, S., deBaetselier, P., Tartakovsky, B., Feldman, M.
& Segal, S. (1983)
Alterations in major histocompatability complex phenotypes
of mouse cloned T10 sarcoma cells: Association with shifts
from non-metastatic to metastatic cells.
Journal of National Cancer Institute, 71: 317-324.
Kerbel, R.S., Lagarde, A.E., Dennis, J.W. St Donaghue, T.P.
( 1983)
Spontaneous fusion in vivo between normal host and tumor
cells: Possible contribution to tumor progression and
metastasis studied with a Lectin-Resistant Mutant Tumor.
Molecular St Cellular Biology, 3: 523-538.
Kerr, I.B., Lee, F.D. , Quintanilla, M. St Balmain, A. (1985)
Immunocytochemical demonstration of p21 ras family
oncogene product in normal mucosa and in premalignant and
malignant tumours of the colorectum.
British Journal of Cancer, 52: 695-700.
Kim, U. (1979)
Factors influencing metastasis of breast cancer.
In: Breast Cancer Current Topics, (ed) McGuire, W.L.
Plenum Press, New York and London, 1-49.
Klein, G s< Klein E. ( 1977)
Rejectability of virus-induced tumours and non-
re jectability of spontaneous tumours. A lesson in
contrasts.
Transplantation Proc. 9: 1095-1104.
Klein, G. (1981)
The role of gene dosage and genetic transpositions in
carcinogenesis.
Natute, 284: 313-318.
Klein, G. & Klein E. (1984)
Oncogene activation and tumour progression.
Carcinogenes is, 5^: (4): 429-435.
Koehler, P.R., Feldberg, M.A.M. & van Waes, P.F.G.M. (1984)
Preoperative staging of rectal cancer with computerised
tomography.
Cancer, 5j4 : 512-516.
Koufos, A., Hansen, M.F., Lampkin, B.C. et al (1984)
Loss of alleles at loci on human chromosome 11 during
genesis of Wilms' tumour.
Nature, 309: 170-172.
Kowalski, J., Smith, J.H., Ng, N. & Denhardt, D.T. (1985)
Vectors for the direct selection of cDNA clones
corresponding to mammalian cell mRNA of low abundance.
Gene, 35: 45-54.
Kris, R.M., Avivi, A., Bar-Eli, M. et al. (1985)
Expression of Ki- ras oncogene in tumour cell variants
exhibiting different metastatic capabilities.
International Journal of Cancer, 3J3: 2 27-230 .
Krontiris, T.G., DiMartino, N.A., Colb, M. &
Parkinson, D.R. (1985)
Unique allelic restriction fragments of the human Ha- ras
locus in leucocyte and tumour DNAs of cancer patients.
Nature, 313: 369-374.
Lachmann, P.J. (1984)
Tumour Immunology: a review
Journal Royal Society of Medicine, 77: 1023-1029.
Lam, W.C., Delikatny, E.J., Orr, F.W., Wass, J., Vasani,
J. & Ward, P.A. (1981)
The chemotactic response of tumour cells. A model for
cancer metastasis.
American Journal of Pathology, 104: 69-76.
Land, H., Parada, L.F. & Weinberg, R.A. (1983)
Tumorigenic conversion of primary embryo fibroblasts
requires at least two cooperating oncogenes.
Nature, 304: 596-602.
LeBeau, M.M. & Rowley, J.D. (1984)
Heritable fragile sites in cancer.
Nature, 308: 607-608.
Leveson, S.H., Wiggins, P.A. & Giley, G.R. et al (1985)
Deranged liver blood flow patterns in the detection of
liver metastases.
British Journal of Surgery, 73: 128-130.
13
Lewi, H., Blumgart, C.H., Carter, D.C. et al. (1984)
Pre-operative carcino-embryonic antigen and survival in
patients with colorectal cancer.
British Journal of Surgery, 71: 206-208.
Lewin, B. (1980)
In: "Gene Expression" (vol 2) John Wiley & Sons, New York,
p. 641-684.
Liotta, L.A., Kleinerman, J. & Saidel, G.M. (1976)
The significance of haematogenous tumor cell clumps in the
metastatic process.
Cancer Research, 36: 889-894.
Liotta, L.A., Tryggrason, K., Garbisa, S. et al
Metastatic potential correlates with enzymatic
of basement membrane collagen.
Nature, 284: 67-68.
Little, C.D., Nau, M.M., Cairney, D.N., Gazdar, A.F.
Minna, J.D. (1983) .
Amplification and expression of the c- myc oncogene
human lung cancer cell lines.
Nature, 306: 194-196.
Loewenstein, W.R. (1979)
Junctional intercellular communication and the control of
growth.
Biochim Biophys Acta, 560: 1-65.
Maniatis, T., Fritsch, E.F. & Sambrook, J. (1982)
Molecular cloning: A laboratory manual.
Cold Spring Harbor Laboratory, New York
Maree1, M. (1984)
In: U.I.C.C. Study Group in Basic and Clinical Cancer
Research: Cancer Metastasis, (ed) Fidler, I.J. &
Burger, M.M.
International Journal of Cancer , 3_3 : 1 -3 .
Meyskens, F.L., Soehnlen, B.I., Saxe, D.F., Casey, W.T. &
Salmon, S.E. (1981)
In vitro clonal assay for human metastatic melanoma cells.
Stem Cells, I: 61-72.
Milas, L. (1984)
In: Cancer Invasion and Metastasis: Biologic and
Therapeutic Aspects, (ed) Nicolson, G.L. & Milas, L. Raven
Press, New York: 457-467.
Miller, F.R. & Heppiner, G.H. (1979)
Immunologic heterogeneity of tumour cell subpopulations
from a single mouse mammary tumour.
Journal of National Cancer Institute, 63: 1457-1463.
Minna, J.D., Cairney, D.N., Alvarez, R. et al. (1982)
Heterogeneity and homogeneity of human small cell lung
cancer. In: Tumour Cell Heterogeneity Origins and
Implications, (eds) Owens, A.H., Coffey, D.S. &






Mintz, B. & Illmensee, K. (1975)
Normal genetically-mosaic mice produced from malignant
teratocarcinoma cells.
Proceedings of the National Academy of Science (USA), 72:
3585-3589.
Moertel, C.G. & Thynne, G.S. (1982)
Large bowel. In: Cancer Medicine, (eds) Holland, J. &
Frei, E.
Lea & Febiger, Philadelphia, 1830-1859.
Mooney, B., Critchley, M., Grimes, & Taylor, I. (1981)
Portal vein scanning for early detection of liver
metastasis in colorectal cancer.
Gut, 25: A436.
Mountford, C.E., Wright, L.C., Holmes, K.T. et al. (1984)
High-resolution proton nuclear magnetic resonance analysis
of metastatic cancer cells.
Science, 226: 1415-1418.
Muller, R., Slamon, D.J., Tremblay, J.M., Cline, M.J. &
Verma, I.M. (1982)
Differential expression of cellular oncogenes during
pre and postnatal development of the mouse.
Nature, 299: 640-644.
Murphree, A.L. & Benedict, W.F. (1984)
Retinoblastoma: clues to human oncogenesis.
Science, 223: 1028-1033.
McCoy, M.S., Toole, J.J., Cunningham, J.M. Chang, E.H.,
Long, B.R. & Weinberg, R.A. (1983)
Characterisation of a human colon/lung carcinoma oncogene.
Nature, 302: 79-81.
McGee, J.O'D., Woods, J.C. Ashall, F., Bramwell, M.E. &
Harris, H. (1982)
A new marker for human cancer cells 2. Detection of the
Ca antigen in human tissues with the Cal antibody.
Lancet, ii: 7-10.
Neri, A. & Nicolson, G.L. (1981)
Phenotypic drift of metastatic and cell surface properties
of mammary adenocarcinoma cell clones during growth
in vitro.
International Journal of Cancer, 28 : 731-738.
Netland, P.A. & Zetter, B.R. (1984)




The pathway of eukaryotic mRNA formation.
Annual Review of Biochemistry, 52: 441-466.
Nicolson, G.L. (1982)
Cancer metastasis: organ colonisation and the cell surface
properties of malignant cells.
Biochem Biophys Acta, 695: 113-176.
13
Nicolson, G.L. (1984)
Cell surface molecules and tumour metastasis.
Experimental Cell Research, 150: 3-22.
Nicolson, G.L., Miner, K.M. & Reading, C.L. (1981)
Tumour cell heterogeneity and blood-borne metastasis.
In: Fundamental Mechanisms in Human Cancer Immunology,
(eds) Saunders, J.P., Daniels, J.C., Seron, B., Rosefeld,
C & Denney, C.B.
Elsevier North Holland Inc, New York.
Nicolson, G.L. & Poste, G. (1976)
The cancer cell: Dynamic aspects and modifications in cell
surface organisation.
New England Journal of Medicine, 295: 197-203 and 253-258.
N.I.H. Consensus Statement (1981)
Carcinoembryonic antigen: Its role as a marker in the
management of cancer.
British Medical Journal, 282: 372-37 5.
Nowell, P.C. (1976)
The clonal evolution of tumour populations.
Science, 194: 23-28.
O'Brien, S.J., Nash, W.G., Goodwin, J.L., Lowy, D.R. and
Chang, E.H. (1983)
Dispersion of the ras family of transforming genes to four
different chromosomes in man.
Nature, 302: 839-842.
Old, L.J. (1981)
Cancer Immunology: The search for specificity.
Cancer Research, 4JL: 3 61-375.
Old R.W. & Primrose, S.B. (1981)
In: Principles of gene manipulation, Blackwell
Scientific Publications, Oxford. 102-126.
Ossowski, L. & Reich, E. (1980)
Experimental model for quantitative study of metastasis.
Cancer Research, 40: 2300-2309.
Paget, S. (1889)
The distribution of secondary growths in cancer of the
breast.
Lancet, iL: 571-573.
Paterson, M.C., Smith, B.P., Lohman, P.H.M. et al (1976)








Journal of Pathology, 143: 1-10.
1
Pauli, B.U., Anderson, S.N., Memoli, V.A. & Kuettner, K.E.
(1980)
Development of an in vitro and in vivo epithelial tumour
model for the study of invasion.
Cancer Research, 40: 4571-4580.
Pauli, B.U., Cohen, S.M., Alroy, J., Weistein, R.S. (1978)
Desmosome ultrastructure and the biological behaviour of
chemical carcinogen-induced urinary bladder carcinomas.
Cancer Research, 38: 3276-3285.
Perlstein, E., Salk, P.L., Yogeeswaran, G. & Kiarpatkin,
S. (1980)
Correlation between spontaneous metastatic potential
platelet-aggregating activity of cell surface extracts and
cell-surface sialylation in 10 metastatic variant
derivatives of a rat renal sarcoma cell line.
Proceedings of" the National Academy of Science, 77:
4336-4339.
Perry, R.P. (1981)
RNA processing comes of age.
Journal of Cell Biology, 91: 28s-38s.
Phillips, R.K.S., Hittinger, R., Blesovsky, L., Fry, J.S. &
Fielding, L.P. (1984)
Large bowel cancer: surgical pathology and it's
relationship to survival.
British Journal of Surgery, 71: 604-610.
Pierce, G.B., Lewis, S.H., Miller, G.J., Moritz, E. &
Miller, P. (1979)
Tumorigenicity of embryonal carcinoma as an assay to study
control of malignancy by the murine blastocyst.
Proceedings of the National Academy of Science (USA), 76:
6649-6651.
Pitts, J.D. (1980)
The role of junctional communication in animal tissues.
In vitro, 16: 1049-1056.
Poirier, L.A. & de Serres, F.J. (1979)
Initial National Cancer Institute Studies on mutagenesis
as a prescreen for chemical carcinogens: An appraisal.
Journal of National Cancer Institute, 62: 919-926.
Poste, G., Doll, J. & Fidler, I.J. (1981)
Interactions among clonal subpopulations affect stability
of the metastatic phenotype in polyclonal populations of
B16 melanoma cells.
Proceedings of the National Academy of Science (USA), 78:
6226-6230.
Poste, C. & Fidler, I.J. (1980)
The pathogenesis of cancer metastasis.
Nature, 283: 139-145.
1
Poste, G. & Nicolson, G.L. (1980)
Arrest and metastasis of blood-borne tumour cells are
modified by fusion of plasma membrane vehicles from highly
metastatic cells.
Proceedings of the National Academy of Science (USA) , 17_:
399-403.
Prehn, R.T. (1972)
The immune reaction as a stimulator of tumour growth.
Science, 176: 170-171.
Prehn, R.T. (1977)
Immunostimulation of the lymphodependent phase of
neoplastic growth.
Journal of National Cancer Institute, 59: (4): 104 3-1050.
Pritchett, C.J., Senior, P.V., Sunter, J.P., Watson, A.J.,
Appleton, D.R. & Wilson, R.G. (1982)
Human colorectal tumours in short-term organ culture. A
Stathmokinetic Study.
Cell & Tissue Kinetics, 15: 555-564.
Pulciani, S., Santos, E., Lauver, A. et al (1982)
Oncogenes in solid human tumours.
Nature , 300: 539-542.
Rabotti, G. (1959)
Ploidy of primary and metastatic human tumours.
Nature, 183: 1276-1277.
Raz, A. & Ben Ze-ev, A. (1983)
Modulation of the metastatic capability in B16 melanoma
by cell shape.
Science, 221: 1307-1309.
Raz, A., McLellan, W.L., Hart, I.R., Bucane, C.D., Hoger ,
L.C., Sela, B-A., Dragsten, P. & Fidler, I.J. (1980)
Cell surface properties of B16 melanoma variants with
differing metastatic potential.
Cancer Research, 40: 1645-1651.
Reichman, A., Riddel, R.H., Martin, P. & Levin, B. (1980)
Double minutes in human large bowel cancer.
Gastroenterology, 7J9: 3 34-339.
Reudelhuber, T. (1984)
A step closer to the principles of eukaryotic
transcriptional control.
Nature, 311: 301.
Roberts, A.B., Anzano, M.A., Wakefield, C.M. et al. (1985)
Type B TGF: A bifunctional regulator of cellular growth.
Proceedings of the National Academy of Science (USA), 82:
119-123.
Rockwell, S. (1980)
In vivo - in vitro tumour cell lines: Characteristics and
1imitat ions as models for human cancer.
British Journal of Cancer, 41: Suppl.iv: 118-122.
1
Rognum, T.O., Brandtzaeg, P. & Thorud, E. (1983)
Is heterogeneous expression of HLA-DR antigens and CEA
along with DNA-profile variations evidence of phenotypic
instability and clonal proliferation in human large bowel
carcinomas?
British Journal of Cancer, 48: 543-551.
Rosenberg, M. & Court, D. (1979)
Regulatory sequences involved in the promotion and
termination of RNA transcription.
Annual Review of Genetics, 13: 319-353.
Rothberg, P.G., Spandarfer, J.M., Erisman, M.D.,
Staroscit, R.N., Sears, H.R., Peterson, R.O. &
Astria, S.M. (1985)
Evidence that c- myc expression defines two genetically
distinct forms of colorectal adenocarcinoma.
British Journal of Cancer, 52: 629-632.
Rothenburg, E. & Baltimore, D. (1976)
Synthesis of long, representative DNA copies of the murine
RNA tumour virus genome.
Journal of Virology, 17: 168-176.
Sainsbury, J.R.C., Malcolm, A.J., Appleton, D.R., Farndon,
J.R. & Harris, A.L. (1985)
Presence of epidermal growth factor receptor as an
indicator of poor prognosis in patients with breast
cancer.
Journal of Clinical Pathology, 38: 1225-1228.
Salsbury, A.J. (1975)
The significance of the circulating cancer cell.
Cancer Treatment Reviews, 2: 55-72.
Sanger, F., Nicklen, S. & Coulson, A.R. (1977)
DNA sequencing with chain-terminating inhibitors.
Proceedings National Academy of Science (USA), 74:
5463-5467 .
Santos, E., Martin-Zanca, D., Reddy, P., Pierotti, M.A.
Delia Porta, G. & Barbacid, M. (1984)
Malignant activation of a K- ras oncogene in lung
carcinoma but not in normal tissue of the same patient.
Science, 223: 661-664.
Sargent, N.S.E., Price, J.E. & Tarin, D. (1983)
Effect of enzymic removal of cell surface constituents on
metastatic colonisation potential of mouse mammary tumour
cells.
British Journal of Cancer, 48: i: 569-577.
Schimke, R.T. (1984)
Gene Amplification, Drug Resistance and Cancer.
Cancer Research, 44: 1735-1742.
1
Schirrmacher, V. & Bosslet, K. (1980)
Tumour metastases and cell-mediated immunity in a Model
System in DBA/2 mice X. Immunoselection of Tumour
variants differing in Tumour Antigen Expression and
Metastatic Capacity.
International Journal of Cancer, 25: 781-788.
Schlag, P & Schreml, W. (1982)
Heterogeneity in growth pattern and drug sensitivity of
Primary tumour and metastases in the human tumor colony-
forming assay.
Cancer Research, 42: 4086-4089.
Schour, L. & Faraci, R.P. (1974)
Preferential splenic metastases in parabiotic animals.
Journal of Surgical Oncology, j>: 109-115.
Scott, M., Westphal, K. & Rigby, P.W.J. (1983)
Activation of mouse genes in transformed cells.
Cell, 34: 557-567.
Serfling, E., Jasin, M. & Schaffner, W. (1985)
Enhancers and eukaryotic gene transcription.
Trends in Genetics, JL: (8): 224-230.
Sheppard, J.R. , Koestler, T.P., Corwin, S.P. et al. (1984)
Experimental metastasis correlates with cyclic AMP
accumulation in B16 melanoma clones.
Nature, 308: 544-547.
Sherbet, G.V. (1982)
The Biology of Tumour Malignancy,
Academic Press, London. 83-96.
Sherbet, G.V., Lakshmi, M.S. & Guy, D. (1980)
A possibility of predicting metastatic ability of tumours
by implantation into chick embryos.
European Journal of Cancer, 16: 561-568.
Slack, N.A. & Bross, I.D.J. (1975)
The influence of site of metastasis on tumour growth and
response to chemotherapy.
British Journal of Cancer, 32: 78-86.
Slamon, D.J., deKernion, J.B., Verma, I.M. & Cline, M.J.
(1984)
Expression of cellular oncogenes in human malignancies.
Science, 224: 256-262.
Spandidos, D.A. & Kerr, I.B. (1984)
Elevated expression of the human ras oncogene family in
premalignant and malignant tumours of the colorectum.
British Journal of Cancer, 49: 681-688.
Spandidos, D.A. & Wilkie, N.M. (1984)
Malignant transformation of early passage rodent cells
by a single initiated human oncogene.
Nature, 310: 469-475.
Sporn, M.B. & Roberts, A.B. (1985)
Autocrine growth factors and cancer.
Nature, 313: 745-747.
Sporn, M.B. & Todaro, G.J. (1980)
Autocrine secretions and malignant transformation of
cells.
New England Journal of Medicine, 303: 878-880.
Stackpole, C.W. (1981)
Distant lung-colonising and lung-metastasizing populations
in B16 mouse melanoma.
Nature, 289: 798-800.
Stanbridge, E.J., Der, C.J., Doersden, C.J. et al (1982)
Human cell hybrids; analysis of transformation and
tumorigenicity.
Science, 215: 252-259.
Stark, G.R. & Wahl, G.M. (1984)
Gene Amplification.
Annual Review of Biochemistry, 53: 447-492.
Steck, P.A. & Nicolson, G.L. (1983)
Cell surface glycoproteins of 13762NF mammary
adenocarcinoma clones of differing metastatic potentials.
Experimental Cell Research, 147: 255-267.
Steel, G.G. (1982)
Cytokinetics of neoplasia. In: "Cancer Medicine",
(eds) Holland, J. Sc Frei E.
Lea Sc Febiger, Philadelphia, 177.
Steele, J.G., Rowlatt, C. , Sandall, J.K. Sc Franks, L.M.
(1983)
Cell surface properties of high-and low-metastatic cell
lines selected from a spontaneous mouse lung carcinoma.
International Journal of Cancer, 32: 769-779.
Stutman, O., Shen, F.W. (1978)
H-2 restriction and non-restriction of T cell mediated
cytotoxicity against mouse mammary tumour targets.
Nature, 276: 181-182.
Sugarbaker, E.V., Cohen, A.M. Sc Ketcham, A.S. (1971)
Do metastases metastasize?
Annals of Surgery, 174: 161-166.
Sugarbaker, E.V. Sc Ketcham, A.S. ( 1977)
Mechanisms and prevention of cancer dissemination: An
overview.
Seminars in Oncology, <4: (1): 19-31.
Sukumar, S., Pitcairn, S., Doniger, J.A. et al. (1984)
A transforming ras gene in tumorigenic guinea pig cell
lines initiated by diverse chemical carcinogens.
Science, 223: 1197-1199.
Supowit, S. Sc Rosen, J.M. (1980)
Gene expression in normal and neoplastic mammary tissue.
Biochemistry, 19: 3452-3460.
14
Sweet, R.W., Yokoyama, S., Kamata, T., Faramisco, J.R.,
Rosenberg, M. & Gross, M. (1984)
The product of ras is a GTP-ase and T24 oncogenic mutant
is deficient in this activity.
Nature, 311: 273-275.
Talbot, I.C., Ritchie, S., Leighton, M.H., Hughes, A.O.,
Bussey, H.J.R. & Morson, B.C. (1980)
The clinical significance of invasion of veins by rectal
cancer.
British Journal of Surgery, 67: 439-442.
Talmadge, J.E., Starkey, J.R. & Stanford, D.R. (1981)
In vitro characteristics of metastatic variant subclones
of restricted genetic origin.
Journal of Supramolecular Structure, 15: 139-151.
Tao, T., Matter, A., Vogel, K., Burger, M.M. (1979)
Liver-colonising melanoma cells selected from B16 melanoma
International Journal of Cancer, 23: 854-857.
Tarin, D. (1976)
Cellular interactions in neoplasia. In: Fundamental
Aspects of Metastasis, (ed) Weiss, L.
North-Holland Publishing Company, 151-185.
Amsterdam, Oxford.
Tarin, D., Hoyt, B.J. & Evans, D.J. (1982)
Correlation of collagenase secretions with metastatic-
colonization potential in naturally occurring murine
mammary tumours.
British Journal of Cancer, 46: 266-278.
Tarin, D. & Price, J.E. (1979)
Metastatic colonisation potential of primary tumour cells
in mice.
British Journal of Cancer, 39: 740-754.
Tarin, D., Price, J.E., Kettlewele, M.G.W., Souter, R.G.,
Vass, A.C.R. & Crossley, B. (1984)
CIinicopathological observations on metastases in man
studied in patients treated with peritoneo-venous shunts.
British Medical Journal, 288: 749-751.
Tatosyan, A.G., Galetzki, S.A., Kisseljova, A.A. et al.
(1985)
Oncogene expression in human tumours.
International Journal of Cancer, 35: 731-736.
Taylor, I. (1981)
Studies on the treatment and prevention of colorectal
liver metastases.
Annals of the Royal College of Surgeons of England, 63:
270-276.
Taylor, I., Machin, D., Muller, M., Trotter, G., Cooke, T.
& West, C. (1985)
A randomised controlled trial of adjuvant portal vein
cytotoxic perfusion in colorectal cancer.
British Journal of Surgery, 72: 359-363.
14
Thayer, R.E. (1979)
An improved method for detecting foreign DNA in plasmids
of Escherichia coli.
Annals of Biochemistry, 98: 60-63.
Thomas, P. (1980)
Hybridisation of denatured RNA and small DNA fragments
transferred to nitrocellulose.
Proceedings National Academy of Science (USA), 77:
5201-5205.
Thor, A., Horna-Hand, P., Wunderlich, D., Caruso, A.,
Muraro, R. & Schlom, J. (1984)
Monoclonal antibodies define differential ras expression
in malignant and benign colonic diseases.
Nature, 311: 562-564.
Tobin, A.J. (1979)
Evaluating the contribution of post-transcriptional
processing to differential gene experession.
Developmental Biology, 68: 47-58.
Toda, T., Uno, U., Ishikaura, T. et al. (1985)
In yeast, ras proteins are controlling elements of
adenylate cyclase.
Cell, 40: 27-36.
Tsai, S.Y., Tsai, M.J., Lin, B. & O'Malley, B.W. (1979)
Effect of oestrogen on ovalbumin gene expression in
differentiated non-target tissue.
Biochemistry, 18: 5726-5731.
Tveit, K.M. & Pihl, A. (1981)
Do cell lines in vitro reflect the properties of the
tumours of origin? A study of lines derived from human
melanoma xenografts.
British Journal of Cancer, 44: 775-785.
Vieira, J. & Messing, J. (1982)
The PUC plasmids, an M13mp-7-derived system for insertion
mutagenesis and sequencing with synthetic universal
primers.
Gene, 19: 259-268.
Vindelov, L.L., Hanse, H.H., Christensen, I.J. et al.
(1980)
Clonal heterogeneity of small cell anaplastic carcinoma
^f the lung demonstrated by flow-cytometric DNA analysis.
Cancer Research, 40: 4295-4300.
Vitetta, E.S., Krolick, K.A., Migama-Inaba, M., Cushley,
W. & Uhr, J.W. (1983)
Immunotoxins: A new approach for cancer therapy.
Science, 219: 644-650.
Vogt, V.M. (1973)
Purification and further properties of single strand
specific nuclease from Aspergillus Coryzae.
European Journal of Biochemistry, 33:, 192-200.
Vollmers, H.P. & Birchmeier, W. (1983)
Monoclonal antibodies that prevent adhesion of B16
melanoma cells and reduce metastases in mice; cross-
reaction with human tumor cells.
Proceedings National Academy of Science (USA), 80:
6863-6867.
Vousden, K.H. & Marshall, C.J. (1984)
Three different activated ras genes in mouse tumours;
evidence for oncogene activation during progression of a
mouse lymphoma.
The EMBO Journal, 3^: 913-917.
Wainscoat, J.S. & Thein, S.L. (1985)
Polymorphism in human DNA: application to cancer studies.
Trends in Biochem, 1^: 474-476.
Wallich, R., Bulbuc, N., Hammerling, G.J., Katsav, S.,
Segal, S. & Feldman, M. (1985)
Abrogation of metastatic properties of tumour cells by
de nova expression of H-2K antigens following H-2 gene
transfection.
Nature, 315: 301-305.
Warner, J.F. & Dennert, G. (1982)
Effects of a cloned cell line with NK activity on bone




A pathobiologic overview of metastasis.
Seminars in Oncology, _4: (1): 5-17.
Weiss, L., Holmes, J.C. & Ward, P.M. (1983)
Do metastases arise from pre-existing subpopulations of
cancer cells ?
British Journal of Cancer, 47: 81-89.
Weiss, L., Voit, A. & Lane, W.W. (1984)
Metastatic patterns in patients with carcinomas of the
lower oesophagus and upper rectum.
Invasion and Metastasis, j4: 47-60.
Weiss, R.A. & Marshall, C.J. (1984)
DNA in Medicine: Oncogenes.
The Lancet, (ji-jL) : 1138-1142.
Welch, J.P. & Donaldson, G.A. (1978)
Detection and treatment of recurrent cancer of the colon
and rectum.
American Journal of Surgery, 135: 505-511.
Whittaker, M. & Goligher, J.C. (1976)
The prognosis after surgical treatment for carcinoma of
the rectum.
British Journal of Surgery, 63: 384-388.
Wiedemann, L.M., Burns, J.H. & Birnie, G.D. (1983)
Differences among the polyadenylated RNA sequences
of human leucocyte populations: an approach to the
objective classification of human leukaemias.
The EMBO Journal, 2: (1): 9-13.
Wilkes, P.R., Birnie, G.D. & Paul, J. (1979)
Changes in nuclear and polysomal poladenylated RNA
sequences during rat-liver regeneration.
Nucleic Acids Research, J5: 2193-2208.
Williams, A.R.W., Piris, J., Spandidos, D.A. & Wyllie,
A.H. (1985)
Immunohistochemical detection of the ras oncogene p21
product in an experimental tumour and in human colorectal
neoplasm.
British Journal of Cancer, j52: 687-694.
Williams, J.G., Hoffman, R. & Penman, S. (1977)
The extensive homology between mRNA sequences of normal
and SV40-transformed human fibroblasts.
Cell, 11: 901-907.
Williams, J.G. & Lloyd, M.M. (1979)
Changes in the abundance of polyadenylated RNA during
slime mould development featured using cloned molecular
hybridisation probes.
Journal of Molecular Biology, 129: 19-35.
Williams, J.G. (1981)
The preparation and screening of a cDNA clone bank.
In: Genetic Engineering Vol 1, (ed) Williamson, R.
Academic Press, London, New York, 1-59.
Williams, G.T. (1985)
Commentary : transitional mucosa of the large intestine.
Histopathology, 9^: 1237-1243.
Willis, R.A. (1973)
The spread of tumours in the human body.
London, Butterworths.
Wolley, R.C., Schreiber, K., Koss, L.G., Kakas, M &
Sherman, A. (1982)
DNA distribution in human colon carcinomas and its
relationship to clinical behaviour.
Journal of National Cancer Institute, 69: 15-22.
Wood, C.B. (1980)
Prognostic indices in colorectal cancer. In: Recent
Advances in Surgery, (ed) Taylor, S.
Churchill Livingstone, London.
Wood, S. (Jnr). (1958)
Pathogenesis of metastasis formation observed in vivo
in the rabbit ear chamber.
Archives of Pathology, 6j5: 5 50-568 .
Woodruff, M.F.A. (1982)
Interaction of cancer and host.
British Journal of Cancer, 46: 313-322.
X
Woodruff, M.F.A. (1983)
Cellular heterogeneity in tumours.
British Journal of Cancer, 47: 589-594.
Wright, N. (1984)
In: Recent Advances in Histopathology, (eds)
MacSween, R.N.M. & Anthony, P.P.
Churchill Livingstone, Edinburgh, London, p.17-35.
Yamamato, M., Maehara, Y., Takahashi, K. & Endo, H. (1983)
Cloning of sequences expressed specifically in tumours of
rat.
Proceedings of the National Academy of Science (USA), 80:
7524-7527.
Yogeeswaran, G. & Salk, P.L. (1981)
Metastatic potential is positively correlated with
cell surface sialylation of cultured murine tumour
cell lines.
Science, 212: 1514-1516.
Young, B.D., Birnie, G.D. & Paul, J. (1976)




The chromosomal basis of human neoplasia.
Science, 221: 227-236.
Yunis, J.J. & Soreng, A.L. (1984)
Constitutive fragile sites and cancer.
Science, 226: 1199-1204.
Ziff, E.B. (1980)




Isolation of putative metastasis-related cDNA clones from colorectal cancer
I.B. Kerr, I.G. Finlay, G.D. Birnie, C.S. McArdle
Departmsnt of Surgery, Royal Infirmary and Beatson Institute for Cancer Research,
Glasgow.
Vfe have shown that prognosis following "curative" resection for colorectal
cancer is principally determined by the presence or absence of occult disseminated
disease at surgery (1) . Studies of rates of growth of metastases suggest that
the capacity to metastasise may oe due to inherent differences between tumours (2).
This study aims to utilise novel technology to characterise colorectal cancer by
cloning complementary DMA (cDNA) libraries representing their abundantly expressed
mRNAs.
cDNAs have been transcribed from the polyadenylated RNA prepared from two
colorectal cancers, one from a patient with disseminated disease and the other frcm
a patient who remains apparently disease-free. These were ligated into the plasmid
pUC8 which was used to transform E coli JM 83. Approximately 1000 recombinant
clones were picked from each transformation and homologous and heterologous screeni
was performed using radio-labelled probes.
Eighty four clones which showed differences between the two libraries have bee
identified. These clones are now being used to screen a series of tumours to
ascertain whether these findings may be consistently correlated with clinical
behaviour.
These cloned probes may have considerable potential in defining clinical
behaviour and in predicting the presence of occult disseminated disease in patients
with colorectal cancer.
(1) Finlay IG and McArdle CS. The identification of patients at high risk
following curative resection for colorectal carcinoma
Br J Surg 1982; 69: 583-4
(2) Fmlay IG, Brunton EF, Meek D and McArdle CS. Rate of growth of hepatic
metastases in colorectal carcinoma.
Br J Surg 1982; 69: 689
British Journal of Surgery (1983), 70 : 486.
(Surgical Research Society Abstract)
CLINICOPATHOLOGICAL SIGNIFICANCE AND CELLULAR
DISTRIBUTION OF ras FAMILY ONCOGENE EXPRESSION
IN NORMAL AND NEOPLASTIC COLORECTUM
I. B. Kerr,1 A. Balmain2 and F. D. Lee1
University Department of Pathology.' Royal Infirmary, Glasgow and
Beatson Institute for Cancer ResearchBearsden, Glasgow
We have previously demonstrated a variably elevated expression of ras family oncogenes
in a series of polyps and carcinomata (n= 12) of the colorectum and have now correlated
this with conventional staging criteria (Dukes' staging and tumour differentiation) and
clinical outcome with particular reference to the development of metastatic disease. No
relationship was evident between these parameters suggesting that although abnormal
expression of ras oncogenes may be critical in the development of malignancy, variations
in the level of their expression do not appear to be related to clinically evident
phenotypic differences. Study of the distribution of the ras encoded p21 protein using
the monoclonal antibody Y13-259 shows this protein to be apparently homogeneously
distributed in all cells in both adenomatous polyps and carcinomata and throughout the
normal foetal and adult colorectal mucosal population. This suggests that the presence
of this protein is a feature of normal cellular metabolism in certain cell types and is not
restricted to those involved in cell proliferation. It thus appears that neither cells at
different stages of carcinogenesis nor variants of a malignant phenotype can be identified
by these means.
fournal of Pathology (1985) : 145
(Pathological Society Abstract)
Br. J. Cancer (1984), 49, 681-688
Elevated expression of the human ras oncogene family in
premalignant and malignant tumours of the colorectum
D.A. Spandidos* & I.B. Kerr
The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow, UK.
Summary Study of expression of ra.s-related oncogenes in human premalignant polyps and malignant
tumours of the colorectum, as well as in normal colorectal mucosa, shows a significant elevation in the
premalignant and malignant tissues as compared to their respective colorectal mucosa. These results suggest
that activation of the ras oncogene family occurs in the development of colorectal tumours and that elevated
expression at a premalignant stage may well be critical in the process of carcinogenesis but not in itself
sufficient.
Analysis of colorectal cancer at the molecular level
has been stimulated by the finding that activated
cellular oncogenes capable of transforming NIH3T3
mouse cells are present in adenocarcinomata of the
colon (Pulciani et ai, 1982) and in established cell
lines derived from colorectal adenocarcinomata
(McCoy et ai, 1983). Although expression of
cellular oncogenes analogous to retroviral one genes
has been studied in fresh and culture derived
human haematopoietic neoplastic cell types at
various stages of differentiation and a variety of
human cell lines (Westin et al, 1982a, b; Eva et ai,
1982), similar studies on human solid tissues have
not been reported. In this study we quantified the
RNA transcripts from the Ki-ras, Ha-ras and sis
human oncogene families from a series of
premalignant adenomatous polyps and malignant
tumours of the colorectum, normal colorectal
mucosae and various established cell lines. We
wished in particular to determine whether there are
significant variations in the level of expression of
these genes in tumours of the colorectum and in
their postulated premalignant state as compared to
normal colorectal mucosa. Adenomatous polyps of
the large bowel are now generally thought to
represent premalignant lesions with a potential for
malignant change over a period of 10-15 years
varying from 5% for the predominantly tubular
variety to nearer 40% for the predominantly villous
(Morson, 1974). Interestingly, one of the specimens
was reported as being a metaplastic polyp, which is
not generally thought to be premalignant, although
this is disputed (Jass, 1983; Rognum & Brandtzaeg,
1983). Our study included representatives of all the
major histological types. None of them came from
patients known to be suffering from any familial
syndrome.
*Permanent address: Hellenic Anticancer Institute, Athens,
Greece.
Correspondence: D.A. Spandidos.
Received 26 January 1984; accepted 13 March 1984.
Materials and methods
Tissue specimens were collected and stored in liquid
nitrogen. These were subsequently pulverized under
liquid nitrogen and RNA and DNA was extracted
as previously described (Spandidos & Paul, 1982).
Briefly, the tissue or cells were homogenized in
guanidine-HCl buffer (8.0 M guanidine HC1, 20 mM
sodium acetate, 50 mM EDTA, 5% [i-
mercaptoethanol, pH 7.0). Cell lysates were made
2% with SDS and heated at 65°C for 2min. After
vortexing, 5 ml of cell lysate were placed on a 3 ml
cushion of CsCl solution (5.7 M CsCl, 50 mM
EDTA pH8.0) and centrifuged for 48 h at 40Krpm
at 15°C in a 10 x lOTi rotor. The RNA pellet was
resuspended in 2.0 M LiCl2, 4.0 M urea and left at
4°C overnight. RNA was pelleted at lOKrpm for
15min in a Sorvall centrifuge, resuspended in
0.1 x MOPS buffer (lxMOPS = 20mM NaMOPS,
5mM sodium acetate, 1 mM EDTA, pH 7.0) and
dialyzed in the same buffer for 2h before
lyophilization. Before each experiment the quality of
RNA preparations was examined by formaldehyde-
agarose gel electrophoresis, followed by ethidium
bromide staining, transfer to nitrocellulose and
hybridization to DNA probes (see below). Ten /rg of
total cell RNA was spotted per dot as described
(Spandidos et al., 1981). Hybridizations were
performed in 5 x SSC, 50% formamide for 24 h at
42°C with lOngml-1 probe as described (Wahl et
al., 1979) using 2 x Denhardt's solution (Denhardt,
1966). 32P-labelled DNA probes with specific
activities of 2-3 x 108cpm/rg_1 DNA were made by
nick-translation (Rigby et al., 1977). The
nitrocellulose sheets were washed in 0.5 x SSC at
60°C and exposed to hypersensitized X-ray films at
— 70°C (Lasky & Mills, 1977). The filters were
hybridized sequentially with 32P-labelled nick-
translated HiHi3 (Ellis et al., 1981), BS9 (Ellis et al.,
1980), pL335 (Dalla Favera et ah, 1981), pHR28
(Sproul & Birnie, unpublished results) or pAM91
(Minty et al., 1982) recombinant probes carrying
the viral Kirsten ras (v-Ki-ras), viral Harvey ras (v-
© The Macmillan Press Ltd., 1984
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Ha-ras), human cellular sis (H-c-sis) and human
28S ribosomal and mouse actin DNA sequences
respectively. Probes were removed by washing the
nitrocellulose at 65°C with double distilled H20 for
2h. Approximately 100 pg of each insert oncogene
DNA were spotted as a positive control.
Fractionation of RNA in formaldehyde containing
agarose gels and blotting on to nitrocellulose have
been described elsewhere (Spandidos & Paul, 1982).
Results
RNA spot hybridization analysis
The relative levels of human Ki-ras, Ha-ras and sis
transcripts in total cell RNA made from
premalignant and malignant tissue, normal colonic
mucosa and cell lines were determined using an
RNA spot hybridization assay (Spandidos et al.,
1981). Quantification of the intensities of the
autoradiographic spots was carried out using
densitometric scanning as previously described
(Spandidos et al., 1981). Probe excess was confirmed
by obtaining a linear autoradiographic response to
serial dilutions of the various RNAs (data not
shown). Results of the RNA spot hybridization
analysis are shown in Figure 1 and Table I. These
show firstly that transcripts from the human Ki-ras
and Ha-ras related oncogenes could easily be
detected in most premalignant, malignant tissues
and cell line RNAs but are barely detectable in
normal tissue. The human sis oncogene is expressed
at very low levels in all types of tissue examined.
Secondly, the amount of human Ki-ras and Ha-ras
specific RNAs varied in different cells and tissues
whereas little variation was observed in sis RNA
levels. In particular, in the first three patients where
samples were available from all three types of tissue,
Ki-ras RNA levels in premalignant and malignant
tissues varied between 9.5-20 and 3.5-19 x higher
respectively than the levels seen in normal
colorectal mucosa. A slightly different picture was
seen when expression of the Ha-ras oncogene family
Table J Expression of human c-Ki-ras and c-Ha-ras oncogenes in solid
tumours, normal tissue and cell lines studied by RNA spot hybridization
analysis."
Tissue histology
Patient Normal0 Premalignantd Malignantc
no. and
cell lineb Ki-ras Ha-ras Ki-ras Ha-ras Ki-ras Ha-ras
1 1.0 0.3 19 31 6.3 4.5
2 2.0 3.5 20 8.0 3.5 14
3 2.0 2.3 9.5 9.1 19 9.0
4 1.7 1.0 7.0 7.6
5 2.3 1.0 3.5 1.5
6 1.0 1.0 6.5 1.5
7 1.0 1.3 7.0 1.5









"The autoradiographs (Figure 1) were scanned and the concentrations of
HiHi3 (v-Ki-ras) or (v-Ha-ras) specific RNAs are given at arbitrary units
for each probe.
bHistological examination was carried out in part of the specimen and
the remaining tissue was stored in liquid nitrogen until RNA and DNA
were isolated. No. 1-12, colorectal carcinoma; No. 13, a breast carcinoma;
CHB, an established cell line from an adenocarcinoma of the colon; HL60,
a promyelocytic and K562 an erythroleukaemic cell line.
"Colorectal mucosa.
dl-2 Colorectal polyps (predominantly tubular), 3, Colorectal polyp
(metaplastic) and 8, colorectal polyp (tubulovillous).
"Adenocarcinoma of the colorectum.
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HiHi 3 probe BS9 probe pL335 probe pHR28 probe pAM91 probe
Figure 1 RNA spot hybridization analysis of (a) Ki-ras; (b) Ha-ras; (c) sis; (d) rRNA and (e) actin gene
expression in human cells. Extraction of RNA from cells and spotting on to nitrocellulose is described in
Materials and methods. Malignant: 1-12 = colorectal adenocarcinomata; 13 = breast adenocarcinoma;
CHB = an established cell line from an adenocarcinoma of the colon; HL60, a promyelocytic and K562 an
erythrolaeukemic cell line. Premalignant: 1-2 = predominantly tubular adenomatous polyps; 3 = metaplastic
polyp, and 8 = tubulo villous polyp. Normal: histologically normal colorectal mucosa removed from
colectomy specimens several centimetres distant from tumour site.
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was examined. The relative levels of Ha-ras
transcripts varied between 8.0-31 and 4.5-
14 x higher in premalignant and malignant tissues
respectively as compared to normal colorectal
mucosa for the same first three patients as described
above (Figure 1 and Table I). In patient No. 1
RNA from two separate polyps (PI and P2) was
examined gave similar results. In other malignant
tumours there was some variation in the degree of
elevation of Ki and Ha-ras expression (Table I).
Oncogene expression in some but not all of the
premalignant lesions was in fact significantly higher
in comparison to the corresponding malignant
tumours. Among the latter a more marked variation
in expression was observed. Finally in the four
other samples, a breast carcinoma RNA (No. 13),
an established cell line from adenocarcinoma of the
colon (CHB), a promyelocytic (HL60) and an
erythroleukaemic (K562) cell line, expression of Ki-
ras was elevated, but Ha-ras RNA levels were
increased only in patient No. 13. As an additional
control to check the relative amount of RNA from
each sample spotted on to nitrocellulose, the filter
was hybridized with pHR28, (a human ribosomal),
or pAM91 (a mouse actin) DNA probe. As shown
in the autoradiographs (Figure Id and le) and
confirmed by scanning the dots, there is no
substantial difference in the amount of ribosomal or
actin RNA present in these samples.
Northern blot hybridization analysis
Northern blot hybridization analysis was carried
out to measure the sizes of c-one related transcripts.
A v-Ki-ras probe, HiHi3 recombinant (Ellis et al.
1981), revealed the presence of one main band of
~5.8kb in total cellular RNA (Figure 2a and c). In
several cases a much less intense band of ~2.2kb
was seen as well as some other nondiscrete
hybridization probably due to degradation or
possibly to cross hybridization with other ras gene
family transcripts. As shown in Figure 2b, d after
scanning across this 5.8 kb band, the ki-ras related
transcript was found in higher amounts in
premalignant and malignant tissues of the
colorectum as compared to normal mucosa. A
similar sized major transcript was also found in
RNA from HL60 and K562 cells. As shown in
Figure 2e when a v-Ha-ras probe, BS9 recombinant
(Ellis et al., 1980) was used, the same size band of
5.8 kb was also present, again more intensely in
some premalignant and malignant tissues as
compared to normal colorectal mucosa (Figure 2f).
These results confirm and extend the spot
hybridization analyses. The nature of these
transcripts was further investigated by isolating
polyA' RNA and Northern blot hybridization
analysis. As shown in Figure 2g,i, Ki-ras and Ha¬
ras related transcripts of 5.8 kb in size were again
found to be elevated in premalignant and malignant
tissues as compared to normal colorectal mucosa.
We also detected the 5.8 kb sized transcripts using
pT24-C3 (Santos et al., 1982), a recombinant
carrying a 6.6 kb Bam HI human DNA fragment
containing the whole bladder carcinoma oncogene
c-Ha-ras 1 (data not shown). The exact nature of
these transcripts is still incompletely understood.
However mechanisms accounting for varied Ki-ras
transcripts in terms of alternative splicing patterns
have been recently described which include the
generation of such a 5.8 kb species (Shimizu et al.,
1983; McGrath et al. 1983). It seems most likely
that the same sized transcript seen with the Ha-ras
probe represents in fact hybridisation with products
of another member of the ras gene family. Northern
blot hybridization analysis of total of polyA+ RNA
using a sis probe failed, however, to show any
discrete RNA transcripts.
Discussion
Other studies with RNA from human cells have
demonstrated the presence of 1.2 kb Ha-ras related
transcripts in the T24 human bladder carcinoma
cell line (Goldfarb et al., 1982) and two ~6.0kb
Ha-ras related transcripts in human haematopoietic
cell lines (Westin et al., 1982b). More recently, using
an N-ras probe 3 different sized transcripts of 5.8,
2.2 and 1.5 kb have been found in normal human
fibroblasts and established human cell lines and it
has been claimed that the 2.2 kb transcript is related
to the N-ras oncogene (Hall et al., 1983).
The human genome contains at least four genes
homologous to the transforming genes of Kirsten
Figure 2 Northern blot hybridization analysis of transcripts related to human Ki-ras and Ha-ras oncogenes
in RNAs from samples of normal premalignant and malignant tissues of the colorectum. Total RNAs were
isolated as described in Materials and methods. Poly A+ RNA was isolated using an oligo(dT)-cellulose Type
3 from Collaborative Research Inc. (Spandidos & Paul, 1982). In (a), (c) and (e), 20yg of total cell RNA and
in (g) and (i) poly A+ RNA isolate from 100/tg total cell RNA were analyzed in 1% agarose-formaldehyde-
containing gels, blotted on to nitrocellulose and hybridized with one probes. The HiHi3 (Ellis et al., 1981)
recombinant containing the v-Ki-ras sequences was used as a probe in panels (a), (c) and (g). The BS9 (Ellis
et al., 1980) recombinant containing the v-Ha-ra.s sequences was used in (e) and (i). N = normal colorectal
mucosa, P = premalignant polyps, M= malignant adenocarcinomata. The autoradiographs are shown in (a),
(c), (e), (g) and (i) and the scans across the 5.8 kb bands in (b), (d), (1), (h) and (j).
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and Harvey murine sarcoma viruses (Chang et al.,
1982) which are dispersed in different chromosomes
(O'Brien et al., 1983). Moreover, recent transfection
studies have revealed the presence of a distantly
related N-ras oncogene (Hall et al., 1983). Our
results demonstrate that cellular sequences related
to the transforming genes of Kirsten and Harvey
murine retroviruses are actively transcribed in
human tissues. The demonstration that Ki-ros and
Ha-ras related transcripts are elevated in
premalignant and malignant tissues as compared to
normal colorectal mucosa shows that the expression
of these one genes is associated with the
transformed state of the cells and suggests that
elevated expression of these genes in premalignant
state(s) may be critical in the process of
carcinogenesis. The fact, however, that only a
relatively small proportion of these premalignant
polyps progress to frank malignancy although
elevated oncogene expression was observed in all,
suggests that, consistent with the concept of
carcinogenesis being a multi-step process
(Spandidos, 1983) the elevation observed here is not
in itself sufficient to produce malignant change.
Parallel studies in this laboratory, of carcinogen
induced mouse skin papillomata, which have a
similar potential for malignancy, have also
demonstrated elevated Ha-ras oncogene expression
and in addition, the DNA from these tumours has
acquired transforming activity in transfection assays
(Balmain et al., 1984).
The cellular homologues of several retroviral
oncogenes have been shown to exhibit tissue-
specific patterns of transcriptional activity (Westin
et al., 1982a, b, Gonda et al., 1982). Expression of c-
onc genes during mouse development (Muller et al.,
1982; 1983) and liver regeneration (Goyette et al.,
1983) has lent further support to the hypothesis
that cellular oncogenes play a role in normal
developmental processes. Abnormal expression of
these genes could be directly involved in the
development of the transformed phenotype of
tumour cells. Although meaningful in vivo studies of
proliferation rates in these tumours involving
repeated sampling and labelling would present
obvious ethical problems, the most recent studies
on human material in vitro comparing malignant
tumours to normal mucosa using stathmokinetic
(Pritchett et al., 1982) and 3H-Thymidine labelling
(Bleiburg et al., 1976) techniques suggest that cell
birth rate and turnover time respectively, were only
very slightly increased in tumours or not
significantly different. Similar findings have been
reported for premalignant polyps in human
(Weisburger et al., 1975), and in experimentally
induced rodent tumours, where similar proliferation
rates for benign and malignant tumours were
reported (Sunter et al., 1980). In the tumours,
furthermore, the growth fraction is probably
actually lower than in the normal mucosa. Thus the
marked elevation of ras related transcripts we
observe would not appear to be comparable to the
two-three fold increase seen in regenerating liver
(Goyette et al., 1983).
Gene amplification seems not to be involved in
the generation of elevated one transcript levels
found in our present study since Ha-ras and Ki-ras
related DNA sequences in the various tissues were
at approximately the same level when examined by
DNA spot hybridization analysis (data not shown).
However, oncogene amplification remains a
possibility particularly since we have observed such a
phenomenon in DNA from a different
adenocarcinoma of the colon (our unpublished
results). Such a phenomenon has recently been
described for c-myc (Collins & Groudine, 1982;
Dala-Favera et al., 1982) and Ki-ras (Schwab et al.,
1983).
Since our results demonstrate that both the
premalignant and malignant tumours examined
here are characterized by elevated levels of ras
family transcripts and if the gene product is
unaltered, the question obviously arises as to the
nature of the further event(s) involved in the
acquisition of the malignant phenotype and their
relationship with the changes in gene expression
observed here. To address this question may require
the use of further assay systems, although as an
initial step it will clearly be of interest to clone the
ras genes involved directly from the tumours since
they may not readily be detected in transfection
experiments, and such studies, as well as
transfection studies using DNA from these
tumours, are currently in progress in our
laboratory.
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The relation of ras family oncogene expression to
conventional staging criteria and clinical outcome in
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Summary The elevated levels of rax-related cellular RNA in a series of colorectal carcinomata (n=12) was
correlated with conventional staging criteria (tumour morphology and Dukes' staging) and with clinical
outcome with particular reference to the development of metastatic disease. No direct relationship was evident
between these parameters suggesting that although abnormal expression of ras oncogenes may be critical in
the development of malignancy, variations in the level of their expression do not appear to be directly related
to clinically evident phenotypic differences.
The characterisation of transforming cellular
oncogenes in a variety of human tumours has
contributed an initial understanding of cancer and
the process of carcinogenesis at the molecular level
(for a review see Cooper, 1984), although the extent
to which abnormal expression of these genes is
directly related to variations in the clinical
behaviour of tumours is not yet clear. Elevated
levels of transcription of several oncogenes have
now been shown in a wide range of tumours
(Slamon et al., 1984; Spandidos & Agnantis, 1984;
Spandidos et al., 1985) and it has recently been
shown that amplification of an N-tnyc oncogene is
related to tumour stage in neuroblastoma (Brodeur
et al., 1984) whilst a study of c-myc expression in a
series of human leukaemias showed increased
expression to be apparently related to a more
immature phenotype (Birnie et al., 1986).
Activation of a ras oncogene has also been
suggested to be related, in a mouse lymphoma, to
the generation of a more aggressive tumour variant
(Vousden & Marshall, 1984).
Staging of colorectal carcinoma is currently
undertaken using Dukes' classification (Dukes &
Bussey, 1958) based on the extent of tumour
invasion and spread through bowel wall. However,
it has long been recognised that this classification
constitutes no more than a relatively crude
indication of prognostic probability (Woods, 1980),
and the clinical outcome for patients within the
different stages may vary significantly. Tumour
morphology similarly yields only a very broad
correlation with prognosis with marked inconsis-
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tencies occurring between degree of differentiation
and clinical outcome (Finlay & McArdle, 1982).
Despite initial enthusiasm regarding the potential
of carcinoembryonic antigen as a tumour marker
(see NIH Consensus Statement, 1981) it has now
been shown that the presence of elevated pre¬
operative serum levels does not correlate with
clinical outcome (Lewi et al., 1984) and that
subsequent elevations are not an invariable feature
of advanced recurrent or disseminated disease
(Finlay & McArdle, 1983). Studies of ploidy in
these tumours have shown in general an inverse
relation between increasing degrees of aneuploidy
and prognosis although this is not absolute (Wolley
et al., 1982). We have recently shown, in a study
of 'occult' metastatic disease using computerised
tomography (Finlay & McArdle, 1982), that the
presence or absence of metastatic disease at the
time of clinical presentation, long known to be
associated with a dire prognosis (Bengtsson et al.,
1981), is in fact the most critical prognostic factor,
regardless of Dukes' staging and accounts almost
entirely for the anticipated pattern of mortality.
Studies of the rate of growth of these metastases
show that they in fact had been present for a mean
period of 3 years prior to surgery. This raises the
possibility that these tumours may behave consis¬
tently from an early stage as metastasising or non-
metastasising variants (Finlay et al., 1982). However
the phenotypic determinants or, possibly, features
of a host response which might be responsible
for such variation remain poorly understood and
there is in particular no means of predicting the
metastatic potential of a tumour, clearly of impor¬
tance in determining further therapeutic strategies.
Since we have previously reported a variable
elevation of expression of ras family oncogenes in a
© The Macmillan Press Ltd., 1986
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series of premalignant and malignant tumours of
the colorectum as compared to normal colonic
mucosa (Spandidos & Kerr, 1984), it was obviously
of interest to determine whether the variation in
expression we observed was related in any way to
conventional staging criteria and whether, in
particular, this could be used to predict the clinical
behaviour of these tumours.
Materials and methods
Random blocks from a series of tumours and
corresponding colonic mucosa were dissected out
from operative specimens and snap frozen in liquid
nitrogen. Our procedure for extraction of RNA for
spot hybridisation assays has already been
described in detail. (Spandidos & Kerr, 1984).
Briefly 10 /zg aliquots of total cellular RNA were
hybridised sequentially on nitrocellulose paper with
32P-labelled nick-translated HiHi3 (Ellis et al.,
1980) and BS9 (Ellis et al., 1981) recombinant
probes containing the viral Kirsten ras and viral
Harvey ras DNA sequences and, subsequently, as
controls to check the quantity of RNA present,
with the pL335 (Dalla Favera el al., 1982), pAM91
(Minty et al., 1982) and pHR28 probes containing
the human cellular sis, mouse actin and human 28S
ribosomal DNA sequences respectively. Similarly,
the quality of our RNA preparations were checked
by formaldehyde-agarose gel electrophoresis,
followed by ethidium bromide staining, blotting
onto nitrocellulose and hybridisation to DNA
probes.
Quantitation of the spot hybridisation reactions
following autoradiographic exposure was performed
by densitometric scanning as previously described
(Spandidos et al., 1981) and our figures were based
on an arbitrary value obtained when the ras probes
were hybridised with normal mucosa.
Histopathological reports were based on standard
6 ;tm paraffin embedded sections stained with
haematoxylin and eosin.
Patients in the study were followed up as out¬
patients at 3 monthly intervals with biannual
ultrasonography and further radiological
investigations as indicated.
Results
It is evident from Figures 1 and 2 that the degree
of elevated expression of Kirsten or Harvey ras
related sequences in our series does not appear to
correlate with either tumour morphology or Dukes'
staging since the range of values obtained, ranging
from ~2 to 20 fold for the Kirsten to 1.5 to 14
Table I Relation of Ki and Ha-ra^ related oncogene
expression to age, sex and clinical outcome.
Follow-up
Patient Age Sex in months Status A7-ras Ha-ras
1 52 M 27 ND 6.3 4.5
2 83 F (9) ND1 3.5 14
3 62 F (19) DDa 19.0 9.0
4 61 F 33 LD 7.0 7.6
5 60 M (5) DDa 3.5 1.5
6 54 F (6) DD' 6.5 1.5
7 81 F (4) DD" 7.0 1.5
8 72 M 24 ND 9.0 1.5
9 75 M 36 ND 5.0 1.5
10 78 F (-) NDac 4.4 1.5
11 79 M (-)
(post op.)
a, b 6.5 11
12 51 F (8)
(post op.)
DDa 1.9 14
Status of patients at follow-up or death was assessed
and abbreviated as follows: ND—no evidence of disease;
DD—disseminated disease; LD—local disease; Mead; bnot
known; cpost-mortem assessment.
fold for the Harvey-related sequences, clearly
overlaps all histological grades and Dukes' stages.
Although follow-up is in some cases relatively
short it is, however, known that of those who will
ultimately develop disseminated disease the
majority would be expected to do so within a
period of two years (Finlay et al., 1982c). The
information in Table I thus shows that the level of
expression of these sequences does not appear to be
related to clinical outcome in general nor to the
development in particular of metastatic disease.
Discussion
Our results therefore indicate that, although some
elevation of Kirstcn and Harvey-related ras
oncogene expression is seen in all these tumours,
variation in the amounts of RNA homologous to
the ras probes is not related to clinically apparent
phenotypic variation nor clinical outcome. If the
hypothesis relating to a heterogeneity of cells with
metastatic potential in a primary tumour (Hart &
Fidler, 1981), currently held by several authors to
be extremely contentious (Weiss et al., 1983;
Alexander, 1983), were indeed true in this tumour
type, then random sampling could obviously not be
expected to identify such variation. We have,
however, already presented evidence showing that
these tumours appear to behave consistently as
metastasising or non-metastasising variants (Finlay
et al., 1982). In addition, although a heterogeneous





















Figure 1 Relation of (a) Ki-ra.? and (b) Ha-ras related oncogene expression to Dukes' stage (i) and degree of
tumour differentiation (ii). In one case histology was not available.
pattern of p21 expression has been reported in
• formalin-fixed paraffin-embedded sections of these
tumours by immunocytochemical techniques (Thor
et al., 1984), we (Kerr et al., 1985) and others
(Williams et al., 1985) have demonstrated, using the
monoclonal antibody Y13-259 (Furth et al., 1982)
on frozen sections of these tumours, widespread
positive staining of tumour cells with little reactivity
of underlying stroma. It is unfortunately not possible
to quantitate expression using such techniques. Thus,
although some variation within individual cells
cannot be excluded, it is clear from the evidence
based on presently available methods of study that
neither the presence of ras oncogene expression nor
observable differences in its level can be used to
predict variations in clinical behaviour in these
tumours.
These findings are consistent with a recently
published study which showed similar elevations of
p21 protein levels in these tumours but which was
also unable to correlate these absolutely with
conventional staging criteria, although, interestingly,
it was shown that metastatic tumour contained
relatively low levels of p21 (Gallick et al., 1985).
Although activity of a number of cellular proto-
oncogenes has been demonstrated in a variety of
tissue types and at various developmental stages
(Westin et al., 1982a, b\ Muller et al., 1982,1983), it
is not yet clear in the majority of cases what their
exact physiological roles might be. It is widely
hypothesised, however, that they may be
concerned with cell growth control and regulation
(Heldin & Westermark, 1984). Nor is it precisely
understood what part they play in the process of
carcinogenesis although they have been identified in
several cases as the active transforming genes in
3T3 transfection assays, including an activated Ki-
ras from a colonic carcinoma (Pulciani et al., 1982).
We have previously shown elevated expression of
ras family oncogenes in malignant and
premalignant tumours of the colorectum and
elevated expression as well as transforming activity
of a Ha-ras oncogene has been shown in
experimentally induced mouse skin carcinomata
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and in premalignant papillomata (Balmain et al.,
1984). It is also of interest in this context that
during experimental in vitro transformation of early
passage rodent cells, transfection with either an
activated, mutated Ha-ras oncogene or with a
normal Ha-ras proto-oncogene linked to an
enhancer induces immortalisation alone, and that
only when linked to transcriptional enhancers can a
mutated form of the gene induce complete
malignant transformation (Spandidos & Wilkie,
1984). Such results would be consistent with a role
for both quantitative and qualitative changes in ras
gene expression within an overall multi-step process
of carcinogenesis.
If indeed, as we have previously hypothesised,
activation of these genes at a premalignant stage
may be critical in the process of carcinogenesis but
not in itself sufficient, it may be that subsequent
event(s) whose nature is not yet clear, perhaps
involving activation of a variety of other gene loci
and possibly associated with some form of genomic
instability, are more directly involved in the
expression of a frankly malignant phenotype and its
variants. It is, however, possible that variation in
the nature of the mutation previously shown to be
associated with ras activation (Reddy et al., 1982;
Shimizu et al., 1983; Santos et al., 1984) may also
be significant in this context, although in a series of
urothelial tumours recently reported (Fujita et al.,
1984) neither the presence of a transforming ras
oncogene in DNA in a small percentage of cases
nor the presence or absence of a documented
mutation in these, appeared to be related to tumour
stage. Nonetheless, study of such variation and of
abnormal expression of cellular oncogenes, already
shown in the context of neuroblastoma even in
gross tumour specimens to be clinically significant,
as well as of other event(s) involved in the
generation of malignancy will clearly be important
in attempting to define the behaviour of these
tumours more fully.
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